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“It is not the critic who counts; not the man who points out how the strong man stumbles, 
or where the doer of deeds could have done them better. The credit belongs to the man 
who is actually in the arena, whose face is marred by dust and sweat and blood; who 
strives valiantly; who errs, who comes short again and again, because there is no effort 
without error and shortcoming; but who does actually strive to do the deeds; who knows 
great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the 
best knows in the end the triumph of high achievement, and who at the worst, if he fails, 
at least fails while daring greatly, so that his place shall never be with those cold and timid 
souls who neither know victory nor defeat”. 
 
Theodore Roosevelt 1910 
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Abstract 
 
 
High energy open fractures are prone to delayed and non-union, necessitating secondary 
reconstruction or amputation and are associated with prolonged pain, disability and loss of 
income.  Current strategies for accelerating healing require the addition of high 
concentrations of bone morphogenetic proteins or ex vivo expansion and/or viral 
transduction of autologous, marrow-derived stem cells for re-implantation.  It is established 
that prompt cover with vascularised tissue is required to prevent bony infection.  Coverage 
with muscle improves healing time and union strength in an experimental model but the 
reason for this finding remains unclear.  
 
The fracture environment, simulated by supernatant produced using human fractured bone 
fragments was found to promote the migration and osteogenic differentiation of human 
skeletal muscle derived cells (MDSC). These cells displayed a mesenchymal stromal 
phenotype. TNF-α and IL-6 promoted osteogenic differentiation of MDSC.  TNF-α and IL-6 
also promoted the migration of MDSC in vitro but did not appear to influence their 
proliferation.  Using an in vivo periosteally stripped (high energy) fracture model, the P55 
(TNF receptor-1) knockout exhibited early delay. Recombinant TNF-α promoted fracture 
healing in wild type mice but was inhibitory at high concentrations. The peri-fracture 
inflammatory infiltrate was comprised mainly of neutrophils.  T cells were also present.  
Severe, combined immunodeficient mice exhibited delayed fracture healing. 
 
The study establishes the role of muscle derived stromal cells as an osteoprogenitor 
population, which may be important in healing high-energy fractures stripped of 
periosteum.  These cells migrate and differentiate down an osteogenic lineage in response 
to TNF-α, present in the fracture environment.  Fracture healing is critically dependent on 
TNF-α concentration locally and a high local concentration may be inhibitory.  Fracture 
healing may be promoted by manipulating inflammation locally.  Neutrophils and T cells are 
both potential sources of TNF-α. 
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1.1 The clinical Problem  
 
 
1.1.1 Anatomical considerations of the lower limb 
 
The anatomical leg is defined as the part of the lower limb between the knee and the foot.  
The bones of the leg include the tibia, which is the weight bearing bone, and the fibula, 
which serves as a mechanical scaffold for the insertion of the muscles which effect foot and 
toe movements.  The tibia lies subcutaneously for one third of its circumference, with the 
remaining two-thirds surrounded by the muscles of the anterior and deep posterior 
compartments.  The leg is divided into 4 osseofascial compartments, containing the muscles 
of the leg.  A cross sectional anatomic representation of the leg is shown in Figure 1.1.   
 
  
1.1.2 Open tibial fractures 
 
An open fracture is characterised by discontinuity of the bony cortex associated with loss of 
the protective soft tissue envelope such that the bone communicates with the external 
environment.  These injuries usually occur as a consequence of moderate to high energy 
trauma.  Around 4% of lower limb fractures are open (Ruedi et al., 2007).  A fracture of the 
tibial diaphysis is the most common open fracture, accounting for up to 45% (Court-Brown 
et al., 1998).  Associated soft tissue injuries are common. The clinical features of open 
fractures include periosteal stripping (with devitalisation of adjacent cortical bone), 
segmental bone defects or bony comminution (Gustilo and Anderson, 1976), ischaemic (and 
non ischaemic) vascular injury (Gustilo et al., 1984; Waikakul et al., 1998), neural injury  
(Bosse et al., 2005) and bacterial contamination of the fractured cortex and surrounding 
soft tissue (Patzakis et al., 1974).  In children, growth plate disturbances are also a feature of 
these injuries (Buckley et al., 1996; Hope and Cole, 1992). These injuries are prone to 
delayed and non union, mal-union, infection and a rise in lower limb compartment 
pressures which may lead to compartment syndrome (Bosse et al., 2002; Rush et al., 1989).   
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Figure 1.1 Cross-sectional anatomy of the left leg, observed from below   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.3 Classification of open tibial fractures 
 
Open long bone factures, including tibial fractures are classified using various systems; the 
most commonly used being that described by Gustilo and Anderson (Gustilo and Anderson, 
1976) and later modified (Gustilo et al., 1984).  The Gustilo classification is summarised in 
Table 1.1.   
 
 
 
Figure 1.1 The tibia lies subcutaneously for about one third of its circumference anteromedially.  The 
fibula, protected by muscle circumferentially, assists in stabilisation of the ankle and serves as a point of 
attachment for muscles of locomotion of the ankle and foot.  The musculature of the lower limb is 
described, with the arterial supply (red); the venous supply (blue) and the nerve supply (yellow).  (Adapted 
from Gray’s Anatomy, 40th edition, Churchill Livingstone, 2008)   
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Table 1.1 The Gustilo and Anderson classification of open fractures (Gustilo and Anderson, 
1976; Gustilo et al., 1984) 
 
 
Type Wound description Other criteria 
    
I  <1cm (puncture wounds) 
 
Low energy injury. clean 
II  >1cm  
 
Moderate energy without extensive soft tissue 
damage, flap or avulsion 
 
III Segmental fractures, farm injuries or any occurring in a contaminated environment, high 
velocity injuries 
 
IIIA >1cm with adequate soft tissue 
cover 
 
 
IIIB >1cm, inadequate soft tissue 
cover 
High energy injury with periosteal stripping 
 
IIIC  With vascular injury requiring repair 
 
 
 
 
The purpose of the Gustilo classification is the identification of the likely contamination of 
the open fracture and the requirement for soft tissue reconstruction.  It was not intended as 
a means of describing the fracture morphology.  Inter-observer variability has been 
reported with the use of the Gustilo and Anderson classification (Brumback and Jones, 
1994).  It should be applied following surgical debridement of the fracture, and not on 
arrival in the emergency department.  It is, however, widely used and most series described 
in the literature use this method of classification. The Arbeitsgemeinschaft für 
Osteosynthesefragen (AO) classification provides a means of describing a fracture in terms 
of morphology, using an alpha-numeric system.  The AO classification is a useful research 
tool, but is rarely used in clinical practice.  Tibial diaphyseal fractures are numbered “42”, 
with a letter A, B or C.  “A” represents a simple fracture pattern; “B” represents a more 
complex fracture pattern, and “C” represents a comminuted fracture.  An AO score for soft 
tissue injury can be included in the classification of fractures by this method.  Fractures 
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characterised by loss of the soft tissue envelope, periosteal stripping and comminution are 
most likely to encounter problems such as slow healing (Bosse et al., 2002; MacKenzie et al., 
2006) 
 
 
1.1.4 Epidemiology 
 
Overall 
The overall incidence of fractures is estimated to be between 90 and 228 per 10,000 
persons per year in the UK (Court-Brown and Caesar, 2006; Johansen et al., 1997) with a 
similar incidence in the US of around 280 per 10,000 per year (Melton et al., 1999).  In up to 
19% of cases more than one bone may be involved (Melton et al., 1999).   
 
Closed tibial fractures 
The incidence of closed tibial fractures is around 6-15 per 10,000 persons per year (7.2-15 
per 10,000 per year for males and 4.7-14.6 per 10,000 per year for females) (Johansen et al., 
1997; van Staa et al., 2001).  A bimodal fracture pattern is observed for males, with a peak 
incidence of 52 per 10,000 persons per year between 15 and 34 years.  A second, smaller 
peak is observed over the age of 90 years (Singer et al., 1998).  For females, the incidence of 
a closed tibial facture is 12 per 10,000 per year (Singer et al., 1998) with a uni-modal peak 
observed in the elderly (Singer et al., 1998; van Staa et al., 2001).  Court-Brown observed an 
incidence of tibial diaphyseal fractures of 2.15 per 10,000 persons per year, of which 61% 
occurred in males.  The average age was 40 years (Court-Brown and Caesar, 2006).  
Incidence fell with age for males and increased with age for females.   
 
High energy open fractures 
Up to 43% of all fractures may be associated with high energy trauma (Melton et al., 1999).  
Of 515 open long bone fractures admitted to a single orthopaedic trauma unit over a 5 year 
period 57.5% occurred as a result of a road traffic accident.  Forty-four percent were 
pedestrians hit by motor vehicles. The majority of the remainder (31%) occurred as a result 
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of a fall, especially falls from height (Court-Brown et al., 1998).    Trauma from firearms  
(McHenry et al., 2002) and from industrial accidents (Xenakis et al., 1995) is also common 
causes of open fractures of the lower limb.  The mean age at which males sustained open 
long bone fracture from road traffic accidents was between 35 and 37 (Bosse et al., 2002; 
Court-Brown et al., 1998).   
 
Open tibial fractures 
Of 515 open long bone fractures, 230 (44.7%) involved the tibial diaphysis, making this the 
most common open fracture.  Thirty percent were classified Gustilo IIIB and 36% were 
classified AO type C according to the fracture morphology (Court-Brown et al., 1998).   
Bosse et al reported that 3.4% of 384 reconstructed and 24.8% of 161 amputated high 
energy tibial fractures were of the AO type C fracture morphology (Bosse et al., 2002).  
Court-Brown et al reported 36 Gustilo IIIC injuries of which all eventually underwent 
amputation (Court-Brown et al., 1998). In a review of 101 cases of Gustilo IIIC fractures, the 
mean age was 31 years, and 94% were male (Glass et al., 2009b).  
 
Fractures in children 
The incidence of fractures in children (less than 18 years) was found to be around 133 per 
10,000 per year (Cooper et al., 2004).  An estimated one-third of children have sustained at 
least one fracture by the age of 17 years.  The incidence of tibial fractures is 11.3 per 10,000 
per year for boys and 6.7 per 10,000 per year for girls. Only 7% of open tibial fractures were 
reported as Gustilo IIIB fractures (Glass et al., 2009a).  
 
 
1.1.5 Complications 
 
Union time/non union 
The average time to union of high energy Gustilo IIIB tibial fractures is 28 to 58 weeks 
(Keating et al., 2000; Naique et al., 2006; Rohde et al., 2007; Yazar et al., 2006).  Yazar et al, 
in a study of 174 patients with open distal and ankle fractures, reported a mean union time 
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of 49 weeks when covered by muscle flaps and 58 weeks when covered by fasciocutaneous 
flaps (Yazar et al., 2006).  The cohorts were not randomised.  Rohde, in a series of 38 
patients reported a non union rate of around 30%, but included all cases requiring late 
surgical intervention to facilitate union (Rohde et al., 2007).  Bosse et al reported a primary 
non union rate in Gustilo IIIB tibial fractures of 29% (Bosse et al., 2002).  Naique et al, in a 
series of 73 patients (82% of who were male, with a mean age of 42) reported a non union 
rate of around 3% (Naique et al., 2006). The non union rate reported by Yazar was around 
2% (Yazar et al., 2006).    Delayed union (absence of radiological or clinical union at 43 
weeks, or the requirement for further surgical intervention to facilitate union) was reported 
in 15-17% (Naique et al., 2006; Yazar et al., 2006).  A delayed union rate of 22% and primary 
non union rate of 13% has been described for children (Glass et al., 2009a).  Shorter union 
times for younger children have been described (Jones and Duncan, 2003).   
 
Importantly, an established non union is an entirely different clinical entity from a high 
energy fracture at risk of non union and the management of established fracture non union 
may be considered separately.  
 
Infection 
The prevalence of osteomyelitis following high energy open tibial and ankle fractures was 8-
18% (Bosse et al., 2002; Keating et al., 2000; Naique et al., 2006; Rohde et al., 2007; Yazar et 
al., 2006).  Excluding primary amputations, the amputation rate resulting from osteomyelitis 
was 18-33% (Naique et al., 2006; Rohde et al., 2007; Yazar et al., 2006).   Secondary 
amputations were also performed for poor post reconstructive function.  The primary 
salvage rate was dependent on the severity of the injury.  Twenty-three of 101 (23%) 
Gustilo IIIC tibial and femoral fractures reported in the literature underwent secondary 
amputation (Glass et al., 2009b).  It is likely that this figure under-represents the true total, 
as the unreported amputation rate for these severe injuries is likely to be much higher.   
Trans-tibial amputations are associated with better long-term functional outcomes than 
through knee or trans-femoral amputations (MacKenzie et al., 2004). 
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Lifestyle factors 
As demonstrated by the LEAP (lower extremity assessment project) study group, a number 
of additional complications following high energy open fractures can also reflect the 
personal and social resources of the patient (Castillo et al., 2006; McCarthy et al., 2003).  
Castillo et al investigated levels of chronic pain 7 years following limb threatening lower 
extremity trauma.  They found that around 30% reported high levels of pain interference 
with daily activities.  Lower levels of chronic pain were reported among patients with a 
higher education status.  Low socio-economic status and alcohol misuse were predictive of 
chronic pain in this population (Castillo et al., 2006).  McCarthy et al found that almost 40% 
of patients reported at least one positive moderate to severe symptom of psychological 
distress two years following injury.  Alarmingly, this did not reduce over time.  The study 
identified young age, low socio-economic status, lack of self efficacy and alcohol 
dependency as predictors for persistent psychological distress following severe lower 
extremity trauma (McCarthy et al., 2003).    
 
Limb threatening lower extremity trauma was also associated with significant interference 
with both work and recreational activity at 24 months, with only around half of all patients 
returning to employment (Bosse et al., 2002).  Younger patients and those with high levels 
of self efficacy and education were more likely to return to work. About 40% were found to 
have returned to work by 1 year and this levelled off at around 60% by 7 years (MacKenzie 
et al., 2006).  Naique et al reported that 61 of 73 (84%) had returned to work four years 
post injury (Naique et al., 2006). Around half of all patients with high energy fracture of the 
tibial shaft achieve a physical and psychosocial sickness impact profile sub scores which are 
equivalent to the general population.   The salvage of an insensate foot at presentation was 
not a marker of adverse outcome, as commonly plantar sensation returned (Bosse et al., 
2005). Reduced plantar flexion range of motion was associated with the poorest functional 
outcome (walking speed and gait deviation) and suggested that trans-tibial amputation 
should be considered in patients with severe open ankle or mid foot fractures (Archer et al., 
2006).   
 
CHAPTER ONE                                                                                                                                                 INTRODUCTION 
 27
 
1.1.6 The surgical management of open tibial fractures 
 
Standards for the management of high energy lower extremity injuries have recently been 
published (Nanchahal et al., 2009).  The sequence of the initial management of these 
injuries is detailed in Table 1.2.  A high index of suspicion for ischaemic vascular injuries 
must be maintained, as limb salvage is critically dependent on ischaemic time.  Skeletal 
muscle is susceptible to ischaemia, with a study by Labbe et al demonstrating 2%, 30% and 
90% tissue necrosis at 3, 4 and 5 hours of ischaemia of the gracilis muscle in a canine model 
(Labbe et al., 1987).  Forrest et al demonstrated 41% and 71% necrosis after 4 and 5 hours 
respectively (Forrest et al., 1989). Following re-establishment of circulation, Hammersen et 
al demonstrated histological changes in the microcirculation of human skeletal muscle 
consistent with a reperfusion injury after 3 to 4 hours (Hammersen, 1989).  Irreversible 
neural ischaemic may occur as early as 2-3 hours (Kinoshita and Monafo, 1994; Rorabeck, 
1980). A review of the literature demonstrated decreased limb survival with an ischaemic 
time beyond 3-4 hours (Glass et al., 2009b).  If the vascular compromise is not reversed by 
fracture reduction, prompt surgical exploration of the fracture is recommended, with 
vascular lacerations bypassed initially using a shunt, to permit rapid revascularisation and 
assessment of tissue viability (Glass et al., 2009b).   
 
Immediate surgical exploration is also advocated in the event of compartment syndrome.  
Compartment syndrome is characterised by an increase in pressure within an unyielding 
osseo-fascial compartment, which compromises capillary perfusion, resulting in tissue 
hypoxia, ischaemia and necrosis (Pearse et al., 2002).   As the pressure rises, venous return 
is compromised before arterial inflow, further adding to the rise in compartment pressure. 
Trauma, vascular injury and reperfusion injury following anatomical reduction of a fracture 
with vascular compromise can all result in compartment syndrome.  The management is 
prompt surgical fasciotomy.  Further surgical exploration of the lower extremity injury can 
be performed at this time. Gross or agricultural contaminations are indications for early 
surgical intervention.   
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Table 1.2 The sequence of surgical management of major trauma to the lower limb 
 
Sequence Action 
 
  
1 Management of life-threatening problems consistent with the ALTS principles: 
Airway, Breathing and Circulation, assessment of neurological function and head to 
toe examination to determine all other injuries. 
 
2 Specific neurovascular examination of the injured limb 
 
3 Analgesia as appropriate 
 
4 Reduction of the fracture and splinting to maintain alignment 
 
5 Repeat neurovascular examination 
 
6 Removal of gross contaminants from the wound 
 
7 Photographic documentation of the wound 
 
8 Coverage of the wound with sterile, saline soaked gauze and an adhesive film 
dressing 
 
9 Prophylactic antibiotic cover  
 
10 Tetanus prophylaxis if required.  (additional tetanus immunoglobulin if high risk 
contamination) 
 
11 Radiographic sequence, demonstrating fracture in two orthogonal views, with joint 
above and below fracture visualised 
 
12 Ortho-plastic referral at specialist centre 
 
 
 
 
 
 
High energy, open fractures of the lower extremity are commonly contaminated by 
environmental flora and particulate debris.  Antibiotic prophylaxis has been shown to 
reduce the rate of deep infection in these injures (Patzakis et al., 1974; Patzakis and Wilkins, 
1989).  Met analyses have established the role for prophylactic cover against environmental 
From: “Standards for the management of open fractures of the lower limb”, BAPRAS/BOA 
working group, 2009 (Nanchahal et al., 2009). 
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contaminant flora (Gosselin et al., 2004; Hauser et al., 2006; Luchette et al., 2000).  The 
addition of prophylaxis against Gram-negative contaminants has been proposed (Jaeger et 
al., 2006). However, it is nosocomial organisms, and not environmental contaminants that 
are implicated in most deep tissue infections following lower extremity trauma. Hence, in 
anticipation of the evolving nature of the contaminant flora, a dynamic prophylactic 
strategy has been proposed, offering a second prophylaxis against nosocomial organisms 
(Glass et al., 2010; Nanchahal et al., 2009).   
 
Where there are no indications for emergent surgical exploration, early debridement by an 
experienced surgeon is recommended.  In theatre, the limb is washed with a soap solution 
then surgically prepared using an antiseptic skin preparation solution.  Soft tissue 
debridement is performed under tourniquet control, especially where extensive soft tissue 
involvement is present, in order to permit bloodless visualisation of the key structures. 
Adequate visualisation of deeper structures can be achieved by extension of the wound 
along a line which marks the fasciotomy incision.   Adherence to this line prevents iatrogenic 
injury to the perforating vessels which supply blood to the skin.   
 
Skin, fat, muscle and bone are assessed sequentially, and all non viable or contaminated 
tissues excised.  Degloving injuries of the skin occur due to torsion, crush and avulsion.  They 
may be single, or multi-planar (Arnez et al., 2010, Nanchahal, 2009).  With the tourniquet 
deflated, fixed staining of the skin, consistent with dermal and sub-dermal thrombosis, is 
indicative of non viable degloving and necessitates excision.  Evaluation of muscle is based 
on colour (pink), contractility, consistency (devitalised muscle tears easily on manipulation 
by surgical forceps) and evidence of bleeding (with the tourniquet deflated).  Following 
delivery of the bone ends through the wound, bony debridement is performed, and loose 
fragments removed.  Assessment of the capacity of the bone ends to bleed is a useful 
determinant of viability, and the bone ends may be trimmed until viable, bleeding bone is 
reached.   
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Following wound debridement, the fracture and soft tissue injury can be classified, in order 
to help determine the reconstructive options.    Irrigation of the wound with low pressure 
lavage is recommended, prior to reduction of the fracture and temporary closure of the 
wound prior to definitive reconstruction.  The purpose of the dressing is to prevent bacterial 
ingress and avoid desiccation of the tissues.  Negative pressure wound dressings are often 
used for this purpose but are not a substitute for prompt definitive soft tissue cover 
(Bhattacharyya et al., 2008; Dedmond et al., 2006).  Antibiotic-impregnated beads can also 
be used in cases of segmental bone loss prior to definitive management (Ristiniemi et al., 
2007b).  
 
 
1.1.7 Definitive skeletal management 
 
Skeletal stabilisation can be achieved by means of internal or external fixation.  The choice 
of skeletal fixation depends on the mechanism of the injury, the level and configuration of 
the fracture and the associated soft tissue involvement.  Low to moderate energy, single 
level diaphyseal fractures without a comminuted configuration and without substantial soft 
tissue loss and contamination are usually suitable for intramedullary nail fixation.  If using 
this method, definitive soft tissue cover must be performed at the time of intramedullary 
nailing as delayed soft tissue reconstruction over an intramedullary nail is associated with 
an increased risk of deep infection (Gopal et al., 2000).  If definitive soft tissue cover 
requires a vascularised free flap, the fracture is often stabilised with an external fixator and 
definitive fixation performed at the same time as the flap.   
 
High energy, single level diaphyseal fractures with comminution or bone loss, or multi-level 
fractures, or fractures involving the metaphysis may be suitable for external fixation using a 
circular frame.   Any fracture complicated by gross contamination is also suitable for this 
method.  Here, following surgical debridement and classification, an external fixation device 
is applied and completed or adjusted at the same time as definitive soft tissue 
reconstruction.  Using this method, bone transport techniques can be employed to manage 
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segmental bone loss. Bone grafting can also be performed with circular frame fixation as the 
current gold standard in the management of non union (Friedlaender et al., 2001).   
 
 
1.1.8 Soft tissue management 
 
Fracture is a traumatic insult not only to bone but to marrow, periosteum and adjacent soft 
tissue (Buckley and Panaro, 2010).  For Gustilo grade I and some grade II injuries, 
debridement and skeletal fixation can be followed by direct closure of the soft tissue 
envelope.  For injuries with more extensive soft tissue loss, the envelope must be 
reconstructed.  Vascularised soft tissue is recommended in all cases (Byrd et al., 1981).  
Local perforator flaps (which mobilise a section of fasciocutaneous tissue around its 
perforating blood supply) are often employed for the closure of open fractures when the 
deficit is relatively limited and the perforator is intact.  The alternative is a pedicled muscle 
flap, where a muscle (for example the medial or lateral head of gastrocnemius) is mobilised 
on its blood supply to cover a defect.  Pedicled muscle flaps can be covered by skin grafts to 
complete the soft tissue reconstruction.  The option largely depends on the size and site of 
the soft tissue defect.  For Gustilo grade IIIB injuries, with more extensive soft tissue loss on 
account of high energy impacts, contamination or degloving, free vascularised flap are 
usually required. This technique imports more tissue than is available locally, by 
microvascular anastomosis of the imported tissue to recipient vessels out of the zone of 
injury.   
 
Free vascularised flaps include muscle and fasciocutanous flaps.  A typical example of a free 
muscle flap is the latissimus dorsi flap, which harvests all or a portion of the latissimus dorsi 
muscle with its vascular pedicle; the thoracodorsal artery and veins (Watson et al., 1979).  A 
typical example of a fasciocutanous flap used commonly is the anterolateral thigh flap, 
where a paddle of fasciocutaneous tissue is harvested on the sub-fascial plexus, based on 
the musculocutaneous or septocutaneous perforators of the descending branch of the 
lateral circumflex femoral artery and its venae comitantes (Song et al., 1984).  Definitive 
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closure should be achieved early to reduce the risk of infection, and certainly within 7 days 
of injury (Nanchahal et al., 2009).   
 
 
1.1.9 Comparison of muscle versus fasciocutaneous flaps 
 
Several authors have favoured the use of muscle flaps for the coverage of open tibial 
fractures (Byrd et al., 1981; Georgiadis et al., 1993; Gopal et al., 2000).  Geogiadis et al, 
evaluating evidence from previous studies suggested that muscle flaps were associated with 
improved healing times and reduced rates of osteomyelitis (Georgiadis et al., 1993).  Small 
and Mollan reported a higher complication rate with the use of fasciocutaneous flaps (Small 
and Mollan, 1992).  Gopal et al, reporting high energy fractures only, (79 Gustilo grade IIIB 
and 5 grade IIIC) achieved a limb salvage rate of 95% with the use of muscle flaps (75 free 
and 9 pedicled) (Gopal et al., 2000).  Gopal et al later reported favourable functional 
outcomes and suggested that they believed muscle flap cover to be important in bringing as 
yet undefined cellular and humoral elements to the healing fracture (Gopal et al., 2004).  
 
The use of fasciocutaneous flaps for reconstruction of soft tissue defects of the lower limb 
was championed by Ponten (Ponten, 1981).  Hallock reported that fasciocutaneous flaps 
could be used to cover previously infected defects (Hallock, 1991), and donor site morbidity, 
except where a skin graft was used, was comparable between flap types (Hallock, 1993). 
Hong et al described the use of fasciocutaneous flaps for cover following osteomyelitis of 
the lower limb.  They observed that the flap provided a satisfactory ankle contour and 
provided easy assess for re-exploration (Hong et al., 2005). 
 
Hallock reported comparable results with the use of muscle and fasciocutaneous flaps, with 
outcome dependent on prompt soft tissue cover (Hallock, 2000).  Yazar et al, in a non-
randomised study of 177 free flaps in 174 patients reported no difference in the prevalence 
of post-operative infection with muscle compared with fasciocutaneous flaps (11.2% vs. 
12.7%) and primary bone union (84.5% vs. 81%).  There was a non significant reduction in 
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osteomyelitis with the use of muscle flaps (9.3% vs. 12.7%).  They reported that while 
muscle provided a better fit for complex tissue defects, fasciocutaneous tissue provided an 
alternative for cover around the less 3-dimentional distal tibial and ankle defects (Yazar et 
al., 2006).   
 
In a canine model using random pattern flaps, muscle was superior to fasciocutaneous 
tissue in eliminating bacteria from the wound bed (Chang and Mathes, 1982).  Comparing 
bacterial load following inoculation at the deep surface of local musculocutaneous and 
fasciocutaneous flaps, the same group later reported that muscle reduced the bacterial 
growth and exhibited improved healing histologically (Calderon et al., 1986).  Using local 
TNF-α levels as a marker of inflammation, Brown et al established, in a canine open tibial 
fracture model inoculated with staphylococcus aureus, that muscle flap cover reduced 
fracture site inflammation, regardless of the presence of bacteria (Brown et al., 2000).  
Using a canine open tibial fracture model, with a periosteally stripped tibial osteotomy 
covered by muscle or skin, Richards et al reported a significantly increased callus volume 
(Richards et al., 1987), bone blood flow (Richards and Schemitsch, 1989) and bony union 
(Richards et al., 1991) when the tibia was covered by muscle. However, muscle was in 
contact with the fracture in both groups, as the muscles of the posterior and lateral 
compartments were not excluded.  Moreover the fascial layer deep to the skin was excised 
in the “skin” group, and therefore this arm of the study does not represent a 
fasciocutaneous flap as used clinically.     
 
In summary, clinical series have failed to establish the supremacy of one type soft tissue 
over others.  This is due to the heterogeneous nature of these injuries, variations in the pre-
morbid condition of the patient, especially as these injuries can occur in the context of 
multi-system trauma, and the lack of prospective, randomised trials.  Similarly, experimental 
data are beset with methodological problems which limit their translational appeal.   
 
For this reason, our group developed a murine open tibial fracture model. To replicate high 
energy injuries, the periosteum was stripped circumferentially for a distance of around 
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10mm centered on the mid shaft of tibia.  A mid-tibial osteotomy was performed.  Fracture 
fixation was achieved by an intramedullary steel pin.  A strip of impermeable 
polytetrafluoroethylene (PTFE) was used to exclude the fasciocutanous tissue anteriorly, or 
the muscle posteriorly to ensure that contact between the fracture and fasciocutaneous 
tissue or muscle was exclusive to one tissue type only (Harry et al., 2008).   Skeletal injury 
without soft tissue exclusion, and sham fracture (without mid tibial osteotomy) were used 
as a controls.  The model was reliable with an operative failure rate of 2.3%.  There were no 
infectious complications reported.   
 
All tibiae were subject to micro CT and 4-point bend testing at 28 days post fracture.  Callus 
volume, callus mineralisation and load to failure were significantly greater when muscle was 
in contact with bone exclusively, with similar parameters to the control limbs.  Moreover, a 
comparison of the vascularity of the muscle and fasciocutanous tissues revealed that for all 
time points tested, the vascular density of fasciocutanous tissue was greater than muscle.  
This finding established that blood supply was not responsible for improved fracture healing 
under muscle (Harry et al., 2009).   
 
This study therefore aimed to establish why muscle promoted fracture healing.  An 
understanding of this observation may have direct translational implications for the soft 
tissue management of high energy open fractures.   
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1.2 The biology of bone healing 
 
 
1.2.1 Overview of bone biology  
 
Functions of bone 
Bone is a specialised connective tissue that has biomechanical, synthetic and metabolic 
functions (Baron, 1999).  Additionally, the medullary cavity of long bones harbours the 
marrow, which regulates blood cell homeostasis.  Bone also provides a store of calcium, 
phosphorous and fatty acids (Broadus, 1999, Rodan, 1998 #25). Growth factors such as the 
bone morphogenetic proteins are released from bone (Mundy, 1999) and bone helps 
regulate acid-base balance by the absorption or release of alkaline salts (Green and 
Kleeman, 1991).   
 
Gross anatomy of a long bone 
The skeleton contains both flat bones and long bones.  Flat bones, such as those of the skull 
grow predominantly by a process known as intramembranous ossification.  Long bones 
grow circumferentially by intramembranous ossification and longitudinally by remodelling 
of a cartilaginous intermediary at the epiphyseal plates.  This is known as endochondral 
ossification (Baron, 1999).  The macroscopic anatomy of a long bone is shown in Figure 1.2.  
In a growing bone, the epiphysis and metaphysis represent two independent ossification 
centres and are separated by the epiphyseal (growth) plate (Baron, 1999).  At the diaphysis 
the external cortical bone is thick.  Towards the metaphyses the cortical bone becomes 
thinner and the medullary cavity is filled with trabecular bone housing haematopoetic bone 
marrow.  The bone is lined externally with periosteum and internally with endosteum 
(Baron, 1999).   
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Figure 1.2 Gross anatomy of a long bone   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomechanics of bone 
The biomechanical functions of bone include the maintenance of body shape and the 
protection of organs.  The skull protects the brain, the ribs and sternum protect the heart, 
lungs, liver and spleen, the pelvis protects the bladder and reproductive organs and the 
vertebrae protects the spinal cord.  Bones provide levers from which muscles transmit 
 
Figure 1.2 The CT image is of a murine tibia and fibula, shown from behind, and in cross-section.  The CT 
images were reconstructed courtesy of Dr. Andrew Freidin, Kennedy Institute of Rheumatology, Imperial 
College. 
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mechanical forces through tendons to effect locomotion, breathing, speech and swallowing. 
Bone, as a composite structure, can withstand compressive, tensile and torsional stress 
(Rubin and Rubin, 1999).  Compressive stress is resisted by hydroxyapatitie, the inorganic 
component of the extracellular matrix. Tensile strength is resisted by collagen fibres, which 
are organised into lamellae (Rubin and Rubin, 1999).  The orientation of collagen fibres 
between adjacent lamellae permits resistance to forces acting in different directions and is 
influenced by stresses placed on the bone that promote remodelling.  Specifically, bone may 
remodel to accentuate bending for beneficial redistribution of loads (Skedros et al., 1996).   
 
Lamellar bone 
Normal adult bone is comprised of lamellar (or cortical) bone and cancellous (or trabecular) 
bone.  “Lamellar” bone refers to the densely packed parallel arrangement of the fibres 
which comprise the outer surface of the bone (Baron, 1999).  The structural unit of lamellar 
bone is the osteon, which is a single Haversian system of concentric layers (lamellae) of 
compacted bone tissue around a central, Haversian canal (Cooper et al., 1966).  The 
structure of the osteon is shown in Figure 1.3.  The characteristic lamellar appearance under 
microscopy is due to the alternating orientation of the fibres from layer to layer (Baron, 
1999).  Carried within each Haversian canal is the blood and nerve supply to the bone 
(Cooper et al., 1966).  Osteoblasts that reside in lacunae within osteons are termed 
osteocytes (Baron, 1999).  A network of channels known as “canaliculi” permit osteocytes to 
communication with each other via cell processes that project along the channels.  This 
arrangement facilitates the exchange of nutrients and metabolic waste and cell signalling in 
response to mechanical and chemical factors.  The space between each osteon is occupied 
by the remnants of previous osteons which are undergoing resorption as part of the 
ongoing process of bone remodelling.  Osteons communicate with each other, and with the 
medullary cavity and periosteum by means of interosteonic anastomoses (sometimes called 
Volkmann’s canals) (Cooper et al., 1966).    
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Figure 1.3 The structural anatomy of bone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancellous bone 
Cancellous bone resides within the interior of bones, mainly at the metaphyses and 
epiphyses (Baron, 1999). It is less dense (and hence has a greater surface area) and is 
orientated in the direction of greatest stress, providing structural stability.   However, only 
15-25% of cancellous bone is calcified (Baron, 1999).   The rest is highly vascular, containing 
connective tissue and the hematopoietic and marrow-derived stem cell niche.  It is also a fat 
store (Baron, 1999).  As most of the interface between bone and soft tissues resides here, 
cancellous bone fulfils most of the non-structural functions of bone (Baron, 1999) as well as 
 
Figure 1.3 Adapted from Gray’s Anatomy, 40th edition, Churchill Livingstone 2008)  
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remodelling in response to mechanical stress.  The cells that effect bone formation and 
remodelling include osteoblasts and osteoclasts. 
 
Osteoblasts 
Osteoblasts are mononuclear cells of mesenchymal origin, phenotypically similar to 
fibroblasts.  Sources of osteoprogenitor cells include the periosteum, endosteum and bone 
marrow (Lian et al., 1999).  Osteoblast differentiation occurs by the sequential activation 
and suppression of genes that encode for phenotypic and regulatory proteins and is 
mediated by a number of hormones and growth factors including bone morphogenetic 
proteins (BMPs), parathyroid hormone (PTH) and insulin-like growth factor-1 (IGF-1).  These 
will be discussed in detailed later (Lian et al., 1999).  Mature osteoblasts synthesise ECM 
proteins including type 1 collagen and the non collagenous matrix proteins.  ECM is 
mineralised by the action of alkaline phosphatase.  Mineralised ECM then promotes the 
expression of proteins such as osteocalcin that regulates bone deposition by promoting 
osteoclastic differentiation (Rodan, 1998). Alkaline phosphatase is a useful marker of 
osteoblastic differentiation.   
 
Terminally differentiated osteoblasts are known as osteocytes and are enveloped by 
mineralised ECM.  Osteocytes are not metabolically inert, however, as they communicate 
with each other through cytoplastic cell extensions running in canaliculi (Baron, 1999; Lian 
et al., 1999).  Osteocytes also communicate with surface osteoprogenitor cells.  Hence, it is 
proposed that bone-forming cells communicate responses to physiological stimuli with 
other bone forming cells (Lian et al., 1999).  
 
Osteoclasts 
Osteoclasts are large, multinucleated cells with 4 to 20 nuclei formed by the fusion of cells 
of the monocyte-macrophage lineage (Baron, 1999).  Therefore they are hematopoietic, and 
not mesenchymal in origin.  Osteoclasts attach to the underlying bone via a ring of 
contractile proteins that seals off the interface between the cell and the underlying bone 
(Baron, 1999).  The plasma membrane facing the bone within this “sealing zone” is folded 
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and this is known as the ruffled border.  The ruffled border is lined with proton adenosine 
triphosphate (ATPase) pumps that transport hydrogen ions (produced by the action of 
carbonic anhydrase II) into the sealing zone (Baron, 1999). Hydrogen ions are accompanied 
by chloride that enter through separate chloride channels to maintain electroneutrality 
(Vaananen et al., 2000).  Lysosomes and related organelles are present and aid the 
secretion of lysosomal enzymes into the sealing zone.  These enzymes include Cathepsin K 
and tartrate-resistant acid phosphatase (TRAP) (Baron, 1999).  Osteoclasts also secrete 
metalloproteinases, particularly MMP-9 into the sealing zone (Roodman, 1999).  The acidic 
and enzymatic environment within the sealing zone results in the dissolution of the bone 
matrix.  The bone resorption pits are known as resorption (Howship’s) lacunae which are 
formed as a result of the resorptive activity of the osteoclast.  This arrangement is shown in 
Figure 1.4. 
 
Acid dissolves hydroxyapatite of the ECM while the enzymes digest the organic components 
(Baron, 1999).  Adenosine triphosphate (ATP) and CO2 (required for the production of 
hydrogen ions) are obtained from the mitochondria.  Alkalinisation of the cytoplasm is 
avoided by exchanging bicarbonate for chloride on the basolateral membrane of the cell 
(Baron, 1999; Roodman, 1999).  Mechanisms by which the osteoclasts manage the dissolved 
and digested components of the ECM are unclear.  They may internalise the products and 
transport them across the basolateral membrane (transcytosis) or the sealing zone may 
temporarily relax, releasing the contents of the resorption lacunae locally (Baron, 1999; 
Vaananen et al., 2000). Continued degradation of these products may occur intracellularly 
in transcytotic vesicles (Vaananen et al., 2000). 
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Figure 1.4 Osteoclastic bone resorption 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extracellular matrix 
The acellular part of bone is called the extracellular matrix (ECM).  The ECM is comprised of 
organic and inorganic components.  The organic (unmineralised portion) of ECM is 
comprised of type 1 collagen fibres and ground substance (Baron, 1999). Ground substance 
is comprised of serum proteins and many non collagenous, non serum proteins including 
proteoglycans, glycosylated proteins and τ-carboxylated proteins (Lian et al., 1999).  The 
most abundant serum protein in ECM is albumin.  The proteoglycans include the 
glycosaminoglycan Chondroitin Sulphate.  The glycosylated proteins include Alkaline 
Phosphatase (ALP); an enzyme mediating mineral deposition.  The carboxylated proteins 
include Osteocalcin that regulates osteoclasts and their precursors (Lian et al., 1999).  
Between 20 and 40% of the extracellular matrix is composed of osteoid (Lian et al., 1999).  
The inorganic component of the extracellular matrix is primarily hydroxyapatitie 
(Ca5(PO4)3(OH)2) and accounts for between 50 and 70% (Lian et al., 1999).  Water comprises 
Figure 1.4 The osteoclast forms a sealing zone with bone using intergins such as αvβ3 intergin.  The ruffled 
border is shown.  The resorption (Howship’s) lacuna is exaggerated.  CAII: carbonic anhydrase II; MMPs: 
matrix metalloproteinases; RER: rough endoplasmic reticulum; Cysteine proteases include Cathepsin K.   
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5-10% of the ECM. Less than 3% of the ECM is comprised of lipids that influence 
mineralisation and ion transport (Lian et al., 1999).  
 
Bone remodelling 
The sequence of bone remodelling begins with osteoclastic activation and maturation 
followed by osteoclastic bone resorption.  This is followed by pre-osteoblastic migration and 
differentiation.  Mature osteoblasts synthesise ECM, and the ECM is mineralised.  Finally, 
mineralised ECM envelopes the osteoblast becoming an osteocyte and the cycle is 
complete.  The mechanism initiating bone remodelling is unclear.  Resorption of bone 
within each Haversian system is responsible for cortical bone remodelling.  This results in 
increased porosity.  Bone resorption also occurs at the endosteal surface, while the 
periosteal surface continues to deposit bone.   Remodelling of cancellous bone appears to 
be regulated by the local environment, including bone marrow.  Mechanical stimuli may 
promote cancellous remodelling to provide structural support in response to changing 
mechanical demands on the bone.   
 
The resorptive phase of remodelling may last around 10 days.  Resorption of bone by 
osteoclasts is followed by osteoclast apoptosis.  Osteoclast apoptosis is coupled with the 
recruitment of osteoprogenitors.  This process may occur as a consequence of the release of 
osteoblast recruitment factors by the ECM as it is digested and dissolved.  A number of 
factors including transforming growth factor-β (TGF-β), Bone morphogenetic proteins 
(BMPs) and parathyroid hormone (PTH) have been implicated in this process (Krane, 2005).  
Osteoblast and osteoclast recruitment will be discussed in more detail in section 1.4.5. A 
summary of the processes involved in coupled bone remodelling is shown in Figure 1.5. 
 
Initially, fracture healing deposits woven (non-lamellar) bone. The collagen fibres in woven 
bone are orientated randomly and the arrangement is structurally weak.  The fracture callus 
is remodelled into mature, lamellar and cancellous bone by the same process described 
above.  
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Figure 1.5 Coupled bone remodelling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 The requirements for fracture healing 
 
The requirements for bone healing in response to injury include an osteoconductive matrix, 
as a scaffold for bone repair (Urist, 1965), osteoinductive signals (Sampath and Reddi, 1981; 
Urist and Strates, 1971), osteoprogenitor cells capable of responding to these signals, an 
 
Figure 1.5 Bone remodelling is a process that couples bone resorption with bone formation.  Osteoclast 
maturation is stimulated by macrophage-colony stimulating factor (M-CSF) and receptor activator for 
nuclear factor κ B ligand (RANKL) synthesised by preosteoblasts. Bone resorption by mature osteoclasts 
result in the release of growth factors such as transforming growth factor-β (TGF-β), bone morphogenetic 
proteins (BMPs) and parathyroid hormone (PTH) that stimulate osteoblastic maturation and bone 
formation.  This, in turn inhibits further osteoclastic differentiation by the synthesis of osteoprotegerin 
(OPG).   
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adequate blood supply (Gamradt and Lieberman, 2004; Tseng et al., 2008) and an optimal 
mechanical environment (Giannoudis et al., 2008).    
 
The blood supply to a long bone is provided by the nutrient artery (via the intramedullary 
canal) with an additional supply from the periosteum and the metaphyseal vessels.  The 
nutrient artery, entering the bone via the nutrient foramen, provides 80-85% blood to the 
diaphyseal cortex.  The capillary rich periosteum supplies 15-20% blood (principally to the 
outer cortex) but is capable of increasing the relative delivery of blood in the event of 
disruption to the medullary blood flow via the nutrient artery.  The metaphyseal blood 
supply arises from the periarticular vessels.  These vessels penetrate the cortex at the 
metaphysis and anastomose with the medullary vessels 
 
 
1.2.3 Ossification strategies 
 
Fracture healing is a complex process which involves the up regulation of many groups of 
genes and is similar, though not identical to pre- and post-natal bone development 
(Hadjiargyrou et al., 2002).  It is typically described in relation to the ossification strategy 
involved, although the clinical situation usually involves a combination of these (Einhorn, 
1998).  The end-point of fracture healing is union.  Union can be defined in practical terms 
as the point at which the injured bone has regained enough strength and stiffness to 
function as a weight bearing structure without external support (Marsh and Li, 1999).   
 
Primary union 
Primary cortical healing only occurs in an environment of minimal inter-fragmentary 
motion.  This only occurs following anatomical reduction and rigid fixation of a fracture.  It is 
a direct attempt to re-establish cortical continuity.  However, anatomical fracture 
opposition is not achieved at a microscopic level and the small fracture gaps are first closed 
by direct bone growth at the fracture line.  The fracture gap rapidly fills with woven bone.  
Contact healing then occurs, where osteoclasts tunnel through cortical and woven bone 
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across the fracture line by bone resorption (Einhorn, 1998).  Osteoblasts follow osteoclasts, 
lining the trail edges of the canal produced by the osteoclast and depositing new bone.   The 
histological arrangement is called a cutting cone.  Vascularisation of the cutting occurs via 
arteriolar formation, which delivers nutrients and osteoprogenitor cells (Einhorn, 1998). 
These cones advance around 50µm per day and generate new osteons (McKinley, 2003).  
 
Intramembranous ossification 
The first of the secondary ossification strategies is known as intramembranous ossification, 
and is similar to the process of circumferential bone growth during skeletal development.  
Bone is formed directly, by the differentiation of osteoprogenitor cells in the periosteum 
and endosteum, with additional sources of osteoprogenitors detailed below.  Adjacently 
sited progenitor cells divide until they have formed a dense aggregation of cells.  These 
aggregations are known as nodules.  As cell maturation continues, newly formed 
osteoblasts synthesise osteoid.  Centrally placed osteoblasts become incorporated within 
osteoid circumferentially, becoming osteocytes.  Osteoid becomes mineralised, forming 
small bone spicules.  Many spicules fuse to form new trabeculae.  The interconnection of 
trabeculae forms woven bone, which is remodelled to produce new lamellar bone.  
Intramembranous ossification is enhanced by motion and inhibited by rigid fixation 
(Einhorn, 1998; McKinley, 2003).  Gaps as large as half of the diameter of the bone can be 
bridged this way.   
 
Endochondral ossification 
The second of the secondary ossification strategies is known as endochondral ossification, 
and is similar to the process of longitudinal bone growth at the growth plate during skeletal 
development.  In many ways this is the most complex and interesting strategy as bone is 
formed by the remodelling of a cartilaginous intermediary.  Fracture of the bony cortex is 
followed by bleeding from the cortices and marrow and the formation of a haematoma.  
Classically, the haematoma is thought to be the source of signalling molecules that initiate 
inflammation, neo-vascularisation and cell recruitment (Dimitriou et al., 2005; McKinley, 
2003).  Specifically, platelet degranulation releases platelet-derived growth factor (PDGF), 
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promoting an angiogenic response within the haematoma.  New vessels carry mesenchymal 
stromal cells (MSC) to the fracture site. Transforming growth factor-β (TGF-β) is also 
released by haematoma degradation and promotes proliferation and differentiation of 
these cells.  MSC undergo chondrogenic differentiation.  As chondrocytes they synthesise 
collagen and proteoglycans, forming a vascularised cartilaginous structure called soft callus. 
The chondrocytes hypertrophy and begin to secrete alkaline phosphatase (an enzyme 
essential for mineral deposition) and vascular endothelial growth factor (VEGF).  
Hypertrophic chondrocytes undergo apoptosis while neo-vascularisation enables 
recruitment of both chondroclasts that resorb the cartilaginous intermediary and 
osteoprogenitor cells that lay down new woven bone. This “hard callus” is then remodelled 
to form mechanically competent lamellar bone.  Asymmetrical callus deposition follows the 
original asymmetric pattern of growth in the physes of the bone during development.  In 
the case of the tibia, this asymmetrical callus formation favours deposition proximally, as 
the tibia grows predominantly from its proximal physis (Gerstenfeld et al., 2006).  
Remodelling proceeds from the edges of the callus towards the fracture line (Gerstenfeld et 
al., 2006).  The pro-inflammatory cytokines IL-1, IL-6 and TNF-α have been proposed as 
regulating molecules during early fracture healing (Andrew et al., 1994; Gerstenfeld et al., 
2003b).  A more detailed explanation of this hypothesis will be provided later.   
 
Intramembranous and endochondral bone formation usually occur simultaneously. The 
relative contribution of each is thought to be dependent on movement and shear loading 
with movement favouring endochondral bone healing (Gerstenfeld et al., 2003b).  Excluding 
primary bone healing, which is dependent on rigid stability some movement may be 
beneficial to fracture healing (Claes et al., 1998).  Where the periosteum has been stripped 
from the bone surface, as in the case of high energy fractures, healing occurs almost 
exclusively via endochondral ossification (Gerstenfeld et al., 2003b) and delayed and non 
union are common.   
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Non union 
Non union is a process of bone scar formation where the rate of osteogenesis is outweighed 
by osteoclastic bone resorption.  Histologically, it may be evidenced by cessation of 
periosteal and endosteal new bone formation and medullary sclerosis (Marsh, 1998).  Non 
union can be classified as hypertrophic or atrophic (Marsh, 1998, Tseng, 2008 #11).  In 
hypertrophic non union, periosteal new bone formation does occur, but without fracture 
bridging (Marsh, 1998).  Abundant, immature callus formation is usually a consequence of 
inadequate skeletal stabilisation.  Atrophic non union refers to primary failure to initiate a 
fracture healing response and is often due to avascularity of the bone ends with osteoclastic 
resorption (Marsh, 1998).  Failure of callus to bridge the fracture may be followed by a 
fibrous nonunion.    
 
 
1.2.4 Periosteal and endosteal progenitor cells 
 
Osteoprogenitor cells are a heterogeneous population of cells capable of terminal 
differentiation into bone forming osteoblasts.  They include multi-potent mesenchymal 
stromal stem cells and cells partly differentiated down an osteogenic lineage.  The 
periosteum lines the surface of all bones, with the exception of the joints of long bones and 
is attached to bone by Sharpey’s fibres that extend into the outer circumferential and 
interstitial lamellae.   The periosteum consists of dense, irregular connective tissue and is 
subdivided into an outer “fibrous” layer and an inner “cambial” layer.  It is within the 
cambial layer that osteoprogenitor cells reside and are responsible for bone width during 
normal growth.  The structure of the periosteum is shown in Figure 1.6.  The endosteum 
lines the medullary cavity and is histologically and functionally similar to periosteum.  The 
potential role of periosteal and endosteal progenitor cells in fracture healing include the 
direct proliferation and differentiation to form new bone or cartilaginous intermediary 
(Hutmacher and Sittinger, 2003; Zhang et al., 2005), or the recruitment and activation of 
osteoprogenitors via soluble signals (Bostrom et al., 1995; Zhang et al., 2005).  Similarly, 
primary cortical bone cells (osteocytes) which resemble mature osteoblasts, express soluble 
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or cell contact signals to effect osteogenic differentiation of uncommitted progenitor cells 
(Ahn et al., 2006).    
 
 
Figure 1.6 Anatomy of the periosteum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, tibial fracture healing occurs through both intramembranous and 
endochondral ossification.  Factors such as the mechanical environment, vascular supply, 
presence of growth factors and the availability of progenitor cells all influence this process.  
Intramembranous ossification, in particular uses cells from the periosteal and endosteal 
cambial layer.  However, these are not the only progenitor cells available to the healing 
fracture.  Indeed the availability of these cells is in doubt in high energy injuries with 
periosteal stripping.  Alternative sources include mesenchymal stromal cells (Gerstenfeld et 
al., 2003b).  The origin and potential contribution of these cells to endochondral fracture 
healing is discussed below.   
 
 
Figure 1.6 The periosteum and outermost layers of lamellar bone. Osteocytes lie within the lacunae, and 
communicate through cannaliculi.  Loss of the periosteum results in loss of the osteoprogenitor cells from 
the cambial layer.  The outer cortex is also vascularised by the periosteum through Sharpey’s fibres (not 
shown).    
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1.2.5 An overview of mesenchymal stromal cells in fracture healing 
 
While the periosteum, endosteum and bony cortex provides the healing fracture with a pool 
of progenitor cells for new bone formation, populations of adjacently situated, remote and 
circulating multi-potent cells can contribute to new bone formation when exposed to the 
appropriate stimulus.  The two characteristic features of stem cells are the ability for self 
renewal and for multi-lineage differentiation.  Self renewal is either a function of 
asymmetric cell division, giving rise to one cell for renewal and one cell for differentiation or 
each cell may undergo stochastic differentiation or self renewal (Jankowski et al., 2002; 
Zammit et al., 2006).  The theoretical mechanisms by which “stem” cells differentiate 
include:  
 
1. De-differentiation:  Partially differentiated cell regresses towards multi-potency 
before re-differentiation. 
2. Pluri-potency: Cells exhibit the inherent ability to differentiate down multiple 
embryonic lineages. 
3. Trans-differentiation:  Conversion from cell dormancy to activity.  
4. Fusion:  The transfer of genetic signals from one “master” cell to others (Granero-
Molto et al., 2008).   
 
The immunomodulatory function of human mesenchymal stromal cells (MSC) was 
demonstrated by implantation into sheep uteri, where the cells evaded immunosurveillance 
in the long term (Liechty et al., 2000).  Human MSC have been found to suppress polyclonal 
and antigen-specific T cell responses (Dazzi and Horwood, 2007; Dazzi et al., 2006).  This 
property has been used to treat steroid-resistant graft versus host disease following 
haematopoetic stem cell engraftment. Of 55 patients enrolled, 30 showed complete 
reversal and 9 showed improvements (Le Blanc et al., 2008).  Human MSC have also been 
shown to inhibit dendritic cell differentiation (Ramasamy et al., 2007).  Jones et al 
demonstrated that all stromal cells, regardless of “stem” cell potential exert anti-
proliferative effects and regulate T cell homeostasis and that direct cell to cell interactions 
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and soluble factors are implicated in an as yet poorly understood mechanism. They also 
postulate that human MSCs regulate non-immune cell survival and expansion, with 
implications for fracture healing by osteoprogenitor cells (Jones et al., 2007). 
 
Study of the role of hMSC in tissue regeneration is complicated by difficulties in detecting 
hMSC within the repairing tissue and following the differentiation of hMSC within the 
repairing tissue.  Moreover, consistency in terms of the method of identification using 
markers of hMSC is required, along with a consistent approach in the harvest of autologous 
cells and the method of therapeutic addition.  Cell sex differences in the efficiency of tissue 
regeneration in vitro may have implications for the potential therapeutic use of hMSC 
(Deasy et al., 2007).  The nature of the host immune response to transplanted hMSC has yet 
to be fully elucidated (Dazzi et al., 2006).  
 
Embryonic stem cells have been investigated experimentally for their ability to form bone.  
Ahn et al demonstrated that a co-culture of human embryonic stem cells (hES) with primary 
bone cells (derived by culturing bone chips in standard culture media) led to the formation 
of bone nodules and the expression of osteoblast-specific markers in the hES (Ahn et al., 
2006) thereby suggesting a potential for hES in promoting fracture healing.  Karner et al 
confirmed the osteogenic potential of a number of human embryonic stem cell lines, 
describing the theoretical advantage of an embryonic stem cell over autologous stromal 
cells in terms of their pluripotentiality (Karner et al., 2007).   
 
 
1.2.6 Marrow-derived stem cells in fracture healing 
 
Bone marrow contains two distinct progenitor cell populations.  Haematopoetic stem cells 
and mesenchymal stem cells are considered two distinct populations, separated by lineage 
and displaying distinct phenotypic properties (Friedenstein et al., 1968).  Haematopoetic 
stem cells (HSC) maintain blood homeostasis (Wilson et al., 2008).  They have no osteogenic 
potential.  Marrow-derived mesenchymal stem cells, variably known as bone marrow 
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stromal cells, skeletal stem cells, or human BMSC (Kassem and Abdallah, 2008) are a 
heterogeneous population (Granero-Molto et al., 2008) that occupies a niche within the 
marrow (Friedenstein et al., 1968).  Pittenger et al separated these cells from HSC and 
demonstrated the relatively greater potential of these cells to differentiation into bone, 
cartilage and fat, compared with skin fibroblasts (Pittenger et al., 1999).  They repeated the 
experiment using colonies cultured from single cells to confirm the homogeny of the 
purified cells.  The mechanism by which human BMSCs participate in the regeneration of 
mesodermal tissues (including bone) remains obscure (Granero-Molto et al., 2008).  Human 
BMSC appear to have a regulatory role on HSC within the haematopoetic niche (Dazzi et al., 
2006).  
 
Oe et al confirmed that the fracture haematoma contains an abundance of cells that are 
phenotypically similar to mesenchymal stem cells and possess tri-lineage differentiation 
potential (Oe et al., 2007).  Iwamoto et al demonstrated that BMSC harvested from marrow 
in the vicinity of human long bone fractures formed bone when cultured in standard culture 
medium (Iwamoto et al., 1993).   
 
A number of large animal studies have been performed to investigate the healing of tibial 
and femoral defects by BMSCs.  Bruder et al seeded in vitro expanded autologous BMSC 
onto a ceramic scaffold and implanted the scaffold into a 21mm segmental defect in the 
femora of adult female dogs.  They found that all defects containing the BMSC seeded 
scaffold had healed at 16 weeks, while the scaffold alone had united with bone at the 
interfaces but without associated callus formation bridging the fracture.  Atrophic non 
union occurred in all cases in the non implant group (Bruder et al., 1998).   Kon et al 
demonstrated union of a critical sized defect model in sheep tibiae using a ceramic scaffold 
with or without prior seeding of autologous BMSCs.  They demonstrated increased callus 
formation and torsional stiffness in the BMSC seeded group (Kon et al., 2000). A similar 
model as used by Mastrigiacomo et al, using a synthetic scaffold with greater resorptive 
capacity.  The BMSC seeded scaffold again led to cortical union (Mastrogiacomo et al., 
2005b).  Zhu et al demonstrated cortical union of a 25 mm (critical-sized) femoral defect in 
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goats, when a coral scaffold seeded with BMSCs stimulated by osteogenic differentiation 
media was implanted to bridge the defect (Zhu et al., 2006).    
 
An early, clinical study by Connolly et al demonstrated union in 10 of 10 tibial non unions 
treated with percutaneous, autologous marrow injection and intramedullary nailing, and in 
10 of 10 treated with marrow injection and cast immobilisation (Connolly et al., 1989).  
More recently, Hernigou et al demonstrated concentration-dependent healing of atrophic 
tibial non unions with the injection of concentrated autologous marrow (Hernigou et al., 
2005). However, the concentration of BMSC harvested from this technique is limited and 
variable (Gamradt and Lieberman, 2004). The isolation and ex vivo expansion of BMSC with 
re-implantation in a seeded hydroxyapatite ceramic scaffold was demonstrated in a pilot 
study of 4 patients by Marcacci et al (Marcacci et al., 2007).  The bone defects involved the 
ulna in 2 cases and the tibia and humerus in one case each.  They demonstrated radiological 
and clinical union and long term tolerance of the ceramic scaffold in each case. The case 
against using bone marrow as a source of cells to aid fracture healing is that the 
heterogeneous population of primary bone marrow-derived stromal cells contains a very 
low percentage of osteoprogenitors (Musgrave et al., 2000).   
 
 
1.2.7 Circulating stem cells in fracture healing 
 
Kuznetzov et al demonstrated that cells from peripheral blood could be harvested on the 
basis of their adherence to plastic and that an expanded colony of these cells, implanted 
(using a ceramic carrier) into the sub dermis of severe, combined immunodeficient (SCID) 
mice formed bone at 8 weeks (Kuznetsov et al., 2001).  These data suggested that there is a 
pool of circulating stromal cells which therefore have the ability to contribute to fracture 
healing.  Eghbali-Fatourechi et al reasoned that the characteristic adherence of MSC to 
plastic may lead to sampling errors that underestimate their concentration in peripheral 
blood.  Mononuclear cells isolated from blood samples were subjected to in vitro culture for 
bone nodules and flow cytometry for osteoblast specific osteocalcin and alkaline 
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phosphatase.  They found that osteoprogenitor cells were present in significant numbers in 
human peripheral blood and were up to 5 times more abundant in growing adolescents 
than in adults.  Incidentally, they found that adults who had recently sustained a fracture 
had higher circulating levels of these cells than aged matched controls.  This suggested that 
circulating stromal cells were mobilized in response to fracture (Eghbali-Fatourechi et al., 
2005).   
 
Using a rabbit ulnar osteotomy model, Shirley et al tested the hypothesis that these cells 
were derived from marrow.   Fluorescently labelled BMSC were implanted into marrow 
remotely.  The selective migration of BMSC was demonstrated by the presence of 
fluorescently labelled cells in the callus (Shirley et al., 2005).   
 
Using a GFP chimeric mouse model Taguchi et al similarly demonstrated involvement of 
GFP-expressing grafted marrow cells in the fracture callus of a closed femoral fracture 
model at 3 and 5 weeks (Taguchi et al., 2005).  Colnot et al also used a similar murine model 
of marrow engraftment to investigate the contribution of marrow to the healing of a closed 
tibial fracture.   However, while they demonstrated the presence of engrafted marrow-
derived cells in the fracture callus, they did not identify osteogenically or chondrogenically 
differentiated marrow-derived cells.  Instead, the engrafted marrow-derived cells in the 
callus were neutrophils, monocyte-derived cells and osteoclasts (Colnot et al., 2006).   Thus, 
while BMSC appear to mobilise in response to fracture, localising at the fracture site other 
marrow-derived cells do also. 
 
 
1.2.8 The role of muscle-derived stromal cells in fracture healing 
 
In 1965, a seminal paper by Urist reported that demineralised bone matrix exhibited the 
capacity to induce new bone formation when implanted into a muscle pocket in an 
experimental rat model (Urist, 1965; Van de Putte and Urist, 1965). Katagiri et al 
investigated muscle as a source of stromal cells, demonstrating that a myogenic cell line 
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derived from mouse skeletal muscle (C2C12 myoblasts) could undergo osteogenic 
differentiation on stimulation by BMP2 (Katagiri et al., 1994).  Mastogiacomo et al isolated a 
population of cells from human skeletal muscle that exhibited phenotypic characteristics 
similar to BMSC and were capable of tri-lineage differentiation in vitro as well as bone 
formation on a hydroxyapatitie scaffold when implanted in immunodeficient mice 
(Mastrogiacomo et al., 2005b).   Using the pre-plate technique of Rando and Blau (Rando 
and Blau, 1994), Lee et al subdivided a muscle-derived cell population on the basis of the 
adhesion characteristics of the cell.  The final isolate, characterised by poor plastic adhesion 
formed bone in vitro on stimulation with BMP-2 and after transduction with adenoviral 
BMP-2, when injected into the hind limb of a SCID mouse.  Furthermore, when seeded on a 
collagen sponge, these cells repaired a critical sized bone defect model in mouse calvaria.  
The cells were also capable of myogenic differentiation (Lee et al., 2000).  Similarly, Sun et al 
demonstrated the formation of bone using a similar subpopulation of (rat) muscle derived 
cells seeded onto a BMP-2 impregnated gelatin scaffold in vitro (Sun et al., 2005).  Qu-
Petersen further investigated the “muscle-derived stem cell” population isolated from their 
earlier study (Lee et al., 2000) and established that these cells, phenotypically distinct from 
satellite cells, were capable of both endothelial and neural differentiation. Following 
implantation these cells induced a minimal T cell response; in contrast to satellite cell 
fractions of the muscle cell isolate (Qu-Petersen et al., 2002).  Muscle-derived stromal cells 
have also been shown to be capable of reconstituting the haematopoetic compartment 
(Jackson et al., 1999).  The authors speculated that the cells responsible for this finding were 
satellite cells.    
 
Satellite cells, present within muscle are the primary progenitor cells for myogenesis 
(Zammit et al., 2006).  Sampled satellite cell populations are heterogeneous in nature 
(Jankowski et al., 2001; Mastrogiacomo et al., 2005a; Montarras et al., 2005; Zammit et al., 
2006).  Jankowski and colleagues proposed that true muscle-derived stem cells (MDSC) act 
as progenitor cells for quiescent satellite cells, which in turn become activated satellite cells 
and then terminally differentiated myoblasts for the purpose of myogenesis (Jankowski et 
al., 2001).  The fusion of multiple myoblasts forms the contractile unit of muscle; the 
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multinucleated skeletal myofibre (Zammit et al., 2006).  They postulated that MDSC and 
quiescent satellite cells represent two distinct progenitor cell populations capable of 
forming bone.  They later demonstrated the superiority of MDSC (retro virally transduced to 
synthesise BMP-4) in bone formation in vitro and in vivo (Shen et al., 2004a; Shen et al., 
2004b).  More recently, Dellavalle et al isolated pericytes, a phenotypically distinct cell type, 
from human skeletal muscle and confirmed their myogenic potential in vitro and in vivo 
(Dellavalle et al., 2007).  The osteogenic potential of CD146-positive pericytes has long been 
established (Doherty et al., 1998).  
 
 
1.2.9 Adipose and skin-derived stem cells in fracture healing 
 
Lee et al isolated stromal cells from fat and demonstrated both fat and bone formation in 
vitro.  They also demonstrated fat and bone formation in vivo, following re-implantation of 
cells previously exposed to lineage-specific differentiation media (Lee et al., 2003).  Adipose-
derived stromal stem cells were further characterised by Zannettino et al.  They found that 
a population of adipose-derived stromal cells, capable of osteogenic, chondrogenic and 
adipogenic differentiation resembled cells of the perivascular niche and proposed that 
these pericyte-like cells migrated from the capillary walls to the surrounding soft tissues to 
support tissue regeneration and repair (Zannettino et al., 2008).   
 
Toma et al demonstrated that cells harvested from skin samples of mice formed a multi-
potent cell population capable of forming both neural and mesodermal progeny.  These 
cells exhibited a variable ability to form fat, but a limited ability to form smooth muscle 
(Toma et al., 2001). Recently, Lavoie et al demonstrated the osteogenic potential of dermal 
precursor cells in vitro and demonstrated osteogenic differentiation and integration in a rat 
tibial fracture model (Lavoie et al., 2009).   
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1.2.10 Migration of MSC in response to chemical signalling 
 
Chemokines are small molecules with a molecular mass of between 8 and 10 kDa.  Each 
chemokine is structurally similar to others, with most containing 4 cysteine amino acids that 
interact in pairs to form what is known as “Greek key” structure.  The chemokine families 
are divided on the basis of the spacing of the first 2 cysteine residues.  These families 
include the “CC” group, the “CXC” group and the “CX3C” group.  The “CC” group contains 2 
adjacent cysteine amino acids near the amino terminus.  The “CXC” group contains 2 
cysteines separated by another amino acid.  The “CX3C” group (of which only 1 member has 
been identified) contains 2 cycteines separated by 3 amino acids. This molecule is both a 
chemoattractant and a cell adhesion molecule (von Andrian and Mackay, 2000).  
Chamberlaine et al defined the chemokine receptor repertoire of the hMSC to account for 
the capacity of the cell to migrate in response to injury.  The chemokine receptors identified 
on the hMSC were CCR6, CCR9, CXCR3 and CXCR9 (Chamberlain et al., 2008).  The influence 
of the fracture environment on the recruitment of MDSC and the chemokines that influence 
migration of MDSC remain unclear (Croitoru-Lamoury et al., 2007; Ponte et al., 2007).  
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1.3 Promoting Osteogenesis  
 
It has long been recognised that some fractures exhibit delayed and non union.  A means of 
promoting rapid and predictable union remains elusive.  In order to explain the strategies 
currently being pursued it is first necessary to summarise the literature to date and to 
account for past difficulties translating promising research findings into usable therapeutic 
strategies. 
 
 
1.3.1 Historical perspectives 
 
The study by Urist suggested that osteoinductive factors in demineralised bone matrix 
promoted bone formation (Urist, 1965).  This hypothetical growth factor was named bone 
morphogenetic protein (Urist and Strates, 1971).  In 1984 Sampath and colleagues 
demonstrated that extracts from bone matrix were also capable of inducing chondrogenic 
differentiation in mesenchymal cells derived from embryonic skeletal muscle (Sampath et 
al., 1984).  The study of these growth factors has now revealed many bone morphogenetic 
proteins and related factors.  These growth factors are members of the transforming growth 
factor-β super family.   A super family is a group of evolutionarily-related proteins sharing a 
common structure, domain, sequence or function.   
 
 
1.3.2 The TGF-β super family 
 
The TGF-β super family contains four subfamilies.  The two most important are the TGF-β 
subfamily and the decapentaplegic-Vg-related subfamily.  
 
The TGF-β subfamily 
TGF-β is ubiquitously expressed, but found in high concentrations in bone, cartilage and 
platelets (Lieberman et al., 2002).  The TGF-β subfamily includes TGF-β1, TGF-β2 and TGF-β3.  
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TGF-β1 is a 25 kilo Dalton (kDa) protein responsible for proliferation, differentiation and 
apoptosis of many cell types.  Regulatory T-cells secrete TGF-β1 to inhibit the activity of 
cytotoxic T cells and to regulate the production of pro-inflammatory cytokines including 
TNF-α, IL-1β, IL-6 and IFN-γ.  TGF-β1 can increase cytokine expression in immature T-cells. 
TGF-β1 also performs a role in B cell regulation.  The response of cells of the monocyte 
lineage to TGF-β1 depends of the concentration, with low levels promoting cell migration 
and expression of pro-inflammatory cytokines, while high levels have the opposite effect 
(Letterio and Roberts, 1998; Wahl et al., 2006). The receptor for TGF-β1 is TGF-β receptor 1.  
The biological effects are mediated through receptor trans-membrane serine/threonine 
kinases (Dimitriou et al., 2005; Lieberman et al., 2002). TGF-β2 is involved in embryonic cell 
development.  
 
Evidence for the role of TGF-β1 in fracture healing 
During fracture healing, TGF-β1 is expressed in periosteal tissue and in chondrocytes during 
endochondral ossification (Lieberman et al., 2002). Sub-periosteal injections of TGF-β1 
stimulated endochondral ossification of periosteal progenitor cells in a rat model (Joyce et 
al., 1990).  Lind et al demonstrated a small increase in bend strength on 3-point bend 
testing of a rabbit tibial osteotomy model stabilised by internal fixation with a continuous 
infusion of TGF-β (versus no growth factor) for 6 weeks (Lind et al., 1993). Nielsen et al 
demonstrated a significantly greater load to failure on 3-point bend testing of a rat tibial 
fracture model with the injection of 40ng TGF-β every second day for 40 days (versus vector 
only) (Nielsen et al., 1994).  In both cases high and repeated doses of TGF-β were used.  
Thus, the ability of TGF-β to stimulate fracture repair appears limited. 
 
 
1.3.3 Bone morphogenetic proteins 
 
The decapentaplegic-Vg-related subfamily of TGF-β includes the bone morphogenetic 
proteins (BMPs) and the growth and differentiation factors (GDFs).  Of all the members of 
the TGF-β super family, the BMPs have been studied most extensively in relation to bone 
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formation.  Bone morphogenetic proteins share a highly conserved amino acid sequence, 
with seven cysteine amino acid residues at the carboxy terminal portion.  Six of these form a 
rigid “cysteine-knot”.  They also contain N-linked glycosylation sites.     
 
While over 20 BMPs have now been named, BMPs 2, 4 and 7 are thought to play the most 
active roles in bone formation (Kain and Einhorn, 2005; Lieberman et al., 2002).  
Confusingly, some BMPs also have GDF designations.  A summary is provided in Table 1.3. 
 
The hierarchy of bone morphogenetic proteins 
BMP-2 is known to play a critical role in embryonic bone formation.  Mice deficient in BMP-
2 die during development or shortly after birth demonstrating developmental abnormalities 
of skeletal structures and the kidney (Lieberman et al., 2002).  The osteoinductive effect of 
BMP-2 was the first to be established (Kain and Einhorn, 2005).  BMP-2 stimulates 
differentiation of mesenchymal stromal cells to an osteo-chondroblastic lineage.  Cheng et 
al demonstrated that BMPs 2, 6 and 9 were the most potent of the BMPs at inducing 
osteoblast-specific differentiation in pluripotent stem cells while BMPs 2, 4, 6, 7 and 9 
induced osteogenic differentiation of C2C12 preosteoblasts (Cheng et al., 2003).  Expression 
of BMP-2 is elevated on day 1 following fracture; hence BMP-2 has been postulated as the 
initiator of BMP-mediated osteogenic differentiation in uncommitted resident 
mesenchymal cells (Cho et al., 2002).    
 
BMP-7 also plays a critical role in embryonic bone formation, and mice deficient in BMP-7 
also die during development or shortly after birth. Hind limb polydactyly and renal agenesis 
have been described.  In an in vitro study using murine cell lines, BMP-7 was found not to 
promote the osteogenic differentiation of pluripotential stem cells, but was found to 
promote maturation of cells committed to osteogenic differentiation (Cheng et al., 2003).   
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Table 1.3 Summary of the decapentaplegic-Vg-related subfamily of TGF-β 
 
 
Name Alternative name Bone-related function 
BMP 
2 ----- Osteoblast differentiation 
3 osteogenin Antagonist for BMP-mediated osteogenic differentiation 
4 ----- Endochondral bone formation 
5 ----- Signalling molecule of trabecular bone/extra skeletal functions 
6 VGR Osteogenic differentiation of MSC 
7 OP-1 Osteoblast differentiation 
8a ----- Bone homeostasis 
8b OP-2 Bone and cartilage development 
9 GDF-2 Potent experimental orthoptic bone formation (Kang et al., 2004) 
10 ----- Trabeculation of heart muscle 
11 GDF-11 Spinal cord, olfactory, retinal development 
12 GDF-7 Tendon and ligament development 
13 GDF-6 Ectodermal developement 
14 GDF-5 CDMP-1 Chondrocyte maturation 
15 ----- Oocyte maturation/follicular development 
GDF 
1 ----- Mesodermal development/left-right patterning 
3 ----- BMP inhibitor 
8 Myostatin Inhibits myogenic differentiation 
9 ----- Ovarian follicular development 
10 BMP-3b Skeletal morphogenesis 
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Cho et al demonstrated that BMP-7 was expressed from day 14 of a mouse fracture model, 
when ossification of the cartilaginous intermediary first occurred.  Consistent with the 
observation from Cheng et al, they speculated that BMP-7 promoted osteoblast maturation 
(Cho et al., 2002).  The BMP hierarchy is shown in Figure 1.7. 
 
 
Figure 1.7 The osteogenic hierarchy of BMPs on human progenitor cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.4 In vitro studies of osteogenesis using BMPs  
 
Cell lines 
In 1990 Katagiri et al demonstrated that a murine pluripotent (embryonic mesenchymal 
stem) cell line (C3H10T1/2) could be induced to osteogenic differentiation by recombinant 
human BMP-2 (rhBMP-2) (Katagiri et al., 1990).  Using two rat-derived stem cell lines (one 
representative of a multipotent stem cell and the other representative of a pre-osteoblast) 
Yamaguchi et al reported that rhBMP-2 stimulated proliferation and osteogenic 
differentiation of the stem cell-like cell line but not the pre-osteoblast-like cell.  
Furthermore, they established that rhBMP-2 inhibited myogenic differentiation of a clonal 
myoblast line, while TGF-β1 inhibited both myogenic and osteogenic differentiation 
(Yamaguchi et al., 1991). Inada et al demonstrated that BMP-12 and 13 also withdraw 
Figure 1.7 The differentiation of pluripotential mesenchymal stromal cells (MSC) down an osteogenic 
lineage in response to stimulation by BMPs is shown.  Adapted from (Chen et al., 2008) 
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myoblasts from the muscle differentiation pathway, without stimulating osteogenic 
differentiation (Inada et al., 1996).  Katagiri and colleagues later demonstrated that rhBMP-
2 could arrest myogenic differentiation of a clonal myogenic line and redirect the cells 
towards osteogenic differentiation and that the effect was reversible upon discontinuation 
of the BMP stimulus.  They also repeated this finding with rat-derived primary muscle cells 
(Katagiri et al., 1994).  They later demonstrated that rhBMP-2 binding inhibited the 
transcription of myogenic genes (Katagiri et al., 1997).  Like BMP-2, BMP-4 has been shown 
to stimulate osteogenic differentiation of a pre-adipocytic murine marrow stromal cell line, 
although BMP-6 was less capable of stimulating osteogenic differentiation of this cell line 
(Yamaguchi et al., 1996).    
 
O’Shea and colleagues demonstrated that rhBMP-2 and 7 induced C3H10T1/2 cells to an 
endochondral sequence of chondrogenic followed by osteogenic differentiation in a dose 
dependent fashion in the continued presence of BMP.  Upon discontinuation of BMP, the 
cells defaulted to adipogenic lineage (Shea et al., 2003).  
 
Co-culture systems 
Gerstenfeld et al co-cultured C3H10T1/2 cells with hypertrophic and non-hypertrophic 
chondrocytes, calvarial osteoblasts and tendon fibroblasts to determine whether these cells 
of mesodermal origin induce osteogenic differentiation in multipotent stem-like cells.  They 
found that while co-culture with either type of chondrocytes stimulated osteogenic 
differentiation in C3H10T1/2 cells, co-culture with osteoblasts or fibroblasts did not. By 
contrast, BMP-7 led to sequential chondrogenic followed by osteogenic differentiation.  
These data have interesting implications for endochondral fracture healing as bone is 
formed via a cartilaginous intermediary (Gerstenfeld et al., 2002).  Ahn et al cultured cells 
from bone chips and named these cells “primary bone derived cells” (PBD). These PBD's 
induced osteogenic differentiation when co-cultured with human embryonic stem cells and 
expressed BMP-2 and BMP-4 (Ahn et al., 2006). 
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Primary cells 
Kawasaki et al compared the responsiveness of primary cells derived from human bone, 
muscle and skin to rhBMP-2 and parathyroid hormone (PTH).  While all bone and muscle-
derived cells increased ALP expression in response to high (500ng/ml) concentrations of 
rhBMP-2, the magnitude of response was widely variable and did not correlate with 
responsiveness to PTH, suggesting that they promote osteogenic differentiation through 
different pathways (Kawasaki et al., 1998). Using human skeletal muscle-derived cells and 
the pre-plate technique of Rando and Blau to derive cell sub-populations, Musgrave et al 
demonstrated that human muscle-derived cells could be stimulated by rhBMP-2 to undergo 
osteogenic differentiation, especially those selected for their “stem-like” characteristics 
(Musgrave et al., 2002). 
 
 
1.3.5 Animal studies of bone healing using BMPs 
 
Percutaneous injection 
Using a standardised, closed fracture model of a pre-pinned rat tibia, Einhorn et al 
demonstrated that a single percutaneous injection of 80 micrograms of recombinant 
rhBMP-2 resulted in a significant improvement in healing assessed by means of torsional 
biomechanical testing, from 2 week post fracture (Einhorn et al., 2003).   
 
Carrier implantation 
Many studies describe the introduction of BMPs to the fracture environment using 
osteoconductive matrices.  Yasko et al introduced rhBMP-2 on a demineralised bone matrix 
carrier to a rat segmental defect model. Dose dependent radiological, histological and 
mechanical union was observed (Yasko et al., 1992).  Gerhart et al used a similar approach 
in a sheep segmental defect model.  Radiological union had occurred in 14 weeks in all 6 
treated with rhBMP-2, but in none treated with demineralised matrix alone. Bend testing 
revealed that the strength achieved in fractured femora treated with rhBMP-2 approached 
that of the unfractured, contralateral limb at 12 weeks (Gerhart et al., 1993).  One year 
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follow up revealed normal bone remodelling (Kirker-Head et al., 1995).  Cook et al reported 
healing of a canine segmental defect model using rhBMP-7 (Cook et al., 1994); and later in 
ulnar and tibial defect models using non human primates (Cook et al., 1995). 
 
In vivo bone banking was described by Jungushi et al.  Using a rabbit model, they induced 
bone formation in muscle by adding BMP-2 to a pre-formed osteoconductive carrier.  The 
induced bone was then mobilised as a muscle-pedicle auto graft to fill the recipient site 
prior to fixation (Jingushi et al., 2002).  This technique of in-vivo bone banking to produce a 
morphologically controlled vascularised auto bone graft employs all factors which aid bone 
healing, including a vascular supply.  However, there are concerns about the practicalities of 
applying this method in a clinical setting. 
 
Using percutaneous injection or collagen sponge carrier, BMPs were administered as a 
single, supra-physiological dose on day 0.  The typical pharmacokinetic profile of 
recombinant BMP-2 delivered via carriers including type 1 collagen sponge revealed a BMP-
2 spike within a few minutes of implantation and a half life of less than ten minutes.  
Following the spike, secondary release paralleled the degradation of the carrier material, 
where collagen sponge produced a half life in the continuous release phase of between 3 
and 5 days (Uludag et al., 1999; Winn et al., 1999).  The bioavailability of recombinant 
protein administered this way was unclear.   By contrast Cho et al established that the BMP-
2 gene is induced from day 1 following murine fracture, and exhibits a second peak during 
osteogenesis.  By contrast BMP-7 gene expression was restricted to the proliferative, 
osteogenic phase of fracture healing (Cho et al., 2002; Dimitriou et al., 2005).  Hence 
delivery of BMP via carrier did not replicate the temporally spaced, physiological synthesis 
of BMPs.  The argument for endogenously synthesised growth factors is that they are 
presented in a physiologically acceptable manner and persist for longer than exogenously 
applied factors.  This led to the development of a gene therapy approach to BMP 
administration.  
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Gene therapy 
In vivo viral transduction 
Betz et al injected a BMP-2 carrying adenoviral vector directly into critical sized defects of 
rat femora.  At 8 weeks, 75% were healed radiographically with a similar bone mineral 
content to the contralateral femur.  Additionally, 50% were healed histologically and the 
remaining 50% demonstrated evidence of incomplete bridging.  Torsional mechanical 
testing revealed that the healed defects exhibited about one quarter of the strength and 
stiffness of the intact controls (Betz et al., 2006).  Baltzer et al performed a similar study, 
using a lapine segmental defect model. Adenovirus carrying human BMP-2 was introduced 
percutaneously into the segmental defect. Adenoviral vectors expressing TGF-β1 and no 
growth factor were used as controls.  Radiographic and histological healing had occurred by 
12 weeks only in all defects treated with Ad-BMP-2.  Mechanical testing revealed BMP-2 
treated lesions to be stiffer and stronger than when injected with TGF-β1-carrying vector, or 
vector alone (Baltzer et al., 2000).   
 
While the in vivo approach to gene therapy is technically simple, the translational difficulties 
in using this approach include concerns regarding transduction efficiency, tumorigenicity 
and cell specificity (Musgrave et al., 2000).  For this reason an ex vivo approach was 
developed.   
 
Ex vivo implantation 
The ex vivo approach involves focussed transduction of the target cell followed by screening 
for transduction efficiency and reintroduction using an osteoinductive carrier.  The 
technique has been performed using many different models.  Shen et al retrovirally 
transduced muscle derived cells to express BMP-4. Collagen sponge was used to introduce 
the cells to a critical sized femoral defect in a rat model.  They found 12 of 13 healed at 12 
weeks with no healed fractures in the control group.  No significant difference in torsional 
stiffness or energy to failure was observed between the healed samples and the 
contralateral femur (Shen et al., 2004b). Similarly, Wright et al demonstrated that MDSC 
transduced by a retroviral vector encoding BMP-4 developed ectopic bone formation after 
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percutaneous injection into the gastrocnemii of immunocompetent and immunodeficient 
mice (Wright et al., 2002). Li et al adenovirally transduced autologous ADSC to express BMP-
2.  When introduced to a canine ulnar defect model, radiological and histological healing at 
16 weeks was complete for 2 of 6 and exhibited healing of 1, 2 or 3 cortices in the remaining 
3.  None of the ADSC with carrier only controls had healed (Li et al., 2007a).   Similarly, Xu et 
al adenovirally transduced autologous BMSC to express BMP-2.  When introduced to an 
externally fixed goat tibial segmental defect model, radiographic healing was again faster.  
The maximum compressive load endured by the callus was significantly higher in the test 
specimens than in the controls.  A temporary cellular and persistent humoral immune 
response was identified (Xu et al., 2005).  
 
Several studies have investigated the suitability of human stromal cells for viral 
transduction.  Musgrave et al transduced human MDSC with an adenoviral vector encoding 
BMP-2.  When injected into the hind limbs of SCID mice, ectopic bone formation was 
observed radiologically and histologically (Musgrave et al., 2002).  Lee et al described 
closure of a SCID murine calvarial defect over 4 weeks when MDSC adenovirally or 
retrovirally transduced to synthesise BMP-2 were added to the defect on a collagen sponge 
carrier.  They found that untreated MDSC on collagen sponge did not heal the defect.  Using 
in situ hybridisation, they established that only a very small fraction of the newly formed 
bone contained transplanted cells indicating that the technique works principally by the 
delivery of growth factor (Lee et al., 2002).  Petersen et al reported healing of an athymic 
rat femoral defect by human adipose-derived stromal cells transduced by an adenoviral 
vector encoding BMP-2 (Peterson et al., 2005).  
 
Peng et al retro virally transduced MDSC with BMP-4 alone, VEGF alone and BMP-4 with 
VEGF.  Using a critical sized calvarial defect model in a mouse, they reported that VEGF 
potentiated ossification of the defect by BMP-4 expressing MDSC.  VEGF alone did not 
stimulate osteogenesis (Peng et al., 2002).  
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While these studies yielded therapeutic options, the translational potential of ex vivo gene 
therapy is unclear owing to logistic difficulties with the timely isolation, culture and viral 
transduction of autologous muscle derived cells for transplantation, as well as the potential 
allogeneity and tumorigenicity of the implanted cells (Huang and Yang, 2009). The 
responsiveness of humans to virally transduced stromal cells expressing BMPs has yet to be 
fully established.   
 
 
1.3.6 Clinical trials of BMPs in fracture healing 
 
Fridelaender et al prospectively randomised 124 tibial non unions to receive internal 
fixation and either bone auto graft or rhBMP-7 on a bone-derived bovine type 1 collagen 
carrier (at a concentration of 3.5mg rhBMP-7 per gram of carrier).  At 9 months, 81% of the 
non unions treated with BMP-7 and 85% of those treated with auto graft had achieved 
clinical union.  Radiological union was achieved in 75% versus 84% respectively (not 
statistically significant).  While there was no significant difference between groups, the use 
of the BMP-7 implant negated the donor site morbidity associated with auto graft harvest 
(Friedlaender et al., 2001).  The BMP-2 evaluation in surgery for tibial trauma (BESTT) group 
prospectively randomised 450 open tibial fractures to receive intramedullary nailing and 
soft tissue reconstruction with or without the addition of rhBMP-2 in a collagen carrier.  
Two concentrations, 0.75mg/ml and 1.5mg/ml of rhBMP-2 were used.  The study 
demonstrated significantly faster fracture healing in the higher dose group, in terms of 
percentage fractures healed (as determined by clinical and radiological criteria) from 14 
weeks post injury.  There was no significant difference in union times between the lower 
BMP-2 concentration group and the control group (Govender et al., 2002). A non 
randomised study of distal tibial fractures treated with external fixation with or without the 
addition of rhBMP-7 (in a collagen carrier) reported a significantly reduced mean time to 
union (15.7 vs. 23.5 weeks) with the addition of BMP-7, when compared with a case 
matched group (Ristiniemi et al., 2007a).  A control for the osteoconductive carrier was not 
performed in either study.  Geesink et al demonstrated that 2.5mg recombinant human 
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BMP-7 on a type 1 collagen carrier and demineralised bone matrix were similarly able to 
bridge a  1.5cm human fibular osteotomy defect at 6 months and at 1 year (Geesink et al., 
1999).   
 
Criticisms of these studies include the same criticisms of animal studies based on carrier 
delivery of recombinant BMPs.  The delivery of BMPs on collagen sponge mimics neither the 
local concentration nor temporal expression profiles produced in response to fracture.  
Supra-physiological concentrations saturate surrounding tissue with the risk of systemic 
exposure (Termaat et al., 2005).   Moreover, the formation of cyst like voids has been 
reported when using supra-physiological concentrations of rhBMPs (Lieberman et al., 2002).  
BMPs also up-regulate osteoclasts, and it is unclear whether osteoclastic bone resorption is 
a coupled feature of bone formation in fracture healing or represents an unwelcome side 
effect of BMP administration (Einhorn, 2003; Lane, 2001).  It seems likely that the former is 
true as this would make sense physiologically.  Moreover, these studies suggest that BMPs 
under perform in human studies relative to primitive mammalian models (Lane, 2001).   
 
While most studies focus on augmenting a compromised fracture healing environment, 
there exists a challenge to accelerate normal fracture healing as this represents a true test 
of our ability to manipulate the physiology of fracture healing based on an understanding of 
the process (Bostrom et al., 1999).  
 
 
1.3.7 Other growth factors involved in fracture healing 
 
Fibroblast growth factor 
Fibroblast growth factor is produced by cells of the monocyte lineage, mesenchymal cells, 
osteoblasts and chondrocytes (Dimitriou et al., 2005).  Of the 2 common isoforms, FGF-2 (or 
basic-FGF) has been studied most extensively.  FGF-2 is angiogenic and mitogenic for 
osteoprogenitor cells, chondrocytes and epithelial cells (Bostrom et al., 1999; Dimitriou et 
al., 2005; Lieberman et al., 2002).   
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Using an externally fixed, 3 mm segmental tibial defect model in rabbits, Kato et al 
demonstrated that a single percutaneous dose of FGF-2 (>100µg) increased bone volume 
and mineral content after 5 weeks (Kato et al., 1998).  Using an internally fixed canine tibial 
osteotomy model, Nakamura et al demonstrated that a single injection of 200µg of FGF-2 
with carrier increased the periosteal osteoprogenitor population at 2 weeks and resulted in 
increased callus area at 4 weeks and bone mineral content at 8 weeks.  Load to failure on 3-
point bend testing was increased at 16 weeks and 32 weeks (Nakamura et al., 1998).  Using 
a 1-mm osteotomy defect in baboon fibulae, Radomsky et al demonstrated increases in 
callus volume and load to failure when the osteotomy was treated with a single injection of 
FGF-2.  The contralateral fibulae were used as controls (Radomsky et al., 1999). Using an 
internally fixed rat femoral fracture model, Nakajima et al investigated the influence of FGF-
2 on callus maturation. They found that while FGF-2 increased callus volume, maturation 
towards bone was not accelerated, with no difference in callus mineralisation or load to 
failure, and similar temporal expression patterns of osteoprotegerin (OPG), a marker for 
late osteogenic differentiation (Nakajima et al., 2007).  Therefore, while FGF-2 promotes the 
proliferation of osteoprogenitor cells, its role in promoting fracture healing remains 
inconclusive. 
 
Growth hormone/Insulin-like growth factor 
Insulin-like growth factor is synthesised by the liver, as well as chondrocytes, osteoblasts 
and endothelial cells.  Growth hormone from the anterior pituitary stimulates the release of 
IGFs.  IGF-1 is highly up-regulated during early fracture healing, as established by 
transcriptional profiling (Li et al., 2005a).  In a rat tibial fracture model, twice daily injections 
of synthetic human growth hormone commencing prior to fracture and continuing to end 
point harvesting were associated with a higher load to failure on biomechanical testing 
relative to controls (Bak et al., 1990).  Conversely, using a rabbit tibial osteotomy model, 
Carpenter et al demonstrated no difference on biomechanical testing with 5 times weekly 
intramuscular injections of human growth hormone, despite higher serum levels of IGF-1 
(Carpenter et al., 1992).  Thaller et al demonstrated (intramembranous) healing of a critical 
sized rat calvarial defect at 6 weeks with the continuous, subcutaneous infusion of IGF-1 
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(Thaller et al., 1993).  Using an internally fixed tibial segmental defect model in Yucutan 
micropigs, Raschke et al demonstrated increased torsional failure load at 6 weeks following 
daily subcutaneous injections of recombinant porcine growth hormone at 100µg/kg/day. 
Serum IGF-1 levels increased up to around 400% in the treatment group (Raschke et al., 
2001). Using the same model, Kolbeck et al established that the treatment group had larger 
callus areas but not increased mineralisation (Kolbeck et al., 2003).  In each case supra-
physiological levels of growth hormone were used.   
 
Platelet-derived growth factor 
Platelet-derived growth factor (PDGF) is synthesised by platelets, cells of the monocyte 
lineage, endothelial cells and osteoblasts and is a potent mitogen for cells of mesenchymal 
origin (Dimitriou et al., 2005).  Released from degranulating platelets during early fracture 
healing, PDGF attracts neutrophils and macrophages to the fracture site.  These cells serve 
as an ongoing source of PDGF, mediating inflammatory and mesenchymal cell chemotaxis 
and angiogenesis (Hollinger et al., 2008).  A pilot study by Nash et al, using a rabbit tibial 
osteotomy model with 80µg PDGF-BB (the most commonly studied isoform) added on a 
collagen sponge, revealed that the osteotomies treated with PDGF exhibited more 
advanced ossification of callus on histology at day 28 as well as load to failure on 3-point 
bend testing which was comparable with the unfractured, contralateral tibiae (Nash et al., 
1994). A geriatric, osteoporotic rat tibial fracture model treated with recombinant human 
PDGF revealed that in treated rats, torsional strength was similar to the unfractured 
contralateral limbs at 5 weeks, while the control limbs (carrier only) were significantly 
weaker (Hollinger et al., 2008). A randomised trial of PDGF in a synthetic matrix carrier for 
the reconstruction of osseous defects in the periodontal space demonstrated a significant 
gain in percentage bone fill and clinical attachment level (CAL; the height of the gingival 
attachment to the dental enamel) at 6 months at low and high concentrations and an 
increase in the CAL at the low concentration at 3 months.  This demonstrated an optimal 
concentration dose response (Nevins et al., 2005).  PDGF modulates the responsiveness of 
osteoprogenitor cells to BMPs and enhances IGF-1 signalling (Hollinger et al., 2008).  PDGF 
has also been shown to stimulate the osteoclast inhibitory factor osteoprotegerin (OPG) 
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expression by osteoblasts, suggesting a role in regulating osteoclastogenesis and bone 
resorption in remodelled callus (McCarthy et al., 2009).   
 
Growth and differentiation factor-5 
Growth and differentiation factor-5 (GDF-5), also known as BMP-14, is essential for 
appendicular skeletal and joint development (Buxton et al., 2001). It is maximally expressed 
from day 7 to 14 in a murine fracture model, which corresponds with chondrocyte 
maturation in the developing cartilaginous intermediary (Cho et al., 2002).  Using a closed 
femoral fracture model in a GDF-5 knockout mouse, delays in peak callus formation and 
mineralisation of around 2 weeks were demonstrated, which were attributed to delayed 
callus maturation.  The translational potential of this work is unclear as it does not initiate 
endochondral fracture repair but instead promotes callus maturation.  Hence timing of 
administration might prove difficult in practice.      
 
Parathyroid hormone 
Parathyroid hormone (PTH) is the regulatory hormone of serum calcium.  PTH regulates 
serum calcium, in part by mobilising calcium stores in bone and is therefore a protein of 
bone homeostasis.  PTH inhibits osteoblast apoptosis and proliferation and promotes 
osteoblastic differentiation.   PTH also promotes differentiation of pre-osteoclasts and is 
postulated to promote osteoclast-mediated stimulation of bone formation by osteoblasts 
(Khosla et al., 2008).  The balance between bone formation and resorption is dependent on 
the pattern of administration.  Whilst continuous administration of the PTH peptide PTH 1-
34 deceases bone mass through up-regulation of osteoclastic activity, transient doses have 
a net anabolic effect (Li et al., 2007b, Komarova, 2005 #325).   
 
Using a rat tibial fracture model, Andreassen et al demonstrated that when PTH hormone 
was administered at a dose of 200µg/kg/day subcutaneously, load to failure increased by 
75% at day 20 and 175% at day 40 compared to vehicle only controls. A smaller dose 
(60µg/kg/day) increased load to failure by 132% at day 40.  There was no significant 
difference at day 20. The bone mineral content of the fracture callus was also increased.  
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Interestingly, they also observed dose dependent increases in the bone mineral content of 
the contralateral tibiae (Andreassen et al., 1999).  Using a rat femoral fracture model with 
daily injections of PTH subcutaneously at 10µg/kg or vehicle only, Nakajima et al 
demonstrated higher bone mineral content, bone mineral density and load to failure at days 
28 and 42 when PTH was administered.  Histological and immunohistochemical analyses of 
calluses at earlier time points revealed that PTH administration was associated with an 
increase in subperiosteal osteoprogenitors by day 2 and was accompanied by increases in 
ALP, osteocalcin and IGF-1 mRNA.  Osteoclasts were also maximally present in the callus at 
day 7.  This study implied that intermittent PTH enhanced callus formation by stimulating 
osteoprogenitor proliferation and differentiation and osteoclastogenesis during the phase 
of callus remodelling (Nakajima et al., 2002).  Using the same model, Alkhiary et al 
compared 5µg/kg/day with 30µg/kg/day subcutaneous PTH injections.  At day 21 they 
reported increased bone mineral content, bone mineral density and torsional strength in 
the high dose group only.  At day 35, both treatment groups exhibited increased bone 
mineral content and bone mineral density but the torsional strength of the low dose 
treatment group remained similar to the control group.  The enhanced bone mineral density 
in the high dose treatment group persisted 49 days after cessation of treatment (Alkhiary et 
al., 2005).  Subcutaneous daily injections of PTH 1-34 and 1-84 have already been shown to 
promote bone density in clinical trials (Black et al., 2003; Finkelstein et al., 2003).  
 
Sclerostin 
Sclerostin, synthesised by mature osteocytes, is a negative regulator of bone formation.  
Sclerostin inhibits BMP-induced osteoblastic differentiation indirectly by antagonising the 
Wnt signalling pathway (Li et al., 2005b) and not by inhibiting BMP signalling directly (van 
Bezooijen et al., 2007). In an experimental model using cynomolgous monkeys, antibody 
inhibition of scerostin was associated with increases in bone density, trabecular thickness 
and bone strength (Ominsky et al.).  Sclerostin expression is influenced by PTH  (Bellido et 
al., 2005) which may, in part, explain PTH-mediated changes in bone density using the 
models described above.  
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Matrix metalloproteinases/VEGF 
Matrix metalloproteinases (MMPs) digest collagen in cartilage and bone.  Cartilage matrix 
degradation is vital to endochondral ossification.  MMP-9 and MMP-13 are thought to be 
particularly important for both normal skeletal development and cartilaginous remodelling 
as fracture healing in MMP-9 and MMP-13 deficient mice is impaired (Colnot et al., 2003; 
Kosaki et al., 2007).  As cartilage matrix degradation is coupled with neovascularisation 
these MMPs mediate vascular invasion of hypertrophic callus (Colnot et al., 2003; Kosaki et 
al., 2007).  Colnot et al further demonstrated that the impaired fracture healing observed in 
the MMP-9 knockout could be rescued by the exogenous administration of recombinant 
human VEGF, which was hypothesised to stimulate the recruitment and differentiation of 
chondroclasts and endothelial cells (Colnot et al., 2003).  Using an internally fixed, 
periosteally stripped murine femoral fracture model, Street et al demonstrated that 
systemic inhibition of VEGF using a soluble receptor decreased angiogenesis, bone 
formation and callus mineralisation, as assessed by micro CT, and that exogenous 
administration of VEGF increased callus volume and mineralisation.  They also 
demonstrated bridging at 28 days of a critical sized radial defect rabbit model, using a 
continuous infusion of VEGF for the first 7 days. Finally, a dose dependent increase in bone 
nodule formation and ALP expression was demonstrated in human osteoblasts treated with 
VEGF in vitro (Street et al., 2002).  VEGF, synthesised by osteoblasts, is thought to act in an 
autocrine fashion.  Previous studies by our group have demonstrated a biphasic response in 
VEGF synthesis following fracture.  Specifically, VEGF expression peaks at day 3 
corresponding to the peak of the post-fracture inflammatory response (Harry, 2006).  A 
second peak is observed at day 7 when the cartilaginous intermediary is replacing the 
fracture haematoma (Harry, 2006).  Thereafter, VEGF expression falls, before gradually 
rising throughout the remaining fracture healing period to day 28 (Harry, 2006).  These 
studies highlight the importance of neovascularisation and cartilage formation and 
remodelling in endochondral fracture healing (Gerstenfeld et al., 2003b).   
 
In summary, a number of growth factors, hormones and enzymes influence fracture healing 
by their influence on bone, cartilage and vascular formation and breakdown. However, 
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growth factor synthesis in fracture healing is tightly regulated and translating these findings 
into therapeutic strategies is challenging.  Lessons from the study of BMPs in fracture 
healing suggest that growth factor synthesis, including up-stream regulation, must be 
understood from a physiological point of view.  As fracture healing is initiated by an 
inflammatory response it is proposed that inflammatory signals regulate growth factor 
synthesis (Gerstenfeld et al., 2003b; Tsiridis and Giannoudis, 2006).   However, the nature of 
the inflammatory response and the influence of that response on the tissues must be 
understood. 
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1.4 Inflammation and fracture healing  
 
Inflammation is complex biochemical and cellular process the purpose of which is to protect 
the body from injurious stimuli and to initiate tissue repair (Gallin and Snyderman, 1999).  
Classically, it is characterised by heat, swelling, redness, pain and loss of function.  In 
response to injurious stimuli (such as long bone fracture) the body initiates both innate and 
adaptive immune responses.   
 
 
1.4.1 Cells of the adaptive immune response 
 
The adaptive immune response is comprised of B lymphocytes (B cells), T lymphocytes (T 
cells), natural killer cells (NKT cells) and lymphoid dendritic cells.  B cells make antibodies to 
antigens.  B cells circulate in blood and lymphatic tissue, performing immune surveillance.  
The receptor on each B cell is specific for one antigen.  B cells recognise antigen in their 
native forms.  Binding of antigen to a B cell receptor promotes B cell maturation.  The 
immature B cells become mature “plasma cells” which synthesise antibodies unique to the 
antigen that triggered the response.   This is termed humoral immunity.  T cells (T 
lymphocytes) are cells of the cellular immune response.  T cells recognise antigen in their 
processed forms.  Processed antigens are expressed on major histocompatibility (MHC) II 
molecules on antigen presenting cells.  T cells synthesise biochemical signals called 
cytokines that mediate T cell immune functions.  The main types of T cells are as follows: 
 
 Helper T cells promote both innate and adaptive immune responses by other cells. 
 Cytotoxic T cells kill virally infected or damaged cells, including tumour cells 
 Memory T cells recognise further exposure to a previously encountered antigen, 
enabling a rapid immune response to be mounted 
 Regulatory T cells regulate T cell-mediated immunity.  They can inhibit T-cell 
mediated immune responses 
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Cells of the adaptive immune response are derived from a common lymphoid progenitor 
cell which, in turn is derived from haematopoetic stem cells (HSC). Haematopoetic cell 
lineage is shown in Figure 1.8. 
 
 
1.4.2 Cells of the innate immune response 
 
Unlike the adaptive immune response, the innate immune response does not rely on 
antigen recognition and specificity.  Rather, cells of innate immunity respond to antigenic 
challenges but exposure does not confer protection in the event of a future exposure.  The 
functions of the innate immune system are: 
 
1. The recruitment of further cells of the innate immune system by means of cytokine 
signals 
2. Activation of complement cascade to kill bacteria directly 
3. Identification of foreign material to aid clearance, by a process known as 
opsonization 
4. Presentation of antigenic material to the adaptive immune system   
 
Cells of the innate immune response include monocytes, macrophages, neutrophils and 
myeloid dendritic cells.  The term myeloid-derived suppressor cells is sometimes given to a 
heterogeneous population comprising immature versions of these cell types which 
collectively suppress T cell mediated adaptive immune responses.  Hence, the innate and 
adaptive immune responses regulate each other (Gabrilovich and Nagaraj, 2009).    
 
Natural killer (NKT) cells recognise phospholipid and glycolipid antigens presented on the 
HLA class 1-like molecule CD1d, expressed on antigen presenting cells.  These cells secrete 
cytokines within a few hours of activation mediating both innate and adaptive immune 
responses (Kronenberg, 2005).  They can also kill cells directly. NKT cells can respond rapidly 
to antigen presentation without the need for differentiation or clonal expansion 
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(Kronenberg, 2005).  These cells may be regarded as belonging to both the innate and 
adaptive immune systems.  Lymphoid dendritic cells promote both innate and adaptive 
immune responses and may provide a means of communication between the two immune 
responses (Austyn, 1987).   
 
 
Figure 1.8 The haematopoietic stem cell lineage  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monocytes 
Monocytes are types of white blood cell synthesised in bone marrow from haematopoetic 
stem cell precursors called monoblasts.  These cells can phagocytose debris and pathogens, 
either by a process of opsonization, using antibody or complement binding to the foreign 
material, or they can bind directly.  Two types of monocytes have been described.  The first 
Figure 1.8 Cells of the innate and adaptive immune systems are involved in early fracture healing.  Cells of 
innate immunity are derived from a common myeloid progenitor cell.  Cells of adaptive immunity are 
derived from a common lymphoid progenitor cell. 
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expresses high levels of the CD14 cell surface receptor (the CD14++ monocyte) (Moniuszko 
et al., 2009).  The second, also known as a pro-inflammatory monocyte, expresses low levels 
of CD14 but in addition expresses CD16 (the CD14+CD16+ monocyte).  The CD14++ monocyte 
is the source of the CD14+CD16+ monocyte, which is a fully mature version of the cell.  The 
CD14+CD16+ monocytes express TNF-α, among other cytokines, in response to injury or 
infection (Belge et al., 2002).  Around one half of all mature monocytes are stored in the 
spleen. After migrating to the tissues, circulating monocytes can differentiate into 
macrophages or dendritic cells.  These cells exhibit site specificity.   
 
Macrophages 
Following extravasation of monocytes, differentiation into macrophages occurs.  The type of 
macrophage is specific to the tissue, where osteoclasts (bone) and alveolar macrophages 
(lung) are examples of fixed, tissue specific macrophages.  Macrophages play a role in both 
the innate and adaptive immunity.  Following tissue injury monocyte chemotaxis and 
differentiation provide a pool of macrophages to response to tissue damage and to signal 
further inflammatory responses through the expression of pro-inflammatory cytokines TNF-
α, IL-1 and IL-6 (Gerstenfeld et al., 2003b). Additionally, the cells phagocytose debris and 
pathogens, presenting antigenic material to T cells and B cells.  Hence, they are antigen 
presenting.  In health, the fixed, tissue specific macrophages remove cellular debris and 
pathogens from sites of exposure such as the lung, kidney, spleen etc.  Mobile macrophages 
are recruited from circulating monocytes in the event of a pathogenic challenge.   
 
Myeloid dendritic cells 
Monocytes can also differentiate into myeloid dendritic cells.  These cells are the most 
potent of the antigen presenting cells (Steinbrink et al., 2009).  On contact with antigenic 
material, they process the antigen for presentation, and migrate to lymphoid tissue to 
present the antigenic material to T (helper) cells.  Myeloid dendritic cells differ from 
macrophages not only in their migratory capacity but also in that while macrophages 
activate only memory T cells, myeloid dendritic cells can activate naïve T cells (Steinbrink et 
al., 2009).  Their ability to activate T (helper) cells is mediated by pro-inflammatory 
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cytokines (Jonuleit et al., 1997).  Myeloid dendritic cells express TNF-α. This cytokine 
promotes dendritic cell maturation and down-stream expression of IL-1β and IL-6 
(Banchereau and Steinman, 1998; Gerstenfeld et al., 2003b; van Lieshout et al., 2005).   
 
Neutrophils 
Neutrophil granulocytes or “neutrophils” are the most abundant type of leukocyte in 
mammals accounting for 50-60% of all circulating leukocytes (Smith, 1994).  Neutrophils 
patrol the circulation as the first line of defence against bacterial invasion.  They are also 
among the first cells to respond to tissue damage, chemotactic factors from invading 
bacteria and inflammatory signals from other neutrophils (Smith, 1994). They have a short 
life span with a mean of 12 hours in circulation.  Following activation, they migrate into the 
interstitium, surviving for 1-2 days (Smith, 1994).  Neutrophils synthesise cytokines including 
TNF-α, IL-1 ad IL-6, recruiting and activating other cells of the immune system.  Additionally, 
neutrophils phagocytose foreign material and debris and degranulate, releasing 
antibacterial substances into the inflammatory milieu.  A third mechanism for killing 
bacteria is the neutrophil extracellular trap (NET) comprised of chromatin and serine 
proteases that also kill bacterial and act as physical barriers to bacterial spread (Brinkmann 
et al., 2004).  
 
 
1.4.3 Innate and adaptive immune cells in fracture healing 
 
Andrew et al studied the presence of inflammatory cells in normal human fracture callus.  
They found that macrophages were abundant in the early (inflammatory) phase of fracture 
healing, but that the number reduced during bone formation.  They reported that 
macrophages, while present in large numbers in granulation tissue, were present in much 
smaller numbers around debris and in areas of new bone formation suggesting that they 
may have played a regulatory role in early fracture healing (Andrew et al., 1994).  It is 
unclear if these cells migrated to the fracture site, or if they were resident osteal tissue 
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macrophages “OsteoMacs”.  These cells reside in periosteal and endosteal tissues and have 
been shown to promote osteoblast mineralisation in vitro and in vivo (Chang et al., 2008).   
Andrew et al also identified the presence of myeloid dendritic cells within the inflammatory 
infiltrate and T cells in areas of granulation tissue but not in areas of active bone formation 
(Andrew et al., 1994).  They postulated that as T cells appeared to be actively recruited to 
the fracture haematoma and granulation tissue, but not to areas of new bone formation, 
they regulated fracture healing by cytokine production (Andrew et al., 1994).  Szczesny et al 
indentified the presence of CD68+ macrophages, HLA-DR+ expressing dendritic cells, CD4+ 
and CD8+ T-lymphocytes, and stromal cells in healing fracture calluses.  Importantly, they 
identified statistically fewer dendritic cells, macrophages and T-lymphocytes in non-healing 
fractures (Szczesny et al., 2007).  A recent transcriptomic study of fracture healing 
suggested that genes associated with T-cell receptor signalling underwent transient 
activation, while others were down-regulated (Bais et al., 2009).  By contrast, one abstract 
in the literature reported that SCID mice (lacking both T cells and B cells) exhibited 
improved healing as determined by 4-point bend testing, using a murine closed tibial 
fracture model (Gaston et al., 2006). However, this abstract was not subsequently 
published, and the reported findings should be interpreted with caution. 
 
As these cells mediate their actions through cytokines, and in particular the pro-
inflammatory cytokines TNF-α, IL-1 and IL-6 a more detailed discussion of the role of these 
cytokines in fracture healing is necessary  
 
 
1.4.4 An overview of pro-inflammatory cytokines 
 
Cytokines (a category of signalling molecules used in cellular communication) are proteins, 
peptides or glycoprotein’s secreted mainly by cells of the immune system, with an 
immunomodulatory function.  They are autocrine (binding to cells of the same type that 
produced the cytokine) or paracrine (short range mediators acting on adjacently situated 
cells of different types) and thus maintain site specificity, which is vital to their function.  
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While they are integral to both innate and adaptive immune responses, they are also 
involved in tissue development, and tissue regeneration following injury.    
 
1.4.5 TNF-α – introduction and structure 
 
Tumour necrosis factor-alpha (TNF-α) is one of over forty ligands which are members of the 
TNF superfamily (Ware, 2003).  These ligands are type II (N-terminus) transmembrane 
proteins containing a TNF homology domain at the C-terminus (Ware, 2003).   It is 
synthesised as a 26 kDa type II transmembrane protein.  The soluble form of the cytokine is 
produced from the membrane-integrated form via proteolytic cleavage by the enzyme TNF-
α converting enzyme (TACE), also known as ADAM17.  The product of proteolytic cleavage is 
a 17 kilo Dalton protein (Vandenabeele et al., 1995).   The name “tumour necrosis factor” 
was first given to a protein produced by macrophages that exhibited the ability to kill mouse 
fibrosarcoma cells.  A cytotoxic protein produced by lymphocytes had earlier been 
described and named lymphotoxin.  The structure of the two proteins was later found to be 
similar, and the names were changed to TNF-α and TNF-β to reflect the structural and 
functional homology.  Homology is conserved through mammalian species, with human 
TNF-α more than 99% similar to murine TNF-α.  Human TNF-α binds to the murine P55 
receptor but not to the P75 receptor (Vandenabeele et al., 1995). 
 
TNF-α is synthesised by most cells, but especially those of the monocyte lineage, namely 
macrophages and dendritic cells in response to inflammatory stimuli (Bazzoni and Beutler, 
1996; Carpentier et al., 1998; Vandenabeele et al., 1995) and T lymphocytes (Van Antwerp 
et al., 1996).  Further cells producing TNF-α include mast cells, endothelial cells, fibroblasts 
and adipose tissue. TNF-α has a broad spectrum of biological activity with potent pro-
inflammatory effects (Bazzoni and Beutler, 1996).   TNF-α is an important regulatory 
cytokine for both innate and adaptive immune responses. 
 
TNF-α contributes to the normal regulatory process of bone turnover by stimulating 
osteoclastic bone resorption (Bertolini et al., 1986).  Kobayashi et al reported that TNF-α 
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stimulated murine osteoclastic differentiation in the presence of M-CSF, an effect that was 
not inhibited by OPG (osteoclastogenesis inhibitory factor) (Kobayashi et al., 2000).  TNF-α 
promotes osteoclastic differentiation from monocyte/macrophage precursors and activates 
mature osteoclasts by regulating expression of RANKL on osteoblasts and stromal cells 
(Boyle et al., 2003; Jimi et al., 2004).  Furthermore, inhibition of TNF-α, but not IL-6, 
prevented oophorectomy-associated osteoporosis in a murine model (Kimble et al., 1997).  
When added to osteogenic media (containing ascorbic acid and/or β-glycerolphosphate), 
TNF-α was also shown to inhibit osteogenic differentiation of osteoblasts; an effect 
mediated through the P55 receptor (Gilbert et al., 2005).  Similar effects were seen with 
osteoprogenitor (rat calvarial) cells when the concentration of TNF-α added was 10-
100ng/ml or when any TNF-α was added after day 7 (Gilbert et al., 2000).  Lacey et al 
demonstrated that at >1ng/ml TNF-α inhibits osteogenic differentiation of murine 
mesenchymal stromal cells cultured in osteogenic media (Lacey et al., 2009).   
 
However, in a co-culture system of osteoblasts and marrow-derived cells (acting as a 
precursor population for osteoclasts), Balga et al demonstrated that at a concentration of 
1ng/ml, TNF-α decreased osteoclast number by >90%.  At concentrations greater than 
1ng/ml, osteoclastogenesis sharply increased.  Furthermore, supernatant derived from 
osteoblasts cultured in the presence of TNF-α and vitamin D3 (1,25(OH)2D3) inhibited 
osteoclastogenesis, an effect that was not reversed by the addition of antibodies to TNF-α.  
These findings suggest that TNF-α may regulate the equilibrium between bone resorption 
and deposition and that the concentration of TNF-α is critical to that equilibrium (Balga et 
al., 2006).  Frost et al reported that both TNF-α and IL-1β promoted proliferation of human 
osteoblast cells.  They further established that very low concentrations of TNF-α were 
required and that above 30pM, TNF-α mediated proliferation diminished rapidly.  
Proliferation was also impaired by prolonged exposure to TNF-α in culture.  They did not use 
osteogenic media (Frost et al., 1997). A dose response study examining osteogenic 
differentiation of human mesenchymal stromal cells cultured in standard (non-osteogenic) 
culture media with the addition of TNF-α is currently lacking.   
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Human adipose-derived stromal cells were stimulated to undergo osteogenic differentiation 
in differentiation media when agonists for the Toll-like receptor 2 (TLR-2) (peptidoglycan-
PGN) and TLR-4 (lipopolysaccharide-LPS) were added (Hwa Cho et al., 2006).  Both PGN and 
LPS stimulated TNF-α expression by the cells (Hwa Cho et al., 2006).  
 
 
1.4.6 TNF-α receptors and signalling  
 
TNF-α binds to two receptors, namely TNF-α receptor 1 (TNFR1), also known as P55, and 
TNF-α receptor 2 (TNFR2), also known as P75 (Locksley et al., 2001).  Both receptors are 
transmembrane type 1 receptor proteins.  TNF-α receptor 1 is expressed by most tissues.  
Ligands for TNF-α receptor 1 include both the membrane-bound and soluble forms of TNF-
α.  By contrast, TNF-α receptor 2 is expressed mainly on the membranes of cells of the 
immune system and responds only to the membrane-bound form of the cytokine.  P55 is 
constitutively expressed and poorly inducible by pro-inflammatory signals (Vandenabeele et 
al., 1995).  P75 is inducible.  P75 can bind TNF-α, delivering it to the lower affinity P55 
without signal transduction (Vandenabeele et al., 1995).  This permits the P75 receptor to 
initiate a cell response to inflammatory stimuli at much lower concentrations of TNF-α.  
However, cell signalling in response to TNF-α is via the P55 receptor wherever it is 
expressed sufficiently (Vandenabeele et al., 1995).  The TNF-α signalling pathway is shown 
in Figure 1.9.  
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Figure 1.9 TNF receptor 1 (P55) and receptor 2 (P75) signalling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 TNF-α signalling occurs through both mitogen-activated protein kinases (MAPK) and nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation.   Induction of cell death signalling 
also occurs.  Many of these steps involve protein phosphorylation (not shown).  TNF-α MAPK pathway 
induction involves strong activation of the c-JUN N-terminal kinases (JNK) group, a moderate activation of 
p38-MAPK and weak activation of the extracellular signal-related kinases (ERKs- hence not shown). MEKK: 
MAP kinase kinase kinase; MEK: MAP kinase kinase; DD: death domain protein; TRADD: Tumour necrosis 
factor receptor type 1-associated DEATH domain protein; FADD: Fas-Associated protein with Death 
Domain; RIP: receptor-interacting protein; TRAF: TNF receptor associated factor; NIK: NF-kB Inducing 
Kinase; IKK: IκB Kinase; ASK: Apoptosis signal-regulating kinase 
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Upon binding of the ligand to the receptor, a conformational change occurs, leading to 
exposure of the intracellular death domain.  Signalling occurs through two principal 
intracellular adaptor proteins.  These are TRAFs (and death domain (DD) proteins (Locksley 
et al., 2001).  The adaptor protein TRADD (TNF-α receptor 1-associated death domain 
protein) binds to the death domain, and subsequent protein binding occurs on this 
platform. Three pathways are initiated.  They include the activation of NF-κB, which is a 
transcription factor that translocates to the nucleus and mediates transcription of many 
proteins involved in cell function and survival, including an inflammatory response (Hsu et 
al., 1996).  The second pathway involves activation of the MAPK (mitogen-acitvated protein 
kinase) pathways that activates (amongst others) the JNK (c-Jun, N-terminal kinase) group.  
The JNK group is responsive to stress stimuli and effect cell differentiation, proliferation and 
apoptosis.  The third pathway involves apoptosis induced by caspases (Carpentier et al., 
1998).     
 
Murine studies revealed that the P55-/- mouse exhibited loss of TNF-α-induced IL-6 
expression, NF-κB activation in T cells and fibroblasts and fibroblast proliferation 
(Vandenabeele et al., 1995).   Both P55 and P75 null mice were sensitive to LPS induced 
lethality, but the P75 null mice were more resistant.  Unlike the P55 mice, the P75 null mice 
were also sensitive to murine TNF-induced lethality (Vandenabeele et al., 1995).       
 
 
1.4.7 IL-6 – introduction and structure 
 
Interleukin -6 (IL-6) is a pleiotropic peptide cytokine with a molecular weight of between 23 
and 32 kDa (Yang et al., 2007).  It is produced by neutrophils, macrophages and T cells.  It 
stimulates an immune response to trauma; the acute phase response.  IL-6 in bone is 
synthesised mainly by osteoblasts and marrow stromal cells (Heymann and Rousselle, 
2000).  Production of IL-6 can be induced by TNF-α and IL-1, which are up-stream regulators 
of IL-6 production (Carpentier et al., 1998; Kozawa et al., 1997; Mountziaris and Mikos, 
2008).  In the absence of sIL-6Rα, the effect of IL-6 on osteoprogenitor cells is minimal. 
CHAPTER ONE                                                                                                                                                 INTRODUCTION 
 86
However, the IL-6/sIL-6R complex promotes osteogenic differentiation of committed 
osteoprogenitor cells (Erices et al., 2002; Franchimont et al., 2005).  IL-6 and sIL-6R may 
promote osteogenic differentiation indirectly, as the complex has been shown to promote 
IGF-1 and BMP-6 synthesis in rat osteoblasts (Franchimont et al., 2005) and PTHrP 
expression by human osteoblasts (Guillen et al., 2004).  In addition, IL-6/sIL-6R potentiates 
osteogenic differentiation of fetal rat calvarial cells by BMP-7 (Yeh et al., 2002).  It is unclear 
whether the complex promotes osteogenic commitment in stem cells. While Taguchi et al 
demonstrated that embryonic fibroblasts (but not adipocytes, chondrocytes or myocytes) 
underwent osteogenic differentiation in response to the IL-6/sIL-6R complex, Pricola et al 
demonstrated that IL-6 maintained a pool of marrow-derived mesenchymal stem cells in an 
undifferentiated state (Pricola et al., 2009; Taguchi et al., 1998).  IL-6 was shown not to 
influence proliferation of human osteoblast cells (Frost et al., 1997).   
 
In a co-culture of murine osteoblast and bone marrow cells the addition of IL-6 and sIL-6R 
promoted osteoclast differentiation (Tamura et al., 1993).  Osteoclastic differentiation in 
the presence of IL-6 is dependent on sIL-6R expression by osteoblasts (Udagawa et al., 
1995).    
 
As the IL-6-/- mouse is phenotypically normal it could be assumed that IL-6 is not essential 
for bone development and remodelling under physiological conditions (Yang et al., 2007).  
However, with duel roles in osteoblastogenesis and osteoclastogenesis, the role of IL-6 may 
be important in states of increased bone turnover (Franchimont et al., 2005) and hence may 
have a role in fracture healing, especially during remodelling. 
 
   
1.4.8 IL-6 receptors and signalling 
 
IL-6 binds to the receptor subunit IL-6Rα.  The IL-6/IL-6Rα complex interacts with a signal 
transducing component gp-130, which is expressed in most tissues.  Membrane association 
of the IL-6Rα subunit to gp-130 is not required to trigger signalling. Hence, soluble IL-6Rα 
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permits cells expressing gp-130 but not IL-6Rα to become responsive to IL-6 (Franchimont et 
al., 2005).  Binding of IL-6 to IL-6Rα, or binding of IL-6/sIL-6Rα to gp-130 initiates a signal 
transduction cascade via JAKs.  These molecules induce the phosphorylation of signal 
transducers and activators of transcription (STATS), which relocate to the nucleus and 
promote transcription (Guillen et al., 2004).  The source of soluble IL-6Rα is unclear but may 
be produced by cells on which IL-6 acts locally, such as osteoblasts.  Shedding of IL-6Rα to 
form sIL-6Rα can be mediated by TACE.  Soluble gp-130 (sgp-130) acts as an antagonist for 
the IL-6/sIL-6Rα complex (Muller-Newen et al., 1998). A simplified diagram of the IL-6 
signalling pathway is shown in Figure 1.10.   
 
 
1.4.9 IL-1 – introduction and structure 
 
Interleukin-1 (IL-1) is a super family of cytokines and includes the pro-inflammatory 
cytokines IL-1α and IL-1β and the IL-1 receptor antagonist (IL-1RA) (Dinarello, 1988; Weber 
et al.).  IL-1α and IL-1β are synthesised by cells of the monocyte lineage, including 
macrophages and dendritic cells.  Fibroblasts, smooth muscle, endothelial and lymphoid 
tissues also synthesise IL-1α and IL-1β (Dinarello, 1988).  While IL-1α and IL-1β are the 
products of different genes, they both bind to the same receptor and are therefore 
considered to represent two forms of the same cytokine.  Both forms are synthesised as 
31kDa pro-proteins, and undergo intracellular proteolytic cleavage. The active form of IL-1β 
is 17.5kDa.  IL-1β is synthesised from pro-IL-1β by caspase-1.  These cytokines play a key 
role in inflammation as the principal mediator of the acute phase response and in the 
immune response following infection, permitting leukocyte transmigration and activating 
lymphocytes. IL-1 is also a chemoattractant for lymphocytes (Dinarello, 1988).  They also 
influence the hypothalamic thermoregulatory centre to increase body temperature in 
response to infection.   IL-1 plays an important role in haematopoiesis by inducing the 
production of haematopoietic growth factors, including granulocyte and macrophage-
colony stimulating factor and IL-6 (Dinarello, 1988; Fibbe and Willemze, 1991).  IL-1 
stimulates the proliferation of fibroblasts.    
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Figure 1.10 IL-6 receptor signalling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 IL-6 binds to the gp130 receptor complex which includes the membrane-bound IL-6 receptor, 
or binds to the soluble form of the receptor which then binds to gp130.  IL-6 signalling occurs through 
both extracellular signal-related kinases (ERK1 and 2) which are mitogen-activated protein kinases 
(MAPK) and via signal transducer and activator of transcription 3 (STAT3). Ras and Raf: a prototypical 
member of a super family of genes coding for small GTPases (Guanidine triphosphate). MEKK: MAP 
kinase kinase kinase; MEK: MAP kinase kinase; JAK: Janus protein tyrosine kinase. 
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Like TNF-α, IL-1 stimulates osteoclast maturation and has been described as a key cytokine 
is survival and differentiation of osteoclasts (Kim et al., 2009, Suda, 1999 #453).  IL-1 binds 
to IL-1 receptor expressed on osteoclasts, to promote the survival, fusion and activation of 
osteoclasts through the activation of NF-κB (Suda et al., 1999).  TNF-α, by contrast, 
promotes osteoclastic activation of NF-κB by promoting the expression of RANKL on 
osteoblasts and stromal cells (Boyle et al., 2003; Jimi et al., 2004) (see section 1.4.5).    IL-1 
alone cannot stimulate osteoclastic differentiation from precursor cells as they do not 
express the IL-1 receptor. Therefore the expression of IL-1 receptor type-1 on bone marrow-
derived macrophages is of critical importance in osteoclastogenesis.  
 
While the role of IL-1 in osteoclastogenesis and bone resorption has been delineated, its 
role in bone deposition is less clearly defined.  Lacey et al found that IL-1β concentrations 
greater than 1pg/ml inhibited osteogenic differentiation of murine mesenchymal stromal 
cells by osteogenic media (with dexamethasone, ascorbic acid and β-glycerolphosphate) as 
determined by cell staining.  However, the results of osteogenic gene expression were 
unclear, as 1ng/ml IL-1β increased the expression of osteopontin and osteonectin and 
decreased expression of ALP, Runx2 and osterix (Lacey et al., 2009).  Frost reported that IL-
1β dose-dependently enhanced the proliferation of human osteoblasts, although the effect 
was delayed compared with TNF-α (Frost et al., 1997).   
 
The IL-1 receptor 1 knockout mouse exhibited low bone mass, which was found to reflect an 
increase in osteoclast number, suggesting that binding of IL-1 to IL-1 receptor 1 exerts a 
negative feedback regulation on osteoclastogenesis (Bajayo et al., 2005).   
 
 
1.4.10 IL-1 receptors and signalling 
 
Two forms the interleukin-1 receptor (IL-1R) exist.  The type 1 receptor (IL-1R1) binds either 
of the IL-1 isoforms and effects transcription to mediate the pro-inflammatory effects of IL-
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1.  Type 2 receptors competitively bind IL-1, suppressing IL-1 activity.  The IL-1 receptor 
antagonist (IL-1Ra) also suppresses IL-1 activity through competitive binding to IL-1 
receptors without initiating cell signalling (Arend et al., 1998).  Soluble IL-1Ra (sIL-1Ra) is 
synthesised by inflammatory cells including monocytes/macrophages and neutrophils 
(Arend et al., 1998).  The binding of IL-1 to the IL-1 receptor type 1 recruits a signalling 
complex that includes MyD88 and the protein kinases IRAK1 and IRAK4 (Interleukin-1 
receptor accessory protein).  IRAK1 then binds to and activates further proteins which lead, 
ultimately, to the activation of the protein kinases TAK1 (TGF-β-activated kinase-1) and IKKβ 
(Inhibitor of nuclear factor kappa B kinase-β) which trigger protein transcription.  A 
simplified diagram of IL-1 signalling is shown in Figure 1.11.   
 
 
1.4.11 The principle of cytokine-mediated fracture healing  
 
Fracture of bone constitutes an injury, and as such elicits inflammation.  This response 
includes that of innate immunity, characterised by early infiltration with neutrophils and 
cells of the monocyte lineage.  Additionally, an adaptive immune response is mounted, as 
established by the selective presence of T cells in the inflammatory infiltrate (Andrew et al., 
1994).  In 1995, Einhorn et al suggested that the pro-inflammatory cytokines mediating this 
response might influence fracture healing (Einhorn et al., 1995).  It is now accepted that the 
inflammatory post-fracture environment is tightly regulated by cytokines and growth 
factors released in a temporally and spatially controlled manner, which act to effect early 
fracture repair (Kon et al., 2001; Mountziaris and Mikos, 2008).  In a murine model of 
fracture healing this response peaks within 24 hours.  
 
Inflammatory signals from cytokines coordinate the recruitment of osteoprogenitor cells 
(and more inflammatory cells).  Osteoblastic maturation is, in turn, coupled with 
osteoclastic maturation hence bone deposition and resorption.  Progenitor cells also 
undergo chondrogenic differentiation to synthesise a cartilaginous intermediary for 
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endochondral fracture healing.   Remodelling of this intermediary is coupled with neo-
vascularisation. 
 
Figure 1.11 IL-1 receptor signalling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 IL-1 binds to its receptor/accessory protein complex, phosphorylating TNF receptor associated 
factor-6 (TRAF6) through the action of interleukin-1 receptor -associated kinase-1 and 4 (IRAK1/4) and the 
adaptor protein myeloid differentiation primary response gene-88 (MyD88).  IL-1 receptor signalling occurs 
through both mitogen-activated protein kinases (MAPK) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) activation.   MAPK pathways include the both p38 and JNK.  IL-1RA: interleukin-1 
receptor A (and accessory protein); TIR: Translocated intimin receptor; RIP: receptor-interacting protein; 
MEKK: MAP kinase kinase kinase; MEK: MAP kinase kinase; JNK: c-JUN N-terminal kinases group; P38: P38 
mitogen-activated protein kinase; TAK: Transforming growth factor-β-activated kinase; NIK: NF-kB Inducing 
Kinase; IKK: IκB Kinase; 
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Tissue remodelling in fracture healing is also regulated by pro-inflammatory signals as part 
of what is termed a “bi-phasic” inflammatory response (Andrew et al., 1994; Cho et al., 
2002; Einhorn et al., 1995; Gerstenfeld et al., 2003b; Mountziaris and Mikos, 2008; Wang et 
al., 2006).  Cytokine signalling coordinates these processes.  The following section discusses 
the influence of the pro-inflammatory cytokines on fracture healing. 
 
 
1.4.12 TNF-α in fracture healing 
 
The expression of TNF-α and the receptors P55/TNFR and P75/TNFR follows a biphasic 
pattern (Gerstenfeld et al., 2003b; Kon et al., 2001).  In a murine model, the concentration 
peaks at 24 hours, falling to the baseline level after 72 hours (Kon et al., 2001).  This first 
peak is believed to exert chemotactic effects, and to induce the expression of downstream 
mediators of fracture repair.  A second peak has been observed between weeks 2 and 3.  In 
endochondral fracture healing, this peak arises as the cartilaginous intermediary is ossified, 
forming woven bone (see section 1.2.1).  While the first peak represents expression by 
inflammatory cells, including macrophages, the second, smaller (yet more prolonged) peak 
represents expression by osteoblasts and hypertrophic chondrocytes. The temporal pattern 
of expression of pro-inflammatory cytokines after bone injury is shown in Figure 1.12.  
 
Early in vivo studies suggested that TNF-α impaired fracture healing and bone formation.  
Using a murine model, Yoshikawa et al demonstrated that the daily administration of TNF-α 
via intra-peritoneal injection inhibited bone formation around an intramuscular bone-
inducing implant.  They also observed that this was reversible upon discontinuation of TNF-
α administration.  The dose used was 400-4000ng per day (Yoshikawa et al., 1988).  The 
same group then demonstrated that the daily administration of an even higher dose of TNF-
α, injected intraperitoneally impaired healing in a rib fracture model using rats.  
Histologically, these results were attributed to impaired cartilage formation by 
mesenchymal cells in the presence of TNF-α (Hashimoto et al., 1989).  The lower dose 
(40µg/kg/day) was associated with a non-significant improvement in fracture healing over 
the duration of the study, but this was not commented upon.  The dose range used in these 
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studies was very high.  The finding that a lower dose was associated with a non-significant 
improvement in fracture healing would have justified a repeat of the experiment using a 
lower dose range, but this was not done. 
 
 
Figure 1.12 Temporal expression patterns of signalling molecules during fracture healing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 A schematic diagram demonstrating temporal expression of selected genes over 28 days 
following murine fracture (tibia or femur) is shown.  Thick lines represent peaks of expression (the 
actual peak may be anywhere on the line depending on the characteristic expression of the gene 
product).  Intermediate lines represent constitutive expression.  Thin lines represent low or minimal 
positive expression or where expression is disputed. Adapted from: (Dimitriou et al., 2005; Gerstenfeld 
et al., 2003b; Mountziaris and Mikos, 2008).    
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More recently, Gerstenfeld et al investigated the role of TNF-α in fracture healing using a 
simple, closed tibial fracture healing model in dual P55 and P75 (P55-/-/P75-/-) knockout 
mice.  In the absence of TNF-α signalling, by day 7 the mice demonstrated a delay in 
chondrogenic differentiation and maturation and a delay in periosteal bone bridging.  By 
day 14, the receptor knockout mice demonstrated delayed callus resorption and by day 21, 
they demonstrated poor formation of trabecular bone, failure to remodel the callus to form 
a marrow cavity and a poorly differentiated mesenchymal stromal cell infiltrate.  Greater 
callus volume was demonstrated histomorphometrically.  The expression of collagens 2 and 
10, associated with chondrogenic differentiation, was delayed 3-4 days in the knockout 
model, but once chondrogenic differentiation was initiated, enhanced expression was 
observed.  Similarly, osteoclastic delay was followed by a rapid increase in osteoclast 
number after day 21 (Gerstenfeld et al., 2003b).  The same group established that 
chondrocytes produce factors that act in a paracrine fashion to promote osteoblastic 
differentiation (Gerstenfeld et al., 2001).  TNF-α also mediates the expression of proteins 
regulating chondrocyte apoptosis (Aizawa et al., 2001; Gerstenfeld et al., 2003b).  Hence, it 
was proposed that the absence of TNF-α signalling led to delayed callus maturation but 
enhanced cartilage-mediated recruitment of osteoprogenitor cells (Gerstenfeld et al., 
2003a).    
 
Gerstenfeld et al also investigated isolated endosteal bone formation in the P55-/-/P75-/- 
knockout mice.  The model used disrupted the trabecular architecture of the tibia by 
reaming the intramedullary canal using a needle.  Endosteal bone formation occurred in 
isolation as the tibial cortex was not fractured.  The P55-/-/P75-/- knockout mice exhibited 
delayed restoration of the trabecular architecture of the intramedullary canal (Gerstenfeld 
et al., 2001).  These data, together with data from the closed tibial fracture model suggest 
that TNF-α regulates both intramembranous and endochondral ossification (Gerstenfeld et 
al., 2001; Gerstenfeld et al., 2003a).   
 
TNF-α also induces the expression of Angiopoetin-2 and vascular-endothelial growth 
inhibitor (VEGI), that regulate vascularisation of cartilage and MMPs 9 and 14, that promote 
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the enzymatic breakdown of extracellular cartilage matrix (Lehmann et al., 2005).   The up-
regulation of MMP9 and MMP14 during endochondral remodelling was confirmed by a 
large-scale transcriptional profile in the same fracture model (Wang et al., 2006).   
 
 
1.4.13 IL-6 in fracture healing 
 
A study comparing serum samples in human trauma patients revealed that expression of IL-
6 occurs within the first hour of bony injury (Strecker et al., 1999).  As shown in Figure 1.12, 
in a murine model, IL-6 expression rises within 24 hours following fracture, and returns to 
baseline levels by the end of the first week (Gerstenfeld et al., 2003b). Hence, expression is 
limited to the inflammatory phase of fracture healing.  IL-6 is expressed by osteoblasts and 
bone marrow stromal cells and its expression is regulated by TNF-α (Heymann and 
Rousselle, 2000) and IL-1 (Elias and Lentz, 1990).  Both cytokines, expressed within a few 
hours of bone injury, may act synergistically to stimulate IL-6 expression (Elias and Lentz, 
1990).   
 
The role of IL-6 in fracture healing was studied in a closed femoral fracture model using a 
knockout (IL-6-/-) mouse.  Using infrared spectroscopy, reduced callus crystallinity was 
reported in the knockout mouse at 2 weeks post fracture.  Histomorphometry revealed that 
the knockout mouse also exhibited an increase in percentage cartilage in the callus at 1 and 
2 weeks.  Osteoclast density in the callus at 2 weeks, assessed by immunohistochemistry for 
cathepsin K, was greater in the wild type (C57Bl6) control mice than in IL-6 null mice.  A 
ratio of mineralised tissue to unmineralised tissue (assessed by micro CT) was used to 
compare callus maturation between strains.  There were no significant differences in callus 
maturation at 2 or 4 weeks (although callus mineralisation appeared reduced at 2 weeks, 
this was not significant).   The authors stated that their findings suggested that IL-6 was 
associated with early callus maturation and osteoclastogenesis (Yang et al., 2007).  The 
differences were, however, subtle. 
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Rozen et al investigated the sequential local injection of IL-6 and IL-6 soluble receptor, with 
parathyroid hormone fragments 1-34 and 28-48 (PTH 1-34, PTH 28-48), using a closed rat 
tibial fracture model.  They reported a significantly increased callus volume at 14 days with 
the sequential injection regimen compared to the vehicle only control and faster fracture 
healing, assessed radiologically, in the limbs treated with either PTH fragment + IL-6/IL-6sR 
over either fragment, or IL-6/IL-6sR alone.  In addition, 3-point bend-testing at 6 weeks 
revealed that the limb treated with the sequential injection regimen of either fragment with 
IL-6/IL-6sR exhibited a significantly increased load to failure compared with the vehicle only 
control and interestingly, the contralateral unfractured limb appeared weaker than the 
contralateral limb of the vehicle control.  The authors attributed this finding to systemic 
effects of the locally injected agents, resulting in increased remodelling of intact bone.  The 
author’s rationale for choosing PTH as the agent injected first was that it was thought to 
promote chondrogenesis, while IL-6 promoted endochondral maturation.  However, 
redundancy exists within the system and other factors, including TNF-α perform similar 
roles.   This study was interesting in that it demonstrated that a short course of a stimulus 
during endochondral bone formation had prolonged consequences in terms of union 
strength and remodelling (Rozen et al., 2007).     
 
 
1.4.14 IL-1 in fracture healing 
 
As shown in Figure 1.12, in a murine model, the expression of IL-1 follows a biphasic pattern 
similar to TNF-α.  Rising immediately after fracture, the concentration peaks within 24 
hours, falling to baseline levels by 72 hours.  The source of IL-1 in early fracture healing is 
inflammatory cells of the monocyte lineage, especially macrophages (Gerstenfeld et al., 
2003b; Kon et al., 2001).  The influence of IL-1 on the early fracture environment overlaps 
with that of TNF-α, triggering the release of secondary inflammatory mediators including IL-
6.  Similar to TNF-α, the second peak arises about 3 weeks following injury during cartilage 
remodelling, and it is thought that IL-1 influences this process.  Osteoblastic synthesis is 
considered to account for the second peak.  The expression of IL-1 receptor 2 follows the 
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same biphasic pattern as that of its ligand.  By contrast, the expression of IL-1 receptor 1 
occurs only during the inflammatory phase (Gerstenfeld et al., 2003b).  To date, there are 
no in vivo studies on the role of IL-1 in fracture healing.   
 
 
1.4.15 Pro-inflammatory cytokines as upstream regulators of osteogenic growth 
factors 
 
As discussed in section 1.4.5, TNF-α appears to mediate a complex equilibrium between net 
bone formation and resorption by stimulating stromal cells and osteoblast precursors and 
by promoting RANKL-mediated stimulation of osteoclasts.  TNF-α signalling also promotes 
fracture healing in vivo, by promoting bone formation directly and through a cartilaginous 
intermediary.  The influence of TNF-α on bone formation in vitro and in vivo appears to be 
dose dependent.  Early in vivo studies seeking to observe the influence of TNF-α on fracture 
healing chose therapeutic regimens that far exceeded anticipated local physiological 
concentrations.  To date, the precise nature of the relationship between TNF-α and 
osteoprogenitor cells in vitro and fracture healing in vivo remains unresolved.  Additionally, 
the mechanisms by which TNF-α mediates pro- and anti-osteogenic effects is unclear.  
Figure 1.12 summarises the expression of selected genes during the stages of fracture 
healing. 
 
Acting in combination with IL-17, TGF-β and IFN-γ, TNF-α has been shown to stimulate 
autologous BMP-2 synthesis and effect osteogenic differentiation of human mesenchymal 
stromal cells (Rifas, 2006).  TNF-α has also been shown to stimulate BMP-2 (Fukui et al., 
2006) and BMP-4 (Horiguchi et al., 2000) expression by human and murine chondrocytes 
respectively.  In human chondrocytes BMP-2 expression, determined by quantitative real-
time polymerase chain reaction (RT-PCR), increased rapidly at low concentrations of human 
rhTNF-α (around 6-fold at 0.5ng/ml and around 15-fold at 2.5ng/ml relative to the 
untreated control) before levelling off (Fukui et al., 2003).  RhTNF-α inhibited BMP-4 
mediated chondrogenesis at a concentration of 10ng/ml but not 0.1ng/ml in culture 
(Horiguchi et al., 2000).   Similarly, Gilbert et al demonstrated that when added to rat 
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calvarial cells, TNF-α (at 100ng/ml) stimulated BMP-2 expression, but inhibited osteogenic 
differentiation and bone nodule formation (Gilbert et al., 2000).  TNF-α also inhibited 
osteogenic differentiation of murine clonal osteoblastic (MC3T3-E1-14) cells (Gilbert et al., 
2000).  Again, when one considers that TNF-α is present at concentrations of less than 
10pg/ml across vascular beds in peripheral tissues (Mohamed-Ali et al., 1997) the 
concentration used was very high.  Moreover, the cells evaluated were not human cells, and 
thus the relevance of these data is questionable.  Just as Hashimoto et al demonstrated 
delayed fracture healing when rats were exposed to high doses of TNF-α daily, it seems 
likely that excessive local concentrations of TNF-α inhibit osteogenic differentiation.  TNF-α 
has also been shown to induce a concentration-dependent down-regulation of receptor 
expression (hence BMP-2 mediated ALP expression) in osteoblasts (Singhatanadgit et al., 
2006).  This may explain why osteoprogenitor cells failed to differentiate in response to 
BMPs synthesised downstream of TNF-α and is consistent with the hypothesis that the 
effect of TNF-α on osteogenic differentiation of progenitor cells is concentration dependent.   
 
Additionally, IL-1β has been shown to stimulate BMP-2 and BMP-4 induced ALP expression 
in a murine osteoblastic cell line (Nakase et al., 1997).  IL-1β has also been shown to 
stimulate BMP-2 expression by chondrocytes (Fukui et al., 2003).   IL-6 (with soluble 
receptor) has been shown to stimulate BMP-7 induced ALP expression and bone nodule 
formation in fetal rat calvarial cells, and to promote BMP receptor 2 (BMPR-II) expression 
(Yeh et al., 2002).   
 
 
1.4.16 Cell recruitment and proliferation by TNF-α 
 
TNF-α has also been associated with the recruitment of T-cells (von Andrian and Mackay, 
2000; Watanabe et al., 2002), dendritic cells (Cumberbatch and Kimber, 1992) and 
macrophages/monocytes (Blades et al., 2002) in vivo.   It is thought that TNF-α and IL-1 
mediate cell migration through stimulating expression of adhesion molecules including E-
selectin, vascular cell adhesion molecule-1 (VCAM-1) and inter-cellular adhesion molecule-1 
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(ICAM-1) (von Andrian and Mackay, 2000).  Moreover, TNF-α may, in addition, stimulate 
expression of chemoattractant molecules (chemokines) including CXCL-12 (Blades et al., 
2002).  Using an in vitro model of cell migration through a transwell membrane, human 
marrow-derived stromal cells (HMSC) were shown to migrate in response to platelet-
derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1). However, TNF-α was 
shown to up-regulate the expression of chemokine receptors CCR2, CCR3 and CCR4 on 
HMSC, with a subsequent increase in cell migration in response to the chemokine ligands 
for these receptors.  These results indicated that TNF-α primed human stromal cells for 
migration (Ponte et al., 2007).  Human periosteal-derived osteoprogenitor cells have been 
shown to migrate in response to CCL-2, CXCL-8 and CXCL-12 (Stich et al., 2008).  
 
The influence of TNF-α on cell proliferation in culture has also been investigated.  Iwabe et 
al demonstrated that TNF-α (at 20-100pg/ml) promoted proliferation of human endometrial 
stromal cells via the down-stream expression of IL-8 (Iwabe et al., 2000).  TNF-α has also 
been shown to stimulate proliferation of oestrogen-receptor positive ductal breast cancer 
cells (Rubio et al., 2006), and renal carcinoma cells, an effect inhibited by the addition of IL-
4 (Falkensammer et al., 2006).  Additionally, while TNF-α exhibited no direct effect on 
proliferation of CD34+ cells it potentiated IL-3 and GM-CSF-mediated proliferation (Caux et 
al., 1990).  Conversely, TNF-α inhibited stem cell factor (SCF)-mediated proliferation of 
CD34+ cells (Rusten et al., 1994).  Hence the role of TNF-α on cell proliferation remains 
unclear.  The effects may be cell specific, concentration dependent, and may involve co-
factors.   
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1.5 Summary of the introduction 
 
 
Fractures are common injuries occurring in up to 300 per 10,000 persons per year (Melton 
et al., 1999).  Around 5% of all fractures are open (Ruedi et al., 2007).  Closed tibial fractures 
occur in up to 15 per 10,000 persons per year.  The tibia is the most common open long 
bone fracture, accounting for about half of all cases.  Around a third of these are high 
energy (Gustilo IIIB) fractures which are prone to delayed and non union.  Most occur due 
to road traffic accidents, in males with a mean age of around 37 years. Union times of up to 
one year are reported.  Reconstruction of the soft tissue envelope is with muscle or 
fasciocutaneous tissue.  Studies comparing these tissues are complicated by the lack of 
prospective, randomised trials.  Experimental models have suffered from methodological 
flaws.  The model by Harry et al, from this institution provides the best evidence for the 
efficacy of muscle over fasciocutaneous tissue in the healing of high energy tibial fractures.   
 
The ideal fracture healing environment includes a supply of osteoprogenitor cells, 
osteoinductive signals, an osteoconductive scaffold, appropriate stability and an adequate 
vascular supply.  Vascular density was greater in the fasciocutaneous tissue at all time 
points in this model (Harry et al., 2009).  Hence, the findings were postulated to reflect the 
availability of osteoprogenitor cells in muscle.  Skeletal muscle contains a mesenchymal 
stromal population (MDSC) that is one of a number of cell types currently being investigated 
as part of fracture healing strategies (Jankowski et al., 2002; Mastrogiacomo et al., 2005a).  
These strategies involve the ex vivo transduction of MDSC to express osteogenic growth 
factors including bone morphogenetic proteins (BMPs).  The translational problems with 
this work include the potential for allogeneity and tumorigenicity of implanted cells (Huang 
and Yang, 2009).  It is also unclear how this strategy fits with the clinical need for prompt, 
definitive closure.  Soft tissue reconstruction with muscle is an alternative way of placing a 
potential source of progenitor cells adjacent to fracture, which resolves these problems.   
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However, there are also problems with the use of BMPs, as these growth factors have 
under-performed in human trials relative to primitive mammalian models.  Limited clinical 
success may reflect the difficulty in recreating the complex series of biological events in 
fracture healing by the administration of growth factors alone, or in simple combinations.  
Hence, identifying the up-stream regulators of these factors is an attractive next step.  A full 
understanding of the mechanisms regulating fracture repair is needed.   
 
Cells of the post fracture inflammatory infiltrate include neutrophils, 
monocytes/macrophages, myeloid dendritic cells and T cells.  These cells mediate their 
actions through cytokines, including TNF-α, IL-6 and IL-1.  TNF-α appears to regulate a 
balance between bone deposition and resorption.  However, in vitro and in vivo data 
regarding the influence of TNF-α on osteoprogenitor cells lack clarity.   
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1.6 Hypothesis  
 
 
Muscle, placed adjacent to a periosteally stripped mid tibial osteotomy (a model for high 
energy fractures) is an alternative method of supplying the fracture with a source of 
osteoprogenitor cells, which does not involve ex vivo cell expansion and manipulation.  The 
pro-inflammatory cytokines, especially TNF-α mediate the recruitment and osteogenic 
differentiation of these cells and, as up stream mediators of growth factor synthesis, are a 
therapeutic target for fracture healing.   
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1.7 Aims and Objectives 
 
 
The aims of this study are to: 
 
1 Determine why muscle enhanced fracture healing in the study by Harry et al (which was 
based on work at the Kennedy Institute, Imperial college) (Harry et al., 2008). 
2 Establish the nature of the stimulus mediating recruitment, proliferation and 
differentiation of muscle-derived stromal cells to the fracture site 
3 Investigate the influence of the pro-inflammatory cytokines TNF-α, IL-6 and IL-1 on 
muscle-derived stromal cells in vitro 
4 Investigate the role of the pro-inflammatory cytokines TNF-α, IL-6 and IL-1 on fracture 
healing in vivo using selected knockout strains and the model established by Harry et al. 
5 Determine the influence on fracture healing of exogenously administered pro-
inflammatory cytokines  
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Introduction 
 
 
The experimental protocols detailed in this chapter describe the in vitro and in vivo 
experiments performed.  They can be divided broadly into:  
 
1. Those describing the development and utilisation of the in vitro fracture model  
2. Characterisation of the content of fracture-derived supernatant    
3. Investigating the relevance of the in vitro findings using the in vivo fracture model  
 
The proof of concept for the in vitro fracture model was obtained from the murine in vivo 
fracture model, which demonstrated improved fracture healing when the fractured tibia 
was in contact with muscle exclusively.  Cells from the adjacent muscle, but not from other 
surrounding tissues appeared to be differentiating osteogenically in response to adjacently 
situated fractured bone.  The in vitro fracture model was developed using cells derived from 
human skeletal muscle samples.  In each case the muscle sample was obtained following 
free muscle flap harvest and had therefore not been subjected to any prior conditioning by 
proximity to fracture.  The cells were characterised and their osteogenic potential 
investigated.  The characteristics of each cell sample were evaluated in the context of the 
clinical parameters of the donor.  These provisional experiments revealed that cells from 
female donors less than 45 years old and in good pre-morbid health displayed the most 
consistent osteogenic potential.  Age was a more important parameter than cell gender.  
The muscle from which was the sample was obtained was not important.  
 
Not all fracture-derived supernatants promoted osteogenic differentiation of MDSC.  The 
characteristics of the supernatant that did were that they were obtained from recent 
(within 72 hours), non-infected fractures that had not been subjected to a prior surgical 
procedure. Surgically cut supernatants (obtained from segmented tibiae following 
amputation) invariably did not promote osteogenic differentiation.  These criteria formed 
the basis of the in vitro model described in detail below.    
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2.1 Materials 
 
 
2.1.1 Neutralisation antibodies 
 
Table 2.1 
Specificity Antibody Clone No. Catalogue No. 
 
Supplier 
     
BMP-2/4 Mouse IgG1 100230 MAB3552 R+D Systems, Abington, UK 
 
BMP-7 Mouse IgG2B 164311 MAB3541 R+D Systems, Abington, UK 
 
TGF-β Rabbit IgG ---------- AB-100-NA R+D Systems, Abington, UK 
 
TNF-α 
 
Mouse IgG1 6401 MAB2101 R+D Systems, Abington, UK 
 
IL-1β Mouse IgG1 2805 MAB601 R+D Systems, Abington, UK 
 
IL-6 Mouse IgG1 6708 MAB206 R+D Systems, Abington, UK 
 
IL-6sR Mouse IgG1 17506 MAB227 R+D Systems, Abington, UK 
 
CXCL-8 (IL-8) Mouse IgG1 6217 MAB208 R+D Systems, Abington, UK 
 
CCL-2 
 
Mouse IgG1 24822 MAB279 R+D Systems, Abington, UK 
 
IgG1 isotype 
control 
Mouse IgG1 97924 MAB110 R+D Systems, Abington, UK 
 
IgG2B isotype 
control 
 
Mouse IgG2B 20116 MAB004 R+D Systems, Abington, UK 
 
 
2.1.2 Human conjugated flow cytometry antibodies 
 
Table 2.2 
Specificity Antibody Clone No. Conjugate Catalogue 
No. 
Supplier 
      
CD14 Mouse 
IgG2B 
MφP9 Phycoerythrin  347497 BD Biosciences, 
Franklin lakes, NJ. 
USA 
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CD31 Mouse 
IgG1 
WM59 Phycoerythrin MCA1738 AbD Serotec, 
Raleigh, NC. USA 
 
CD34 Mouse 
IgG1 
8G12 Fluorescein 
Isothiocyanate 
340668 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD45 Mouse 
IgG1 
2D1 Allophycocyanin 340942 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD73 Mouse 
IgG1 
AD2 Phycoerythrin 550257 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD90 Mouse 
IgG1 
5E10 Phycoerythrin 555596 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD105 Mouse 
IgG1 
SN6 Fluorescein 
Isothiocyanate 
MCA1557 AbD Serotec, 
Raleigh, NC., USA 
 
CD106 Mouse 
IgG1 
51-10C9 Allophycocyanin 551147 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD117 Mouse 
IgG1 
104D2 Allophycocyanin 341096 BD Biosciences, 
Franklin lakes, NJ, 
USA 
 
CD146 Mouse 
IgG1 
OJ79c Fluorescein 
Isothiocyanate 
MCA2141 AbD Serotec, 
Raleigh, NC., USA 
 
HLA-ABC Mouse 
IgG2A 
--------- Fluorescein 
Isothiocyanate 
MCA81 AbD Serotec, 
Raleigh, NC., USA 
 
HLA-DR Mouse 
IgG2A 
L243 
(G46-6) 
Fluorescein 
Isothiocyanate 
555811 BD Biosciences, 
Franklin lakes, NJ, 
USA 
PE  
isotype 
control 
Mouse 
IgG1 
MOPC-21 Phycoerythrin 559320 BD Biosciences, 
Franklin lakes, NJ., 
USA 
 
FITC 
isotype 
control 
Mouse 
IgG1 
MOPC-21 Fluorescein 
Isothiocyanate 
554679 BD Biosciences, 
Franklin lakes, NJ., 
USA 
 
APC 
isotype 
control 
Mouse 
IgG1 
MOPC-21 Allophycocyanin 554681 BD Biosciences, 
Franklin lakes, NJ., 
USA 
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2.1.3 Murine conjugated flow cytometry antibodies 
 
Table 2.3 
 
Specificity Antibody Clone No. Conjugate Catalogue 
No. 
Supplier 
      
CD31 Rat  
IgG2A 
ER-MP12 Fluorescein 
Isothiocyanate 
MCA1364F AbD Serotec, Raleigh, 
NC., USA 
 
CD34 Rat  
IgG2A 
MEC14.7 Fluorescein 
Isothiocyanate 
MCA1825F AbD Serotec, Raleigh, 
NC., USA 
 
CD45 Rat  
IgG2B 
30-F11 Phycoerythrin 553081 BD Biosciences, 
Franklin lakes, NJ, USA 
CD73 Rat 
IgG2A 
TY/23 Phycoerythrin 550741 BD Biosciences, 
Franklin lakes, NJ., USA 
CD90  
(Thy-1) 
Rat  
IgG2C 
G7 Fluorescein 
Isothiocyanate 
Ab25672-
100 
Abcam Inc. Cambridge, 
MA., USA 
 
CD105 
(Endoglin) 
Rat  
IgG2A 
209701 Fluorescein 
Isothiocyanate 
FAB1320F R+D Systems, 
Abington, UK 
 
CD106 
(VCAM-1) 
Rat  
IgG2A 
MVCAM 
A(429) 
Fluorescein 
Isothiocyanate 
MCA2297F AbD Serotec, Raleigh, 
NC., USA 
 
CD117  
(c-kit) 
Rat  
IgG2B 
2B8 Allophycocyanin 553356 BD Biosciences, 
Franklin lakes, NJ., USA 
Sca-1  
(Ly-6A/E) 
Rat  
IgG2A 
E13 161.7 Fluorescein 
Isothiocyanate 
553335 BD Biosciences, 
Franklin lakes, NJ., USA 
PE  
isotype 
control 
Rat  
IgG2B 
A95-1 Phycoerythrin 553989 BD Biosciences, 
Franklin lakes, NJ., USA 
FITC 
isotype 
control 
Rat  
IgG2A 
R35-95 Fluorescein 
Isothiocyanate 
553929 BD Biosciences, 
Franklin lakes, NJ., USA 
APC 
isotype 
control 
Rat  
IgG2B 
A95-1 Allophycocyanin 556924 BD Biosciences, 
Franklin lakes, NJ., USA 
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2.1.4 Recombinant Proteins 
 
Table 2.4 
Protein Formulation ED50 Catalogue No. Supplier 
 
     
TGF-β1 Lyophilised <50pg/ml 100-21 PeproTech Inc., Rocky 
Hill, NJ. 
 
BMP-2 Lyophilised 0.5-1.0µg/ml 120-02 PeproTech Inc., Rocky 
Hill, NJ 
 
BMP-4 Lyophilised N/A 120-05 PeproTech Inc., Rocky 
Hill, NJ. 
 
BMP-7 Lyophilised 20-40pg/ml 120-03 PeproTech Inc., Rocky 
Hill, NJ. 
 
TNF-α Lyophilised 25-100pg/ml 210-TA R+D Systems, Abington, 
UK 
 
IL-1β Lyophilised <12pg/ml 201-LB R+D Systems, Abington, 
UK 
 
IL-6 Lyophilised 0.2-0.8ng/ml 206-IL R+D Systems, Abington, 
UK 
 
PDGF-AB Lyophilised 1.0-3.0ng/ml 100-00AB PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CCL-2  
(MCP-1) 
Lyophilised N/A 300-04 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CCL-3  
(MIP-1α) 
Lyophilised N/A 300-08 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CCL-4 
(MIP-1β) 
Lyophilised N/A 300-09 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CCL-5 
(RANTES) 
Lyophilised N/A 300-06 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CXCL-8 
(IL-8) 
Lyophilised N/A 200-08 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CXCL-9 
(MIG) 
Lyophilised N/A 300-26 PeproTech Inc., Rocky 
Hill, NJ., USA 
 
CXCL-10 
(IP-10) 
Lyophilised N/A 300-12 PeproTech Inc., Rocky 
Hill, NJ., USA 
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2.1.5 Commercial assays 
 
Table 2.5 
Product Code Supplier 
 
ALP quantification assay kit 291-58601 WAKO pure chemical Ltd., Osaka, Japan. 
 
CellTiter-Glo® Luminescent 
Cell Viability Assay 
 
G7571 Promega Corp., Madison, WI., USA 
SIGMAFAST™ BCIP®/NBT ALP 
stain 
B-5655 Sigma-Aldrich Corp., St. Louis, MO., USA 
   
 
 
2.1.6 Commercial ELISAs 
 
Table 2.6 
Specificity Range Mean MDD Catalogue No. Supplier 
 
     
BMP-2 <4000pg/ml 11pg/ml DBP200 R+D Systems, Abington, 
UK 
 
BMP-4 <2000pg/ml 1.04pg/ml DBP400 R+D Systems, Abington, 
UK 
 
BMP-7 <2000pg/ml 2.44pg/ml DBP700 R+D Systems, Abington, 
UK 
 
TGF-β <2000pg/ml 4.61pg/ml DB100B R+D Systems, Abington, 
UK 
 
IGF-1 <6000pg/ml 26pg/ml DG100 R+D Systems, Abington, 
UK 
 
SCF-1 <2000pg/ml 9.0pg/ml DCK00 R+D Systems, Abington, 
UK 
 
PTH ------------ ------------- S-1178 Bachem AG, Bubendorf, 
Switzerland 
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PTH-rP <25ng/ml ------------- S-1227 Bachem AG, Bubendorf, 
Switzerland 
 
 
 
2.1.7 Commercial Luminex assay 
 
Table 2.7 
Product Code Supplier 
 
Human cytokine 30 plex 
 
LHC6003 Invitrogen Corp., Carlsbad, CA., 
USA 
Cytokines tested: 
 
IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40⁄p70), IL13, IL-15, IL-17, 
TNF-α, IFN-α, IFN-γ, GM-CSF, MIP-1α, MIP-1β, IP-10, MIG, Eotaxin, RANTES, MCP-1, 
VEGF, G-CSF, EGF, FGF-basic, and HGF 
 
 
 
2.1.8 Commercial media/products for media production 
 
Table 2.8 
Product Catalogue No. Supplier 
 
   
GIBCO® Dulbecco’s 
Modified Eagle Media 
(DMEM) + GlutaMAX™ 
 
10565-42 Invitrogen Corp., Carlsbad, Ca., 
USA 
GIBCO®  Foetal bovine 
serum (FBS) 
10100147 Invitrogen Corp., Carlsbad, Ca., 
USA 
 
Penicillin/Streptomycin P11-010 PAA Laboratories GmbH, 
Pasching, Austria 
 
Human (inactivated) 
serum 
 
H4522 Sigma-Aldrich UK Ltd, Dorset, UK 
NH ChonDiff medium 130-091-679 Miltenyi Biotec, Bergisch 
Gladbach, Germany 
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hMSC Adipogenic Bulletkit 
 
PT-3004 Lonza Group, Basel, Switzerland 
 
GIBCO®  Neutral Protease 
(Dispase®) 
 
17105-041 Invitrogen Corp., Carlsbad, CA., 
USA 
Collagenase Type II CLS-2 Worthington Biochemical Corp., 
Lakewood, NJ., USA 
 
4% Trypsin coated agarose 
beads 
PN20230 Thermo Fisher Scientific Inc., 
Waltham, MA., USA 
 
4% cross linked agarose 
beads  
R010-50.1 Cambio Ltd., Cambridge, UK 
   
 
 
2.1.9 Miscellaneous solutions 
 
Table 2.9 
Product Catalogue No. Supplier 
 
Hanks Balanced Salt 
Solution (HBSS) 
14170-112 Invitrogen Corp., Carlsbad, CA., 
USA 
 
Videne® antiseptic 
solution (Povidone-Iodine 
USP 10.0%) 
 
HAS051P Adams Healthcare, Leeds, UK 
Trypsin 0.05% (1x) 
solution 
 
25300-054 Invitrogen Corp., Carlsbad, CA., 
USA 
10% neutral buffered 
formalin 
BAF-0010-02A CellPath Ltd., Powys, Wales, UK 
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2.1.10 Stock solutions 
 
Table 2.10 
Media 
 
Product Volume 
   
Culture 
 medium 
 
GIBCO® DMEM 500ml 
GIBCO® FBS 50ml (10%)  
Penicillin/streptomycin 5ml (1%) 
   
Serum free medium GIBCO® DMEM 500ml 
Penicillin/streptomycin 5ml (1%) 
   
Human serum 
supernatant 
GIBCO® DMEM 50ml 
human (inactivated) serum 5ml (10%) 
Penicillin/streptomycin 0.5ml (1%) 
   
Osteogenic medium Culture media 50ml 
Dexamethasone 100nM 
β-glycerol phosphate 1 mM 
Ascorbic acid 0.05nM 
   
Chondrogenic medium NH ChondroDiff Medium 
(Miltenyi BioTec, Gladbach, 
Germany) 
(commercial) 
   
Adipogenic medium 
(Induction) 
Adipogenic induction medium 
(LONZA): 
(commercial) Aliquot 
concentrations not 
available h-insulin 
L-Glutamine 
MCGS 
Dexamethasone 
Indomethacin 
3-isobutyl-methyl-xanthine (IBMX) 
Penicillin/streptomycin 
   
Adipogenic medium 
(Induction) 
Adipogenic maintenance medium 
(LONZA): 
(commercial) Aliquot 
concentrations not 
available h-insulin 
L-Glutamine 
MCGS 
Penicillin/streptomycin 
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Digestive medium Hanks Balanced Salt Solution (HBSS) 20ml 
Collagenase II 50mg 
Dispase® 100mg 
   
Notes: Dissolve the enzyme powder in HBSS at room temperature.  Filter-sterilise using a 
0.2µm filter tip, then warm to 37°C prior to digestion 
   
FACS wash buffer Phosphate Buffered Saline (PBS) 1L 
GIBCO® FBS 20ml (2%) 
Sodium azide 0.2ml (0.02%) 
   
NP-40 lysis buffer Nonident P -40 5ml/L (0.5%) 
tris(hydroxymethyl)aminomethane 
(TRIS) 
20nM (2.42g/L) 
Sodium Chloride (NaCL) 150mM (8.76g/L) 
   
 
 
2.1.11 Proteomic solutions  
 
Table 2.11 
Solution Addition Volume/Conc. 
   
“Low” salt buffer pH 7.5 TRIS buffer (stock 2M) 50 mM (25ml) 
NaCl solution (stock 4M) 75 mM (18.75ml) 
dH2O 956.25ml 
   
“High salt buffer” pH 7.5 TRIS buffer (stock 2M) 50 mM (25ml) 
NaCl solution (stock 4M) 1 M (250ml) 
dH2O 725ml 
   
TRIS-Glycine running 
buffer (10x) 
TRIS  29g 
Glycine 144g 
SDS 5g 
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2.1.12 Materials used for in vivo model 
 
Table 2.12 Disposable instruments 
 
Product Catalogue No. Purpose Supplier 
    
Surgical scalpels 
blade no. 15 
 
0505 Skin incision Swann-Morton Ltd. Sheffield, 
UK 
27G Micro lance 
needle 
ND635 Reaming of 
intramedullary (IM) 
canal 
 
Medisave UK, Dorset, UK 
(Becton-Dickinson) 
  
BD spinal needle 
22G (box of 25) 
 
405244 IM nail fixation Southern Syringe services, 
London, UK 
(Becton-Dickinson) 
  
Prolene 6.0 suture 
24/box 
 
W8873T 
 
Wound closure Medisave UK, Dorset, UK 
(Ethicon Inc., Somerville, NJ., 
USA) 
 
Clean Cut Micro 
Nipper 
SF09K Surgical osteotomy MAPLIN electronics, 
Rotherham, UK 
(Pro’sKit, Chesterfield, VA., 
USA) 
 
Miniature side 
cutters 
RL85G Wire cutters MAPLIN electronics, 
Rotherham, UK 
 
 
Table 2.13 Reusable surgical instruments 
 
Product Catalogue No. Purpose Supplier 
    
Masing 130mm 
angled needle holder 
BM009R suture of skin Aesculap Inc. Center Valley, PA., 
USA 
Fine tipped surgical 
forceps 
E11 handling of 
skin/suture 
Raymond A. Lamb Ltd. 
Eastbourne, E. Sussex, UK 
 
Curved forceps E13 periosteal stripping Raymond A. Lamb Ltd.  
 
95mm suture scissors BC056R cutting sutures Aesculap Inc. Center Valley, PA., 
USA 
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2.2 Methods 
 
 
2.2.1 Obtaining a muscle-derived stromal cell (MDSC) population  
 
Skeletal muscle was harvested from C57/Bl6 mice and from human subjects following 
surgical debridement and soft tissue reconstruction of lower limb trauma at Charing Cross 
Hospital (COREC No: 07/Q0411/30).  All subsequent procedures were performed under 
sterile conditions in a laminar flow cabinet (Class II microbiological safety, Gelaire, Flow).  
Around 5g of muscle was first washed briefly in Videne® solution then rinsed three times in 
HBSS.  The muscle was finely chopped using sterile scissors and placed in 20ml of digestive 
medium in a 50ml Falcon tube.  The suspension was warmed to 37°C and gently agitated for 
30 minutes.  The suspension was then passed through a cell strainer and the collected 
digestate was centrifuged at 1500 rpm for 5 minutes.  The cell pellet was resuspended in 
12ml culture medium and added to a 10 cm culture plate.  Cell cultures were maintained in 
a humidified atmosphere of 5% CO2 at 37oC.  The culture media was changed at 24 hours 
and the plate assessed at day 3 for the presence of muscle-derived stromal cells (MDSC).   
 
 
2.2.2 Flow cytometry 
 
MDSC were suspended in FACS Wash Buffer, at a concentration of around 1x105 cells per 
ml.  The cells were divided into aliquots of around 1x105 cells (1ml) in a FACS tube, with one 
aliquot for each antibody tested.  The cells were first placed on ice to cool.  The 
fluorochrome-conjugated antibody was then added (volume as per manufacturer 
instructions, usually 10-20µl). To further aliquots, isotype controls were added for each 
antibody and fluorochrome.  To permit gate optimisation in the FACS analysis software a 
final sample was aliquoted, and no antibody was added.    The suspensions were then 
vortexed and incubated in darkness at 4°C for 45 minutes.  The cells were then washed 
twice with FACS Wash Buffer and resuspended in 1ml FACS Wash Buffer before being 
tested, using a BD-LSR bench-top flow cytometer (BD Biosciences, NJ, USA). Typically, 
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staining was measured as an analysis of 10,000 events and expressed as a percentage of 
total cells.  The data were analysed using Flowjo software for windows (Tree Star Inc.).   
 
 
2.2.3 Tri-lineage differentiation 
 
2.2.3.1 Osteogenic differentiation 
 
Staining of MDSC for alkaline phosphatase 
 
1x104 MDSC were added to wells of a 24-well plate in duplicate.  At 24 hours culture media 
was replaced by 1ml osteogenic media, which was changed every 3 days thereafter.   At day 
7 and the monolayer was fixed with 1:1 100% acetone: 100% ethanol for 15 minutes, then 
rinsed 3 times. One SIGMAFAST™ tab was dissolved in 10ml dH2O and 0.5ml added to each 
well.  The plate was incubated at 37°C for 30 minutes.  Positive cells appeared dark purple 
under light microscopy.   
 
Staining of MDSC for bone nodule formation  
 
Again, 1x104 MDSC were added to wells of a 24-well plate in duplicate.  Both osteogenic 
media and human serum supernatant (with or without the addition of pro-inflammatory 
cytokines at the concentrations stated in the figures) were both used in different 
experiments to culture the MDSC.  The experiment was continued for 35 days.  The cells 
were fixed with 2ml 10% neutral buffered formalin at room temperature for 15 min. The 
plate was then washed twice with excess phosphate buffered saline (PBS).  1ml 40 mM 
alizarin red solution (filtered and adjusted to pH 4.1 using 10% v/v ammonium hydroxide) 
was added to each well and agitated at room temperature for 30 minutes.  The excess dye 
was then aspirated and the plate washed four times using distilled water with gentle 
agitation.  Finally, the plates were turned upside-down on paper to dry.  Bone nodules 
appeared red under light microscopy.   
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2.2.3.2 Adipogenic differentiation 
 
Culture of MDSC in adipogenic media 
 
1x104 human MDSC (200µl 5x104 cells/ml in media) were added to wells of a 24-well plate 
(in triplicate).  At 24 hours the media was removed and replaced with 1ml adipogenic 
induction media (Lonza Inc.) formulated as stated in the section 2.1.  At day 3 the media 
was removed and replaced with 1 ml adipogenic maintenance media (Lonza Inc.) also 
formulated as stated in the section 2.1.  During media changes every 4 days, induction and 
maintenance media were used alternately.  At 21 days the cells were then fixed in 10% 
formalin and stained with Oil red O as described below. 
 
Oil-red O staining 
 
Three parts filtered Oil red O stock solution (containing 300mg Oil red O powder and 100ml 
99% isopropanol) were mixed with 2 parts deionised water and left at room temperature 
for 10 minutes.  The fixed monolayer was rinsed gently using tap water.  1ml 60% 
isopronanol was pipetted into the side of each well and left for 5 minutes.  The isopropanol 
was then poured off and 1 ml of the Oil red O solution was added to each well.  At 5 
minutes this was also removed and the wells rinsed with tap water until the water ran clear.  
Fat droplets appeared red. 
 
 
2.2.3.3 Chondrogenic differentiation 
 
Human MDSC (1x105) were added to a 15ml Corning tube (in triplicate), and centrifuged at 
1500 rpm for 5 minutes.  The media was removed, leaving the cell pellet.  To 2 tubes, 1ml 
chondrogenic media (ChondroDiff medium) was added.  To the third, standard (control) 
media was added.  The medium was changed every 3 days.  At day 21, the cell pellet was 
fixed by immersion in 10% neutral buffered formalin for at least 1 hour and stained using 
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Alcian blue (courtesy of Mr David Essex, Department of Histopathology, Charing Cross 
Hospital).   
 
 
2.2.4 Supernatants 
 
Fracture supernatants were produced for the purpose of culturing MDSC in an in vitro 
model to study the influence of the fracture environment on adjacent muscle.  
Supernatants from one donor were cultured with cells from another.  Fracture fragments 
were obtained following debridement and surgical reconstruction of open tibial fractures, 
or following amputation for un-reconstructable severe open tibial fractures under the terms 
of the ethical approval granted by the combined office of research ethics committee (COREC 
No: 07/Q0411/30).   
 
The following criteria were used to define the donor population for fracture fragments: 
 
1. Patient less than 50 years old 
2. Direct referral (hence delay between fracture and harvest determinable) 
3. Delay less than 72 hours 
4. No signs of infection or gross contamination at debridement  
5. No prior washout procedure performed 
 
Following surgical debridement, fragments of devitalised bone produced by the high energy 
impact were collected.  Where the limb was amputated, bone adjacent to the fracture was 
cut using a surgical saw (Stryker).   These samples of bone were used to produce “fracture” 
supernatants.  In patients who underwent amputation for severe ankle or foot trauma 
proximal tibia was harvested, and divided into segments using a surgical saw.  This non-
traumatic, injury free bone was used to make “surgically cut” (control) supernatants.    
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Serum free media was added to fractured or surgically cut bone at 5ml per gram of bone, 
and incubated for 12 hours.  The supernatant was then centrifuged at 6,000 rpm for 15 
minutes to remove all cells and debris, before being filter-sterilised using a 0.2µm filter 
(VWR International Ltd, Lutterworth, Leicestershire, UK).  Finally, the supernatant was 
divided into 10ml aliquots and stored at -80°C prior to use.  See Figure 2.1. 
 
 
2.2.5 Alkaline phosphatase (ALP) quantification assay 
 
1x104 human MDSC (200µl 5x104 cells per ml in media) was added to wells of a 96 well plate 
in triplicate.  At 24 hrs the media was pipetted off and replaced by 200µl test media (either 
supernatant or controls).  The media was changed every 3 days.   At 7 days (unless 
specified), the media was removed and the cells lysed in 20µl NP-40 lysis buffer. An ALP 
quantification assay (WAKO pure chemical, Japan) was used.  Calibration solution from the 
assay (equating to 0.5mmol/L ALP) was then serially diluted to make concentrations of 0.25, 
0.125 and 0.0625 mmol/L. To empty wells, 20µl of each calibration solution was added. To 
another, dH2O was added as a blank control.   100µl reagent (1 tablet per 5ml buffer 
solution) at room temperature was added to each well, and incubated at 37°C for 30 
minutes.  80µl cold (4°C) stop solution was then added to each well and the plate was read 
using an ELISA spectrometer at a wavelength of 405nm.  The concentration of ALP in the 
test wells was determined using the standard curve. 
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Figure 2.1 Production of supernatant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6 MDSC migration through a transwell membrane 
 
Firstly, 8µm pore transwell membranes (VWR International Ltd, Lutterworth, Leicestershire, 
UK) were placed into wells of a 24-well plate, containing 500µl of serum free media.  The 
volume was chosen as it is the volume required to immerse the transwell membrane 
sufficiently.  The transwell membranes were set up in triplicate for each test condition.  
1x104 MDSCs in serum free media were then added to the upper chamber of each transwell 
and incubated at 37°C with 5% CO2 overnight.  
Next, the serum-free media in the lower chamber was replaced with 500µl test media.  The 
transwell membranes were then incubated at 37°C in a tissue culture incubator for 36 
hours.  This configuration is shown in Figure 2.2.    
 
 
 
 
 
 
 
 
Figure 2.1 Fracture supernatant was obtained by culture of bone in serum-free medium for 12 hours.  The 
media was then pipetted off, centrifuged at 6,000 rpm for 15 minutes to remove all debris, and filter-
sterilised prior to cell culture or storage.  The same procedure was used to obtain surgically cut, control 
supernatant.   
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Figure 2.2   Investigation of cell migration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The membranes were then removed from the wells, and the upper chambers cleared of 
cells and cell debris using a cotton bud, in sweeping motions.  The membrane was then 
washed gently using PBS, and added to a well of a further 24 well plate, containing 500µl 
10% neutral buffered formalin.  After 1 hour the fixed transwell membrane was removed 
and washed gently in tap water.  The membrane was then transferred to a well of a further 
24 well plate containing 500µl 1% crystal violet solution for 1 hour.  Finally, the membrane 
was then washed gently with tap water. Using light microscopy at 20-times magnification, 
the number of cells present on the transwell membrane in any random field was counted 
thrice and the mean calculated.  Cell migration was expressed as a percentage relative to 
the control, which (depending on the experiment) was either supernatant only or human 
serum-containing media.     
 
 
 
Figure 2.2 The transwell membrane was set up as shown.  The cells were incubated for 36 hours, and any 
remaining cells cleared from the upper chamber using a cotton bud.  Cells that had traversed the 
membrane pores and were adherent to the underside of the membrane were fixed, stained and counted.  
Each test condition was performed in triplicate, on 3 separate occasions (n=3). 
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2.2.7 MDSC proliferation assays 
 
Luninescence assay 
2.5x103 MDSC (equivalent to 50µl 5x104/ml MDSC) in serum free media were added to wells 
of an opaque-bottomed 96 well plate (Perkin-Elmer, Waltham, MA) in triplicate.  Each 
triplicate was set up to correspond to each condition tested.  Plates were set up for days 1, 
3 and 5.  A further plate, containing one triplicate for day 0 was included, to act a baseline 
measurement for all cells. The next day (day 0), the serum free media was aspirated from 
the plate and replaced by 200µl test media.   The plates were incubated at 37°C in a tissue 
culture incubator.  Plates were harvested at days 1, 3 and 5 by aspirating the test media and 
replacing with 100µl serum free media, followed by 100µl CellTiter-Glo® luminescence assay 
media (Promega Corp., Madison, WI).  The plate was then agitated gently for 10 minutes 
before being read using a Perkin-Elmer fluorescence spectrometer, and “FL WinLab” 
software, on the “Luciferase” setting.  The mean luminescence counts were then calculated 
from the absolute values.    
 
Cell count method 
2.5x103 MDSC (equivalent to 50µl 5x104/ml MDSC) in serum free media were added to wells 
of an 96 well plate in triplicate.   The next day (day 0), the serum free media was aspirated 
from the plate and replaced by 200µl test media.   The plates were incubated at 37°C in a 
tissue culture incubator for 5 days.  The cells were then removed from the wells by 
trypsinisation and counted using a haemocytometer.   
 
 
2.2.8 ELISA methodology 
 
Commercially available ELISA kits were obtained in order to measure the concentrations of 
protein (antigen) in fracture and control supernatants.  The standard, two antibody 
quantitative “sandwich” enzyme immunoassay technique was utilised in all cases.   
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The “sandwich” technique uses first a purified antibody specific for the antigen under 
investigation, which is pre-coated onto a 96-well polystyrene micro-plate.  The supernatant, 
containing the protein (antigen) is added to the well and the antigen is permitted time to 
complex with the bound antibody.  A standard curve is generated by adding a standard 
protein of known concentration, in stepwise dilutions.  After washing, an enzyme linked 
polyclonal antibody specific for the antigen is added to the wells.  Again, the antibody is 
permitted time to bind to the antigen.  After washing to remove any unbound antibody-
enzyme reagent, a substrate solution is added to the wells.  This determines a colour change 
proportional to the amount of bound antigen present.  The colour development is then 
stopped and the colour change quantified spectrophotometrically, with the absorbance 
equated to the amount of antigen bound, and calculated using the standard curve.  The 
specific procedure for each assay was followed as per the manufacturer’s instructions.   
 
 
2.2.9 Luminex methodology 
 
The 30-plex assay (Invitrogen) enables the simultaneous measurement of 30 human 
cytokines, chemokines and growth factors as detailed in the materials section.  The 
multiplex bead immunoassay is a solid phase “sandwich” immunoassay, designed to be read 
using a Luminex xMAP® system (Luminex Corp., Austin TX.).  Polystyrene microspheres 
measuring 5.6 µm in diameter are pre-coated with antibodies specific to the proteins 
(antigens) being tested.    The coated beads were added to each well of a pre-wetted filter 
bottom 96-well micro plate with the sample or standard, and incubated for 2 hours to 
permit binding of the analytes to the beads.  After washing, a solution containing a mixture 
of biotinylated, analyte-specific antibodies was added and incubated for a further 1 hour.  
This stage permits binding of the biotinylated antibodies to the bound analytes on the 
polystyrene beads.  After further washing, streptavidin, conjugated to R-Phycoerythrin (a 
flurorescent protein) was added and incubated for a further 30 minutes.  During this stage, 
the fluorescent protein bound streptavidin binds to the biotinylated antibody forming a 
solid-phase sandwich.  After repeated washing the plate is read using a Luminex 100™ 
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instrument.  The fluidics system of the Luminex 100™ permits a stream of suspended 
microspheres to line up in single file prior to passing through the detection chamber.  As 
each microsphere passes through the detection chamber, a red laser excites both the red 
and infra-red dyes, permitting a unique signature of fluorescence corresponding to a “set” 
on the bead, which in turn represents the site of residence of a named analyte antibody.  
Simultaneously, a green laser excites the bound fluorescent protein (associated with binding 
of the analyte.  Precision is ensured as each particle is read individually, and a mean value is 
generated using the Luminex software.   
 
 
2.2.10 Heat-denaturing of supernatant 
 
1.5ml of filter sterilised supernatant was added to a 2ml screw topped Eppendorf tube and 
heated in a heat block at 95°C for 1, 2, 5, 10 and 20 minutes.  The other half of the same 
aliquot of supernatant was kept at 4°C, as a control. Supernatant was mixed with fresh 
serum free media at 1:1 concentration in order to replace heat-denatured glutamine 
(GlutaMAX™) in the culture media. 200µl aliquots of the mix were added to each well 
containing 1x104 MDSC in triplicate, and cultured for 7 days.  A further aliquot of the same 
heat-treated supernatant was used at day 4 when, as usual, the media was changed 
 
 
2.2.11 Trypsin digestion of supernatant constituents 
 
To a 10ml aliquot of supernatant, 2ml of 4% cross linked trypsin coated agarose beads 
(Thermo Fisher Scientific Inc., Waltham, MA) in PBS was added and incubated at 4°C on a 
turning table for 6, 24 and 48 hours.     To another 10ml aliquot of supernatant, 2ml of 4% 
cross linked agarose beads (Cambio Ltd., Cambridge, UK) in PBS was added and incubated as 
above.  The suspensions were then centrifuged at 1500rpm for 5 minutes to pellet the 
beads and the supernatant pipetted off.  The supernatant was then filter sterilized prior to 
cell culture.    
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2.2.12 Ion column separation 
 
15ml of supernatant was first diluted at a ratio of 1:1 with distilled water to reduce the ion 
content of the supernatant.  A 1ml HiTRAP™ SP HP cation exchange column (GE Healthcare 
UK Ltd., Little Chalfont, Buckinghamshire, UK) was washed through with 5 column volumes 
(5ml) of distilled water to remove the 20% ethanol used to store the column.  The SP 
column binds positively charged molecules.  The recommended flow rate for this column 
was 1ml/min.  The column was then pulsed with 5 column volumes of “high” salt buffer to 
prime the column, followed by 5 column volumes of “low” salt buffer to equilibrate the 
column.  12ml of diluted supernatant was loaded onto the column at a flow rate of 
1ml/minute and the flow-through collected.  The column was then washed through with 
10ml of “low” salt buffer, to remove any residing unbound proteins.  Again, the flow 
through was collected and stored.  The bound proteins were then eluted by loading the 
column with 3ml “high” salt buffer at a rate of 1ml/minute, and again collecting the elutant.  
Finally, the column was washed with a further 5 column volumes of “low” salt buffer.  Prior 
to storage, the column was pulsed with distilled water and finally 5 column volumes of 20% 
ethanol.  The column was stored at 4°C until further use.  This process was repeated 
simultaneously with a 1ml HiTRAP™ Q HP anion exchange column.  This column binds 
negatively changed molecules and also has a recommended flow rate of 1ml/min.  The ion 
column separation set-ups are shown in Figure 2.3.  All flow through steps for both columns 
were then subjected to SDS PAGE electrophoresis and silver staining of the gel.   
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Figure 2.3 Ion exchange columns 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.13 Saline extraction 
 
In order to use the HiTRAP™ SP HP cation exchange column and HiTRAP™ Q HP anion 
exchange column elution products for culture of MDSC, the elution fractions were first 
desalinated to prevent osmotic cell lysis.  A PD-10 Desalting column (GE Healthcare UK Ltd., 
Little Chalfont, Buckinghamshire, UK) containing 8.3ml of Sephadex™ G-25 medium was first 
flushed with 5 column volumes of elution buffer (in this case PBS) to prime the column.  
2.5ml of the eluted protein suspension was then added to the column, and passed through 
under gravity.  The flow-through was discarded.  The column was then eluted using 3.5ml of 
PBS and the elution was collected.  The eluted protein suspension was then added to a 5ml 
concentrating spin column (Sartorius Stedim BioTech GmbH, Goettingen, Germany), and 
 
Figure 2.3 These columns use the static charge of proteins to bind them.  The column is first filled with an 
equilibrated salt solution. As the supernatant is passed through the column, proteins bind to the charged 
particles within the column, and are eluted using a concentrated ionic solution (high-salt buffer).  The 
eluted protein solution is then de-salinated prior to tissue culture.  
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spun at 3,000 rpm for 15-20 minutes until the protein suspension was maximally 
concentrated, then reconstituted in 5ml serum free media.  This volume reconstituted the 
eluted fracture supernatant at a concentration of 1:1.  The suspension was then filter 
sterilised prior to cell culture.  
 
 
2.2.14 Serum protein extraction 
 
In order to aid the identification of non serum proteins in the fracture supernatant, the 
serum proteins were extracted using an IgY-12 high capacity LC10 proteome partitioning kit 
(Beckman Coulter Inc., Fullerton, CA).  The LC10 column immunoglobulin profile consists of 
anti-human serum albumin, anti-IgG, anti-fibrinogen, anti-transferrin, anti-IgA, anti-IgM, 
anti-HDL (anti-apo A-I and anti-apo A-II), anti-haptoglobin, anti-α1-antitrypsin, anti- α1-acid 
glycoprotein and anti-α2-macroglobulin.  The IgY antibodies are covalently conjugated 
through their Fc portion to 60µm polymeric micro beads as a 50% resin.   
 
The LC10 column was connected in series with a Amersham Akta fast protein liquid 
chromatography (FPLC) system, comprising a P920 pump, UPC900 detector, M-925 gradient 
mixer, a INV-907 injection valve and FRAC-950 fraction collector (all Amersham Pharmacia 
Biotech (GE healthcare), Little Chalfont, Buckinghamshire, UK).  The system was controlled 
using Unicorn™ 3.0 software for windows.  The set-up is shown in Figure 2.4.   
 
The buffers (supplied) were as shown in Table 2.14 
 
Buffer Constituents 
  
10x dilution buffer (Tris buffered saline) 100mM Tris-HCl, Ph7.4, 1.5M NaCl 
1M Stripping Buffer 1M-Glycine-HCl, pH 2.5 
1M Neutralisation buffer 1M Tris-HCl, pH 8.0 
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Figure 2.4 Amersham Akta FPLC system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior to running the supernatant through the column, the FPLC system was primed, washing 
pump “A” with 1x dilution buffer and pump “B” with 1x stripping buffer.  Using a 500µl 
capacity loading coil, 500µl supernatant was loaded in series. The flow rate was set to 
1ml/min with a maximum pressure of 0.5 miliPascals (mPa) (column maximum pressure was 
6mPa) and a fraction collection volume of 1ml.  A 1ml capacity, 96 well fraction collection 
plate was loaded onto the fraction collector.  The flow was then commenced with the 
fraction collection, running the loaded supernatant through the column in series.  The 
spectrophotometric trace was then observed for evidence of non-bound (non serum) 
proteins.  These were visible as “spikes” on the spectrophotometric trace.   
 
Optimisation experiments had determined that more than of 2500µl of supernatant could 
traverse the column without saturation.  Hence using a 500µl capacity loading coil, 5 loads 
of 500µl were used prior to column elution.  Using the software control, after the 5th and 
 
Figure 2.4 The 3-way valve permits loading and run-through in isolation.  The supernatant sample was 
loaded onto the loading capacitor (the arrangement shown demonstrates isolation of the loading system).  
The orientation of the valve was then changed to permit the sample to run in series with the serum 
extraction column, and the samples were collected.  The spectophotometric trace guided the collection of 
protein-containing samples and the elimination of waste.   
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final spike had been observed the pH gradient was changed from 0% (dilution buffer) to 
100% (stripping buffer) and the fraction collection was commenced.  The 
spectrophotometric trace was then observed for evidence of eluted proteins.  When the 
trace demonstrated no further proteins in the elution, the gradient was changed back to 
0%, to neutralise the column, and the collection of fractions was terminated.  The 1ml 
fractions collected following commencement of the elution were then neutralised using 
20µl neutralisation buffer (the volume was pre-determined from optimisation experiments 
and confirmed following reconstitution in serum free media by the presence of pH sensitive 
phenol red).  The flow-through protein fractions were then concentrated using a 10ml 
concentrating spin column, and a concentrated sample of flow-through proteins was 
reconstituted in serum free media to an end volume of 2500µl (1:1 volume with 
unfractionated supernatant).  Similarly, the neutralised elution fractions (serum proteins) 
were also concentrated and reconstituted.  The “flow-through” and “elution” fractions were 
then tested for osteogenic differentiation of MDSC by ALP assay of MDSC cultured in test 
fractions.   
 
Prior to closing down the FPLC system, pumps “A” and “B” were washed through with PBS 
containing 0.02% azide using the pump wash programme, then the entire system, including 
the column in series was washed through with PBS + 0.02% azide for 5 minutes.  If the 
column was to be used again within 48 hours, the system and column was instead washed 
through with 20% ethanol prior to shut-down.   
 
 
2.2.15 Supernatant separation using a gel-filtration column 
 
In order to separate the “flow-through” fraction into its constituent proteins by molecular 
size, the “gel-filtration” protein separation was used.  Separation by gel filtration divides 
molecules by size, weight and shape.  The column is packed with porous gel beads, with a 
pore size chosen to permit small molecules to enter the beads and exclude large molecules.  
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As large molecules go round the beads, they exit the column first.  The set-up is shown in 
Figure 2.5.  
 
Figure 2.5 Gel-filtration Chromatography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This system used a XK 16/100 column, packed with 750ml Sephacryl™ S200 HR (GE 
healthcare, Little Chalfont, Buckinghamshire, UK).  PBS was used as the running buffer for 
this step.  Briefly, the column was connected in series with the FPLC (see Figure 2.4) and 
pumps “A” and “B” were washed through the pump-wash programme using PBS.  Next, the 
column was washed through with PBS overnight (if containing PBS in 0.02% azide or 20% 
ethanol used for storage). A 1ml capacity loading coil was used and 1ml of spin-
concentrated flow-through (see above) was loaded into the system in series.  The flow rate 
was set to 1ml/ml and the pressure alarm set to 0.5mPa. Four 1ml-capacity, 96 well fraction 
 
Figure 2.5 A gel-filtration chromatography column was set up and run using the Amersham Akta FPLC 
system (represented diagrammatically in figure 2.4).  The supernatant sample, with serum proteins 
removed (as detailed in section 2.2.14) was run through the column, and the flow-through collected.  This 
flow-through was divided into “fractions” on the basis of the morphology of the spectrophotometric wave 
recorded from the flow-through   
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collection plates were loaded onto the fraction collector.  The flow was commenced, 
observing the spectrophotometric trace for evidence of proteins in the flow-through.  After 
about 20 minutes, flow collection was commenced (as the time taken for the flow-through 
sample to transverse the column was considerable, there was no need to collect the 
fractions immediately).  When the spectrophotometric trace stabilised following after the 
last of the fractions had traversed the spectrophotometer, fraction collection was stopped.  
The pump-wash programme was used to wash through the FPLC with PBS in 0.02% azide or 
20% ethanol, followed by the column (depending on anticipated use).   
 
Unicorn™ 3.0 software for windows marks the co-ordinate corresponding to each well of 
the 96-well plate (A1 to H12) onto the spectrophotometric trace.  Hence, the collected flow-
through was then divided into arbitrary fractions based on the morphology of the 
spectrophotometric wave. Each fraction was collected and mixed in a 50ml falcon tube, 
prior to spin-concentration as before.  The fractions were finally reconstituted in serum free 
media with an end concentration of 1:1 with the unprocessed fracture supernatant and 
filter-sterilised prior to testing by cell culture.    
 
 
2.2.16 Supernatant fraction reconstitution 
 
Using a Vivaspin-15R centrifugal filtration column (Sartorius Stedim Biotech S.A., Aubagne 
Cedex, France) eluted and flow-through protein fractions were concentrated prior to 
reconstitution for cell culture. The membrane of the spin column was first primed by 
spinning 5ml sterile PBS at 3,000 rpm for 5 minutes.   The protein suspension to be 
concentrated was then added to the upper chamber before spinning at 3,000 rpm for 15-20 
minutes.  If necessary, the tube was spun for a further 10 minutes.  The concentrated 
protein suspension was then pipetted into a 50ml falcon tube, noting the volume.  The 
suspension was then made up to the final volume required to reconstitute the protein 
suspension at a ratio of 1:1 with the unprocessed supernatant.  The reconstituted 
suspension was then filter sterilised prior to cell culture.  Alternatively, the concentrated 
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protein suspension was separated into its constituents using SDS PAGE electrophoresis for 
analysis and identification.   
 
 
2.2.17 SDS PAGE electrophoresis 
 
One dimensional (1-D) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS 
PAGE) was performed using a 12% gradient pre-cast gel (Invitrogen Corp., Carlsbad, CA).  
TRIS-Glycine was used as the running buffer in all cases.  Into a mounted gel running buffer 
was added.  Each specimen, consisting of 16µl of supernatant and 4µl of (5x) loading 
solution was added slowly, to avoid bubbles.  A running marker was also added to the 
outermost well.  Running time for each gel was 95 minutes, at 125V (400mA).   On 
completion the gel was added to a clean Pyrex developing dish containing 50% 
methanol/5% acetic acid prior to development by silver staining. 
 
 
2.2.18 SDS PAGE Silver staining 
  
The gel was fixed in a solution containing 50% methanol/5% acetic acid for 20 minutes, then 
washed in 50% methanol for a further 10 minutes before being further washed in distilled 
water for at least 1 hour, and preferably overnight.  The gel was then washed in a sensitising 
solution of 0.02% sodium thiosulphate for 1 minute before being washed twice in distilled 
water.  The gel was then incubated in a cold solution of 0.1% silver nitrate at 4°C for 20 
minutes before being washed twice with distilled water.  The gel was then developed in a 
solution containing 0.04% formalin in 2% sodium carbonate for between 5 and 10 minutes, 
until protein bands were clearly visible.  When the developer solution became cloudy 
(usually after about 3-4 minutes), the developer solution was replaced.  The development 
process was stopped by the addition of 5% acetic acid for at least 5 minutes.  Finally the gel 
was washed with distilled water for 2 further periods of at least 30 minutes.   
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2.2.19 Spectrophotometric analysis 
 
All mass spectrometry and results interpretation was performed by Dr. Robin Wait, (Senior 
Lecturer in Proteomics, Kennedy Institute of Rheumatology).  Digestion of the gel was 
performed using trypsin with an Investigator™ ProGest™ robotic digestion system and 
ProGest™ 2.01.13 software (Genomic solutions, Huntingdon, UK).  Tandem electro spray 
mass spectra were recorded using a hybrid quadrupole/orthogonal acceleration time-of-
flight (Q-Tof) mass spectrometer (Micromass, Manchester, UK) with a Micromass CapLC™ 
chromatograph.  Proteins were identified by correlation of the tandem mass spectra to 
entries in the SwissProt/TrEMBL using ProteinLynx Global Server™.   
 
 
2.2.20 Murine fracture model 
 
Home Office approval for the animal model was obtained (Project Licence No: 70/6502; 
Personal licence No: 70/20417) 
 
The procedure was performed as described by Harry et al (Harry et al., 2008).  All mice were 
skeletally mature, 12-14 weeks of age.  General anaesthesia was achieved by intra-
peritoneal injection of 10ml/kg of a mixture of Hypnorm and Hypnovel (1 part Hypnorm plus 
2 parts water for injection plus 1 part Hypnovel).  The procedure was performed in a 
designated animal theatre at the Kennedy Institute of Rheumatology.  Full surgical 
precautions were observed, with gown, theatre cap, FFP2 standard mask (3M) and sterile 
gloves.  The procedure was performed under loupe magnification (3.5x extended field 
vision, Designs for Vision Inc., Ronkonkoma, N.Y., USA) on a laminar flow table. 
 
Under anaesthesia, the right leg of the mouse was shaved and the skin prepped with 70% 
ethanol.  The leg was then draped with sterile gauze.  A longitudinal incision was made 
through the skin and fascia, along the lateral border of the tibia from the tibial tuberosity to 
the junction of the middle and distal third of tibia. For a distance of about 7mm, 
corresponding to the middle third of tibia, an incision was made through the periosteum 
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onto bone.  Superiorly, the muscle insertions were reflected medially.  Using a curved fine 
forceps, the instrument was hooked under the periosteum and around to the posterior 
surface of the tibia, and the periosteum stripped for a distance of about 7mm.  A reaming 
wire (27G micro lance needle) was then inserted through the anterior cortex of the tibia 
medially, at a point just inferior to the tibial plateau, and advanced as far as possible, using 
a twisting motion to ream the medullary canal.  The needle was then withdrawn and the 
stylet from a 22G spinal needle (with sharp tip clipped) was advanced down the reamed 
canal.  A transverse osteotomy was then created at the mid-point of the tibia using Clean-
cut Micro Nippers, (Pro’sKit, Chesterfield, VA., USA).  The pin was then cut flush with the 
tibial plateau using miniature side cutters.  After checking for haemostasis, the wound was 
closed using 6.0 prolene sutures (Ethicon) in a running horizontal mattress suture 
configuration.  The mouse was then given 1ml of warmed sterile saline subdermally, to 
replace intra-operative fluid loss and maintain blood volume. Post-operative analgesia was 
provided using 25µl of 0.3mg/ml Buprenorphine (Vetergesic®, Alstoe Ltd., York, UK) injected 
intra-muscularly to the right thigh.  This long acting analgesic partially reverses the sedative 
effect of the intra-peritoneal anaesthesia.  Each mouse was recovered in an incubator set to 
31°C.  Following recovery the mouse was returned to a fresh cage with new bedding.   
 
 
2.2.21 Murine welfare and maintenance 
 
The mice were checked each day for the first week following surgery.  The mass (in grams) 
of each mouse was recorded prior to surgery, on the first day following surgery, and 
intermittently thereafter.  The final mass was recorded after sacrifice.  In addition, the 
wound was checked for signs of dehiscence or infection.  Rotational deformity, (caused as 
the pin was fixed distally but not proximally) was noted, along with ambulation.  Animals 
with a rotational deformity in excess of 60° were culled and excluded from further analysis.  
Finally the general appearance and grooming of the mouse was recorded.  Mice were 
returned to the animal facility at the Kennedy Institute of Rheumatology, where stringent 
welfare practices are observed.   
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2.2.22 Time point harvesting of the murine model 
 
The mice were euthanased by means of cervical dislocation.  The right lower limb was then 
harvested at the level of the mid-femur, and placed immediately into 10% neutral buffered 
formalin, where the specimens were to be processed for histology, or 70% ethanol, where 
the bone was to be sent for CT.  Day 3, 7, 14 and 28 days were taken as time points for 
histology.  Day 14 and day 28 were taken as time points for CT and bend testing.  
 
 
2.2.23 Processing of the limb for histology 
 
Limbs were fixed in 10% neutral buffered formalin for 24 hours.  All limbs then underwent 
radiographic imaging using the Faxitron MX-20 radiographic system (Faxitron X-Ray LLC, 
Lincolnshire, IL., USA) at Hammersmith Hospital (as detailed below).  Comminuted fracture 
configurations and pin extrusion configurations were excluded from further analyses.  Limbs 
with acceptable fracture configurations then underwent decalcification for a period of 7 
days in 10% formic acid.  Finally the limbs were bisected longitudinally, using a number 22 
scalpel.  The pin was used to guide the bisection and then removed from the specimen.  The 
half which had contained the pin was then mounted for paraffin imbedding.   
 
 
2.2.24 Radiographic imaging 
 
Plain radiographic images of the harvested fractured limb were taken using the Faxitron 
MX-20 radiographic system (Faxitron X-Ray LLC, Lincolnshire, IL., USA) at Hammersmith 
hospital.  The settings used for the Faxitron® imager were 32 kilovolts, 18 seconds exposure 
time.  The images were processed using DICOM 3.0 compliant software.  Limbs 
demonstrating fracture comminution or pin extrusion were excluded from further study.    
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2.2.25 Histology 
 
All histology was performed courtesy of Mr. David Essex, department of histopathology, 
Charing Cross hospital.  A microtome was used to cut 4µm sections from the paraffin block.  
Sections were then dewaxed with xylene and 99% absolute alcohol (industrial methylated 
spirit), then rehydrated in preparation for staining.   
 
Representative histological sections, first stained with Haematoxylin and Eosin (H+E) were 
chosen and stained using a modified Masson Trichrome technique.  This stain differentially 
demonstrates connective tissues, with muscles and erythrocytes staining red, collagen 
staining green and nuclei staining blue/black.  Here, the sequential application of acid dyes 
in ascending order to size enables differential staining to be achieved due to varying pore 
sizes of connective tissue components.   
 
Briefly, fixed sections were stained with Celestine Blue/haemalum (Surgipath Europe Ltd, 
Peterborough, Cambridgeshire, UK) in sequence.  This pre-treatment prevents 
differentiation of the sections by subsequent acid solutions.  The sections were washed with 
distilled water, then 5% chromic acid for 10 minutes, and then washed with tap, followed by 
distilled water.  Celestine blue was reconstituted (1g in 0.5ml concentrated sulphuric acid, 
with slow addition of 100ml 2.5% ferric ammonium sulphate, 14ml glycerol then 1.4ml 
concentrated sulphuric acid, pH 0.8) and filtered slowly onto the slide for 5 minutes.  The 
slides were washed with tap water, stained with Harris’s haematoxylin (Surgipath Ltd.) for 5 
minutes, washed again with tap water then differentiated with 0.3% acid alcohol to remove 
excess stain.  A further wash with tap water was required prior to the sequence of Masson 
Trichrome staining.  This involved staining with 1% chromazone red (Surgipath Ltd.) in 1% 
acetic acid for 5 minutes.  Sections were then rinsed with distilled water, and differentiated 
with 1% phosphmolybdic acid for between 5 and 10 minutes.  After further washing the 
Trichrome mixture D (1% green light in 1% acetic acid) (Surgipath Ltd.) was added for 10 
minutes.  The sections were then rinsed with 1% phosphmolybdic acid, then 1% acetic acid 
for 2 minutes.  Slides were then dehydrated with 99% absolute alcohol and mounted using 
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“Pertex” (CellPath Ltd, Powys, UK), a xylene based mountant.  Cover slips (Deckglaser, 
distributed by Surgipath Ltd.) were placed onto the slides and pressure applied to remove 
excess mountant.  Alternatively, slides prepared for fluoroscopic visualisation of green 
fluorescent protein were simply cut from the paraffin block using the 4µm microtome and 
dewaxed prior to mounting. 
       
  
2.2.26 Immunohistochemistry 
 
Immunohistochemitry was performed courtesy of Mr. David Essex, department of 
histopathology, Charing Cross hospital and Dr. Chung-Yin Lee at Cancer Research UK.  Cells 
of the inflammatory milieu were identified by means of immunohistochemistry.   
 
Briefly, the standard steps were as follows:  All Sections were incubated overnight at 37°C 
then placed in an oven at 60°C for 1 hour.  Slides were dewaxed by placing in xylene for 2 
minutes, repeated, then placed in 99% IMS for 2 minutes.  Slides were then washed in 
0.02% hydrogen peroxide in methanol for 10 minutes.  Sections were then washed with tap 
water and placed into a water bath containing TRIS buffer at 37°C for 10 minutes digestion 
with protease (pre-digested with protease XXIV for antigen retrieval).  Following immersion 
in running tap water the area of interest was ringed with a PAP pen (DakoCytomation, 
Cambridge, UK) which created a hydrophobic ring around the section to retain the staining 
solutions.  Sections were then incubated with normal swine serum (1:10 in TBS) for 10 
minutes at room temperature, to block non-specific binding of the secondary antibody with 
endogenous immunoglobulin.   
 
The antibody was then added and incubated at room temperature for 60 minutes.  A 
complete list of IHC antibodies (with the conjugated antibody) are shown in Table 2.15. 
After washing twice in TBS, Avidin Biotin Complex (ABC) 1 in 100 was then added and the 
slides incubated at room temperature for a further 45 minutes.   3, 3’-diaminobenzidine 
tetra hydrochloride (DAB, Vector laboratories, Peterborough, UK) was added as a substrate 
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for the peroxidase. DAB/peroxidase was prepared by mixing a 0.5ml aliquot of DAB at 
25mg/ml with 24.5ml TBS and 7.5ml of 30% hydrogen peroxide immediately prior to use.    
 
 
Table 2.15 Immunohistochemistry antibodies 
 
Specificity Antibody Catalogue No. Supplier 
    
Alpha-1-actin 
 
Mouse IgG1 Ab40864 Abcam Inc. Cambridge, MA., 
USA 
 
S100(α-polyclonal) 
 
Rabbit IgG PAI-932 Thermo Scientific, Rockford, 
IL., USA 
Desmin 
 
Goat IgG AF3844 R+D Systems, Abington, UK 
 
P63 
 
Goat IgG AF1916 R+D Systems, Abington, UK 
 
    
Neutrophil elastase 
 
Rat IgG2B Ab1876 Abcam Inc. Cambridge, MA., 
USA 
 
F4/80 
 
Rat IgG2B Ab6640 Abcam Inc. Cambridge, MA., 
USA 
 
CD3 
 
Rabbit IgG Ab5690 Abcam Inc. Cambridge, MA., 
USA 
 
    
 
 
DAB forms a brown reaction product at the site of the antigen and is visible using light 
microscopy.  The sections were incubated with DAB at room temperature for 5 minutes 
then washed with TBS then tap water.  The sections were then counterstained using Harris’s 
Haematoxylin for 1 minute, differentiated in 0.5% acid alcohol, and washed with running 
tap water.  Slides were then dehydrated using 99% IMS, cleared with xylene and mounted 
with Pertex.  
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2.2.27 Image acquisition 
 
The slides were viewed under x4 magnification using an Olympus BX51 microscope 
(Olympus optical, Tokyo, Japan) at room temperature.  Images were taken using an 
Olympus DP71 camera and DP controller and manager, Olympus software, version 
2.3.1.231.   A fluorescent light source was used for the fluorescent images.  
  
 
2.2.28 Processing of the limb for CT 
 
The limbs were immersed in 70% ethanol for at least 24 hours.  The tibia was then isolated 
by stripping of the surrounding soft tissue.  Using fine cutters, and under loupe 
magnification, the intramedullary nail was removed, taking care not to compromise the 
fracture callus.  The isolated tibia was then stored in 70% ethanol at 4°C prior to sending for 
micro-CT scanning.  
 
 
2.2.29 CT imaging 
 
Mineralisation of the fracture callus lesion was assessed using microcomputed tomography 
(micro-CT).  Mouse tibiae were harvested at 14 and 28 days post-fracture. Unfractured 
tibiae were also scanned for comparison of phenotypes.  The specimens were immersed in 
ethanol for transport and wrapped in plastic film for scanning. 
  
Each bone was scanned using a SkyScan 1172 scanner 
(http://www.skyscan.be/products/1172.htm).  All scans were performed at a voltage of 
50kV and a current of 197µA.  A cross-sectional pixel size of 8.370536µm was used.  
Calibration settings were calculated using phantom bone substitutes of known density, as 
well as air and water samples, according to SkyScan protocols.  The density range was thus 
calibrated to bone mineral density, and a threshold density of 350gm/cm3 was selected to 
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distinguish mineralized from unmineralised tissue.  This threshold was derived from earlier 
work (Harry et al., 2008). 
  
The scans were analysed using SkyScan CT Analyser software, version 1.9.3.0 (© SkyScan 
2003-2009).  Bones which exhibited angulation, rotation or hypertrophic non-union were 
excluded.  Some examples of unacceptable morphologies are shown in Figure 2.6.  Scans of 
120 slices per mm permitted fine resolution of tissue structure. A volume of interest (VOI) 
was selected for each bone. 
 
A region of 120 slices (1mm in height), commencing at the fracture site and proceeding 
proximally was selected for analysis. In each case profiles were drawn precisely around the 
callus lesions, thus the total volume of the VOI varied according to the healing process and 
the time point.   
 
 
This narrow region was chosen to avoid potential confounding effects proximally and 
distally. More proximally, the tapering callus was confluent with bone, and the callus tissue 
calcified more rapidly in this region and was therefore likely to have a high density of 
mineralised tissue in all specimens (Gerstenfeld et al., 2006).  More distal to the fracture 
region, the healing tibial callus was encroached upon by the callus forming around the fibula 
fracture, which occurred post-operatively after weight-bearing. 
 
The volume of all callus tissue within the 1mm length selected was measured, with a lower 
threshold set to exclude unoccupied space (Total callus Volume, TCV). The volume of tissue 
that exceeded the threshold density of bone (350gm/cm3) was also calculated (Mineralized 
Callus Volume, MCV).  The percentage mineralisation of the total was calculated as 100 x 
MCV/TCV.  Reconstructions of scans were imaged in SkyScan CTVol™ software: Realistic 3D-
Visualisation, Version 2.1.1.0 (© SkyScan 1983-2008). 
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Figure 2.6 Examples of the three unacceptable fracture morphologies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.30 List of stains investigated using the in vivo fracture model 
 
 
The strains investigated using the in vivo fracture model are shown in Table 2.16  
 
 
 
 
 
Figure 2.6 Fracture morphology was determined by reviewing the 3-dimentional reconstructed images of 
all scanned bones.  Bones were excluded for further analyses if they appeared angulated, impacted or 
rotated, or if hypertrophic non-union occurred as fracture alignment, movement and weight bearing status 
were all considered to influence rate of endochondral callus maturation. 
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Table 2.16 
 
Strain 
 
Background strain Origin 
   
C57/Bl6 
 
--------- Charles River UK. 
P55-/- 
 
C57/Bl6 Kennedy Institute BSU 
P75-/- 
 
C57/Bl6 Kennedy Institute BSU 
IL-1R-/- 
 
C57/Bl6 Kennedy Institute BSU 
IL-6-/- 
 
C57/Bl6 Kennedy Institute BSU 
BALB/C 
 
--------- Charles River UK 
SCID BALB/C Charles River UK 
   
 
 
2.2.31 List of additions to the fracture model 
 
All substances added to the fracture model are listed in Table 2.17.  The total volume used 
per local injection was 20µl in all cases. 
 
Table 2.17 Additions to the fracture model 
 
Substance Order 
No. 
Supplier Route Dose Regimen 
      
rhTNF-α 210-TA R+D Systems, 
Abington, UK 
 
Local 5-500ng/kg 0, 24 hr 
rmIL-1β 201-LB R+D Systems, 
Abington, UK 
 
Local 50ng/kg 0, 24 hr 
rhIL-6 206-IL R+D Systems, 
Abington, UK 
 
Local 50µg/kg 0, 24 hr 
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2.3 Statistical analyses 
 
 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad software, 
San Diego, CA). Alkaline phosphatase (ALP) and cell migration studies were performed using 
muscle-derived stromal cells (MDSC) from three different donors in most cases.  Each 
experiment was performed in triplicate three times, with the mean and standard error of 
the mean (SEM) calculated in each case.  Statistical analyses were performed using one way 
analysis of variance (ANOVA) with Bonferroni’s correction for multiple comparisons.  Where 
multiple results were compared against a standard or control series Dunnett’s post test 
correction was performed.  Comparisons of the cytokine and growth factor concentrations 
in fracture vs. surgically cut; and in active vs. inactive supernatants were analysed using a t-
test (Mann-Whitney) as these concentrations did not exhibit Gaussian distribution.  
 
Using an in vivo murine fracture model callus mineralisation at day 14 and day 28 was 
quantified using computer tomographic (CT) reconstructed images of the healing bone.  
Comparisons were made between knockout strains and the wild type controls.  Moreover, 
comparisons were made between mice treated with recombinant TNF-α and untreated 
controls.  These comparisons were analysed using a t-test with Welch’s correction, as 
percentage callus mineralisation for each strain at each time point did not exhibit Gaussian 
distribution or equal variances.     
 
Results were considered statistically significant when P<0.05.  Significant result were 
expressed using asterisks, where *: P<0.05, **: P<0.01, ***: P<0.001.  This convention was 
used throughout.   
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
The recruitment of muscle-derived stromal cells for 
fracture healing 
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3.1 Introduction 
 
 
Results from our lab suggest that when muscle is excluded from the fracture healing 
environment healing, assessed by callus mineralisation and 4-point bend strength, is 
impaired (Harry et al., 2008).  Tissue vascularity was not a reason for this as had previously 
been hypothesised (Calderon et al., 1986; Schemitsch et al., 1997) as contact with 
fasciocutaneous tissue (which had a greater capillary density) resulted in poorer healing 
(Harry et al., 2009).  It was hypothesised that muscle provided a source of osteoprogenitor 
cells to aid fracture healing in this model.  In order to prove this hypothesis, it was necessary 
to determine the osteogenic potential of samples from muscle and investigate the influence 
of the fracture environment of these samples.   
 
If the hypothesis was true, then a question arose as to the nature of the stimulus from the 
fracture environment responsible for the recruitment and osteogenic differentiation of 
muscle-derived cells.  The study of fracture healing has been hampered by the lack of 
translationally robust models.  Specifically, the temporal and spatial pattern of growth 
factor stimuli required to promote fracture healing in primitive mammals appears to be less 
complex than in humans.  Therefore it was reasoned that the translational potential of a 
study of the recruitment and differentiation of muscle-derived cells would be aided greatly 
by an in vitro model using primary human tissue.  As a reconstructive centre for lower limb 
trauma Charing Cross hospital was an ideal source for this tissue.  Samples were obtained 
with ethical approval and individual consent.   
 
The principle of muscle-derived cell involvement in fracture healing was explored using the 
in vivo model of fracture healing developed by Harry et al.  Cells were isolated from murine 
and human skeletal muscle samples.  Supernatants were harvested from cultured fractured 
bone fragments.  The influence of the supernatants on the cells was established.  Isolation 
of the factor or factors responsible for osteogenic differentiation of muscle-derived cells 
was attempted using chromatographic purification. 
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3.2 Investigating the role of MDSC in fracture healing using a murine 
model 
 
 
Using the murine tibial fracture model developed by our lab (Harry et al., 2008) the 
influence of the fracture environment on the adjacent soft tissues was investigated.  
Specifically, the response of cells from the muscle and fasciocutaneous tissue to the 
adjacent fracture, the isolation and phenotypic characteristics of these cells and the 
response of the cells following exogenous administration adjacent to fracture were 
investigated. 
 
3.2.1 Muscle cells adjacent to fracture expressed the osteogenic marker alkaline 
phosphatase and formed bone nodules in vitro 
 
The murine tibial fracture model was performed as described in section 2.2.20.  A sham 
fracture control that included soft tissue dissection and periosteal stripping but no mid-
tibial osteotomy was used as a fracture control.  The limb contralateral to the fractured tibia 
was used to control for the systemic effects of the tibial osteotomy. 
 
Cells isolated from muscle adjacent (posterior) to fractured tibia demonstrated clustering 
when cultured in media for 72 hours.  Additionally, they strongly expressed alkaline 
phosphatase (ALP).  This is shown in Figure 3.1A.  Conversely, the cells isolated from 
fasciocutaneous tissue adjacent (anterior) to fractured tibia did not exhibit cluster 
formation when cultured for 72 hours.  Moreover, they did not express ALP.   Cells isolated 
from muscle adjacent to the sham fracture exhibited some ALP expression but no clustering 
(Figure 3.1B).  Cells from the fasciocutaneous tissue of the sham fracture were similar to 
those isolated from the fractured limb.  They neither expressed ALP nor clustered.  Cells 
from the muscle and fasciocutaneous tissue of the limb contralateral to the fracture did not 
express ALP and did not cluster (Figure 3.1C).  This experiment demonstrated that cells 
present in muscle were stimulated to undergo osteogenic differentiation while cells from 
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fasciocutaneous tissue were not and that this stimulus was dependent on proximity to 
fracture.   
 
The clustering observed in cells isolated from muscle was suggestive of early nodule 
formation.  Hence the experiment was repeated and the cell culture continued for 28 days.  
The cells were then fixed and stained for bone nodule formation.  The results of this 
experiment demonstrated that cells harvested from muscle adjacent to fracture formed 
bone nodules in culture over 28 days (Figure 3.2A).   As expected, the cell isolates from the 
sham fracture (Figure 3.2B) and the cell isolates from the contralateral limb (Figure 3.2C) 
did not form bone nodules in culture.  This experiment, together with the experiment 
shown in Figure 3.1 demonstrated that following an initial fracture-derived osteogenic 
stimulus, the muscle-derived cells were capable of osteogenic differentiation and cell 
differentiation continued to completion in the absence of the initiating stimulus after day 3.   
 
 
3.2.2 Cells isolated from muscle adjacent to fracture exhibited stromal and 
haematopoetic markers 
 
Cells from the isolates plated in the experiments described in section 3.2.1 were triangular 
or spindle shaped, which suggested that they were stromal cells.   The next experiment 
aimed to further characterise these cells. 
 
Cells were obtained from a digest of muscle adjacent to fracture as before.  Cell aliquots 
were then incubated with fluorochrome-conjugated antibodies to cell surface markers 
CD34, CD45, CD73, CD90, CD105, CD117 and Sca-1 and cell-bound fluorochromes were 
counted using a flow cytometer.  A summary of murine and human cell surface markers are 
shown in Table 3.1.  A typical example of the FACS plots obtained is shown in Figure 3.3. 
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Figure 3.1 Cells from muscle adjacent to fracture exhibit cluster formation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 12 week old female C57Bl6 mice (Charles River Laboratories, Inc., Wilmington, MA) underwent 
right tibial periosteal stripping, intramedullary pin fixation and mid-shaft osteotomy as described in section 
2.2.20.  The mice were sacrificed at day 3. A sample of muscle (posterior) and fasciocutaneous tissue 
(anterior) to the mid-shaft of the tibia was digested enzymatically and plated in culture media.  At 72 hours 
the cells were fixed using 1:1 ethanol: acetone and stained for alkaline phosphatase (ALP), using the 
SIGMAFAST™ ALP stain.  The fractured tibia is shown radiographically in A.  Sham fracture is shown in B.  
The contralateral limb to A is also shown (C).  Cells harvested from muscle and fasciocutaneous tissue are 
labelled.  One experiment used 3 fractured and 3 sham fractured mice and the experiment was repeated 3 
times (n=3). A representative area of one plate is shown for each (x10 magnification). 
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Figure 3.2 Cells from muscle adjacent to fracture exhibit bone nodule formation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 The murine fracture model was performed and the tissues harvested as before.  This time, the 
cells were cultured in media for 28 days, with media changes every 4 days.  The cells were then fixed with 
10% formalin and stained for bone nodules using alizarin red.  A: Fractured tibia. B: Sham fracture (soft 
tissue dissection only). C: Contralateral limb to the fractured limb (A).   Cells harvested from muscle and 
fasciocutaneous tissue are labelled.  One experiment used 3 fractured and 3 sham fractured mice and the 
experiment was repeated 3 times (n=3). A representative area of one plate is shown for each (x10 
magnification). 
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Table 3.1 Cell surface marker summary 
 
Cell surface 
marker 
Common name Species tested Phenotypic characteristic of: 
    
HLA-ABC 
 
human major 
histocompatibility 
complex 1  
(MHC-1) 
Human all nucleated cells 
CD14 
 
---------- Human monocytes 
dendritic cells 
 
CD31 
 
platelet endothelial 
cell adhesion 
molecule-1 
(PECAM-1) 
Human endothelial cells 
macrophages 
neutrophils 
 
CD34 
 
---------- Human/Mouse haematopoetic stromal cells 
dendritic cell (subset) 
endothelial cells 
mast cells 
 
CD45  
 
protein tyrosine 
phosphatase 
receptor –C 
(PTPRC) 
Human/Mouse cells of haematopoetic origin 
CD73 
 
ecto-5-prime 
nucleotidase 
(NT5E) 
Human/Mouse mesenchymal stromal cells 
dendritic cells 
endothelial cells 
B cells 
some CD8+ T cells 
 
CD90 
 
Thy-1 Human/Mouse mesenchymal stromal cells 
marrow-derived haematopoetic stem cells 
neurons 
NK cells 
Precursor T-cells (thymocytes) 
 
CD105 
 
Endoglin Human/Mouse mesenchymal stromal cells 
endothelial cells 
macrophages 
fibroblasts 
 
CD106 
 
vascular cell 
adhesion molecule-
1 (VCAM-1) 
Human endothelial cells 
CD117 
 
c-KIT Human/Mouse marrow-derived haematopoetic stem cells 
CD146 
 
melanoma cell 
adhesion molecule 
(MCAM) 
Human endothelial cells and precursors 
activated (human) T cells 
Sca-1 
 
Ly-6 E/A Mouse murine haematopoetic stem cells 
mesenchymal stem cells 
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Figure 3.3 FACS analysis graphs characterising a murine MDSC population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cell populations were 89% positive for Sca-1 and 75% positive for CD90 (Table 3.2).  
Positivity for CD73 and CD105 was also demonstrated.  These data suggested that 
mesenchymal stromal cells were abundant in the cell populations tested, but that the 
populations were heterogeneous in nature.  Additionally, around 9% were positive for the 
haematopoetic marker CD45, suggesting that cells of haematopoetic, as well as 
mesenchymal origin were present.  Cells from either marrow or blood may have accounted 
for this sub-population.     
 
 
Figure 3.3 C57Bl6 murine muscle-derived cells were assessed for their surface expression of various 
phenotypic markers as described in section 2.2.2.  Briefly, aliquots of 1x105 cells were incubated with 
fluorochrome-conjugated antibodies specific for cell surface markers of mesenchymal, endothelial and 
haematopoetic lineages.  These included PE-conjugated anti-mouse CD45 and 73; FITC-conjugated anti-
mouse CD34, CD90, CD105 and Sca-1; APC-conjugated anti-mouse CD117.  The incubation period was 1 
hour.  Cells were then washed three times to remove unbound antibody.  Isotype controls for the 
fluorochromes were used.  Cell-bound fluorochromes were counted using a BD-LSR bench-top flow 
cytometer (BD Biosciences, NJ, US).   
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Table 3.2 Murine muscle-derived cells exhibit a stromal phenotype 
 
Cell surface marker 
 
% positive cells ± SEM 
CD34 3.18 1.49 
CD45 8.94 2.19 
CD73 38.80 4.19 
CD90 75.03 2.89 
CD105 22.30 3.57 
CD117 0.43 0.19 
Sca-1 89.34 3.79 
   
 
 
 
 
 
 
 
 
 
 
3.2.3 eGFP expressing muscle-derived cells injected into a fractured limb localised 
to fracture callus 
 
As the fracture environment promoted osteogenic differentiation of stromal cells from 
adjacent muscle these cells were added to the fracture environment exogenously and their 
localisation observed in order to determine whether they were utilised by healing bone. To 
the murine tibial fracture model enhanced green fluorescent protein-expressing muscle-
derived stromal cells (MDSC), obtained by enzymatic digestion were injected into the 
muscle adjacent to the fracture (or sham fracture) site. Following histological sectioning at 
day 7, the cells were observed directly under UV microscopy.       
 
 
 
 
 
Table 3.2 C57Bl6 murine muscle-derived cells were assessed for their surface expression of various 
phenotypic markers as described above and in section 2.2.2.  Values represent percentage of cells positive 
for the surface expression of each marker (± SEM) gated against the appropriate isotype control, with a 
background of typically less than 1% (n=3). 
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As shown in Figure 3.4A, at 7 days the central portion of the callus is comprised of 
inflammatory infiltrate, with cartilaginous intermediary forming from the margins of the 
callus.  This is followed by new bone formation, just visible at the extreme margin of the 
callus.   
 
 
Figure 3.4B is the adjacent 4µm sliced section, viewed under UV microscopy.  Using Figure 
3.4A to establish the margins of the callus, it is clear from Figure 3.4B that the MDSC 
migrated and localised in two distinct areas.  These areas include the cartilaginous front of 
the advancing callus (shown at x20 magnification in Figure 3.4C), and the overlying skin 
wound (shown at x20 magnification in Figure 3.4D).  The findings in Figures 3.4C and 3.4D 
suggested that the MDSC preferentially migrated to the two sites of injury; the tibia 
osteotomy, and the pre-tibial incised wound through which the model was performed.  This 
conclusion is supported by the fact that in the sham fracture, shown in Figure 3.4E, the 
MDSC localised to the skin wound only (arrows).   Migration of MDSC to the two sites of 
tissue injury suggested that common injurious stimuli promoted cell recruitment.   
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Figure 3.4 MDSC expressing eGFP localise to newly forming cartilage and bone at the 
margins of the fracture callus, and to the skin wound 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 1x106 MDSC from female C57Bl6 mice expressing eGFP were injected into the calf muscles 
posterior to the tibial fracture within 1 hour of tibial fracture.  At 7 days the mice were sacrificed and the 
limbs prepared for histological sectioning as described in section 2.2.24.  A: section stained with Masson’s 
trichrome to delineate the callus tissues B: slice adjacent to A, unstained, and viewed under UV 
microscopy.  C and D: High magnification image of B, showing callus (C), and skin (D).  E: sham fracture, 
showing localisation of MDSC to the overlying skin wound.  The slides (produced courtesy of Mr. David 
Essex, department of Histopathology, Charing Cross hospital) were viewed under x4 and x20 magnification 
using an Olympus BX51 microscope (Olympus optical, Tokyo, Japan) at room temperature.  Images were 
taken using an Olympus DP71 camera and DP controller and manager, Olympus software, version 
2.3.1.231.  The experiment was performed using 3 mice each for fracture and sham fracture, (n=3) and the 
slides shown represent typical findings.   
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3.3 In-vitro model system of bone formation using stromal cells and 
fracture-derived supernatant  
 
 
While the findings of Harry et al prompted the investigation of muscle as a source of 
osteoprogenitor cells for bone healing, it is clear from difficulties with the translational 
application of the BMP work that rodent models do not adequately replicate clinical 
endochondral fracture healing.   Thus, an in vitro experimental approach using human tissue 
was developed. 
 
3.3.1 Cells isolated from human skeletal muscle expressed stromal markers – 
muscle-derived stromal cells 
 
Samples of skeletal muscle were obtained from off-cuts of vascularised free flaps following 
ethical approval (COREC No: 07/Q0411/30).  In each case the muscle sample had not been 
pre-conditioned by proximity to injurious stimuli.  The muscle was digested enzymatically as 
before and a cell population cultured to confluence.  Cell aliquots were then incubated with 
fluorochrome-conjugated antibodies specific for cell surface markers of mesenchymal, 
endothelial and haematopoetic lineages.  A summary of cell surface markers is shown in 
Table 3.1.  
 
Over 90% of cells were positive for HLA-ABC (Table 3.3).  As the major histocompatibility 
molecule (MHC I) expressed on all human nucleated cells, HLA-ABC positivity was expected.  
Additionally the cells were over 95% positive for CD90 and over 85% positive for CD73.  
Moreover, they were around 65% positive for CD105.  Importantly, the cells did not express 
CD14, CD31, CD34, CD45, CD106, CD117 or CD146.  Together, these data suggested that the 
cells were mesenchymal stromal cells.  The lack of expression of CD31, CD106 and CD146 
suggested that the cells were not endothelial and the lack of expression of CD45, CD117 
suggested that they were not cells of haematopoetic origin.   CD14, also negative, was a 
marker for antigen presenting cells.   
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Table 3.3 Phenotypic analysis of the MDSC cell population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 MDSC exhibited tri-lineage differentiation potential 
 
The muscle-derived cells were mesenchymal stromal cells.  Bone, fat and cartilage are all 
tissues of mesenchymal origin that share a common progenitor cell.  Therefore the ability of 
the muscle-derived stromal cells (MDSC) to differentiate into tissues of mesenchymal origin 
was investigated using differentiation medium specific for osteogenic, adipogenic and 
chondrogenic differentiation respectively.   
 
Table 3.3 MDSC were assessed for their surface expression of various phenotypic markers.  Aliquots of 
1x105 cells were incubated with PE-conjugated anti human CD14, CD31, CD73 and CD90; FITC-conjugated 
anti human MHC I, CD34, CD105 and CD146; APC-conjugated anti human CD45, CD106 and CD117.  The 
incubation period was 1 hour.  Cells were then washed three times to remove unbound antibody.  Isotype 
controls for the fluorochromes were used.  Cell-bound fluorochromes were counted using a BD-LSR bench-
top flow cytometer (BD Biosciences, NJ, US).  Values represent percentage of cells positive for the surface 
expression of each marker (± SEM) gated against the appropriate isotype control, with a background of 
typically less than 1% (n=4, including 2 from 1 donor with 12 cell passages between samples)  
Cell surface marker 
 
% positive cells ± SEM 
HLA-ABC 90.53 5.02 
CD14 0.14 0.14 
CD31 0.59 0.54 
CD34 0.46 0.62 
CD45  0.83 0.81 
CD73 85.59 3.14 
CD90 95.65 3.03 
CD105 64.88 10.29 
CD106 0.22 0.09 
CD117 0.39 0.47 
CD146 0.71 0.52 
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MDSC viewed at x40 magnification exhibited the typical triangular or spindle shaped 
appearance consistent with stromal cells (Figure 3.5A).  When cultured in osteogenic media 
the cells exhibited bone nodule formation demonstrated by Alizarin red staining (Figure 
3.5B).  When cultured in adipogenic media the cells exhibited lipid formation demonstrated 
by Oil red O staining (Figure 3.5C).  A pellet of MDSC cultured in chondrogenic media, then 
fixed, paraffin embedded, sectioned and stained with Alcian blue demonstrated focal areas 
of cartilage formation (Figure 3.5D).  Hence, MDSC exhibited mesenchymal tri-lineation 
differentiation potential.  This suggested that the MDSC population was a progenitor cell 
population for tissues of mesodermal origin.    
 
 
3.3.3 MDSC expressed S100, α-1 Actin and Desmin but not P63 
 
Cell phenotyping using surface markers and differentiation-specific cell culture confirmed 
that the muscle-derived cell populations were stromal cells capable of mesodermal tri-
lineage differentiation.   However, in order to confirm the assumption that the cells were 
myocytes or myocyte precursors and not fibroblasts, marrow-derived stromal cells or 
periosteal osteoprogenitors the cells were stained for myocyte-specific and control 
proteins.   
 
S100 is a multi-functional protein ubiquitously expressed in smooth muscle, chondrocytes, 
osteocytes, fibroblasts and skeletal muscle cells (Zimmer et al., 1995).  As cells from the 
muscle digest were expected to express S100, this protein was used as a positive control.  
Alpha-1 actin is expressed in myocytes and in precursor satellite cells and is a major 
contributor to the contractile property of muscle.  Cellular expression of α-1-actin suggests 
a myocyte or precursor.  Desmin is a protein bound to the Z-line, which delineates adjacent 
sarcomeres and may be important in the organisation of myofibrils (Gard and Lazarides, 
1980).   Expression of Desmin is a measure of myogenic differentiation as expression is low 
in muscle cell precursors and increases with myogenic differentiation.  P63 is a homologue 
of the P53 tumour- suppressor protein and is a marker for myoepithelial cells (Tse et al., 
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2007) and endothelial cells (Yang et al., 1998; Yang et al., 1999).  P63 was chosen as a 
negative control as it is poorly expressed in stromal cells (Tse et al., 2007). 
 
 
Figure 3.5 Tri-lineage differentiation potential of muscle-derived stromal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Human MDSC were cultured in differentiation media then fixed and stained.  For osteogenic and 
adipogenic differentiation, 1x104 MDSC were cultured in a 24-well plates.  Cells were cultured for 28 days 
in osteogenic medium, or for 21 days in adipogenic induction and maintenance media (Lonza Inc.) used 
alternately at each media change (4 days).   Cells were then fixed in 10% formalin and stained using alizarin 
red (osteogenic) or oil red O (adipogenic).  For chondrogenic differentiation 1x105 MDSC were pelleted and 
the cell pellet cultured in chondrogenic media (ChondroDiff medium, Miltenyi BioTec) for 21 days.  The 
pellet was then fixed, paraffin embedded and sections stained using alcian blue.  A: MDSC stained with 
crystal violet to demonstrate morphology.  B: Demonstrating bone nodules stained with alizarin red.  C: 
Demonstrating lipid droplets stained with oil red O.  D: Demonstrating foci of cartilage (blue) stained with 
alcian blue.  The experiment was repeated 3 times and using MDSC for 3 donors.  A typical result for one 
donor MDSC is shown in each case. 
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As expected, S100 was expressed uniformly by the MDSC population, as shown in Figure 
3.6A.  The cells also expressed α-1 actin uniformly as shown in Figure 3.6B. This suggests 
that the cells were myocytes or myocyte precursors.   Expression of Desmin was variable 
between individual cells.  This suggested that the cell population was heterogeneous in 
nature, comprising myocyte precursors with variable differentiation down a myogenic 
lineage and including mature myocytes that strongly expressed Desmin (Figure 3.6C).  The 
cell population did not express P63 supporting evidence from cell surface phenotyping that 
the cells were stromal cells (Figure 3.6D).   
 
 
3.3.4 The osteogenic differentiation potential of MDSC exceeded adipose-derived 
stromal cells and skin fibroblasts  
 
The previous experiments established that muscle was a potential source of progenitor cells 
in fracture healing.  However, to investigate the hypothesis that muscle preferentially 
promotes endochondral fracture healing over fasciocutaneous tissue by virtue of the 
osteoinductive potential of the resident myogenic precursors a direct in vitro comparison of 
the osteogenic potential of muscle and fasciocutaneous tissue (comprising skin and fat) was 
performed.   
 
Muscle-derived stromal cells were obtained by enzymatic digestion was before.  Donor-
matched samples of skin and fat from off-cuts of fasciocutaneous tissue were also digested 
enzymatically to obtain cell populations.  A comparison was also made with matched bone 
marrow-derived cells obtained by plating samples of bone marrow. The matched cell 
populations were cultured in osteogenic media for 28 days and stained for bone nodules.  
The cells were also cultured for 7 days for alkaline phosphatase (ALP) expression.  ALP is a 
surrogate marker for bone formation and was quantified using a commercially available 
assay described in section 2.2 5.    
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Figure 3.6 MDSC express S100 proteins, α-1 actin, and desmin but not P63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both MDSC and BMSC formed bone nodules when cultured in osteogenic media.  Bone 
nodule formation was typically more numerous for MDSC than for BMSC, as shown in 
Figure 3.7A.  Neither adipose-derived stomal cells (ADSC) nor skin fibroblasts (SF) exhibited 
Figure 3.6 MDSC were fixed then incubated with antibodies specific for α-1 actin, Desmin, S100 and P63 
proteins.  The cells were then washed and re-incubated with a secondary, conjugated antibody specific for 
the first.  S100, Alpha-1 actin, Desmin and P63-bound antibodies were stained using 3’-3’ 
Diaminobenzidine (DAB).  Colour variations represent different batches of DAB.   A: S100 (stained red).  B: 
α-1 actin (stained brown). C: Desmin (stained brown).  D: P63 (stained brown).  Counter staining with 
Haematoxylin was performed.  C and D are shown at x10 magnification to permit the inclusion of more 
cells as they were not universally positive.  Immunohistochemical staining was repeated using cells from 3 
donors (n=3), with the representative result from one donor shown.  (Immunohistochemistry courtesy of 
Mr. David Essex, Department of Histopathology, Charing Cross hospital).   
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bone nodule formation when cultured in osteogenic media.  Similarly, both MDSC and 
BMSC expressed ALP at day 7 (Figure 3.7B).  ALP expression in MDSC was significantly 
greater than in BMSC.  ALP expression in BMSC was, in turn, significantly greater than in 
either ADSC or SF’s.    There was no significant difference in ALP expression between ADSC 
and SF’s.  These data suggested that both MDSC and BMSC exhibited osteogenic potential in 
excess of that exhibited by ADSC or SF from fasciocutaneous tissue and that MDSC exhibited 
greater osteogenic potential than BMSC.   
 
 
3.3.5 Fracture-derived supernatant stimulated migration and osteogenic 
differentiation but not proliferation of MDSC  
 
The previous experiments suggested that MDSC may be an important source of 
osteoprogenitors in endochondral fracture healing and that the recruitment of these cells is 
dependent on signals released as a result of bony injury.  Cellular recruitment for tissue 
repair may encompass migration, proliferation and differentiation (Gruber et al., 2004). 
Thus, before the signals that mediate MDSC recruitment in fracture healing were identified, 
it was necessary to determine which aspects of MDSC recruitment were promoted by the 
fracture-derived stimulus.   
 
Fracture-derived supernatants were produced by culture of debrided tibial fracture 
fragments (obtained with patient consent) in serum-free media.  Age and injury-matched 
control specimens were available in the form of surgically cut tibial fragments harvested 
from limbs amputated for severe and un-reconstructable foot and ankle injuries.  The 
influence of these “fracture” and “surgically cut” supernatants on osteogenic differentiation 
of MDSC was studied using the ALP quantification assay.   
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Figure 3.7 Comparison of the osteogenic potential of MDSC with other cell types 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 A: 1x104 matched muscle (MDSC), bone marrow (BMSC) and adipose-derived stromal cells 
(ADSC) together with skin fibroblasts (SF) were cultured in osteogenic media for 28-35 days then fixed and 
stained for bone nodules using Alizarin red.  B: 1x104 MDSC, BMSC, ADSC and SF were cultured in 
osteogenic media for 7 days and Alkaline phosphatase (ALP) expression was quantified using a 
commercially available assay (WAKO pure chemical, Japan) The experiment was performed 3 times, using 
cells from different donors (n=3). In figure part A results from 1 representative donor is shown.  In figure 
part B results shown combine all experiments, ± SEM. **: P< 0.01; ***: P< 0.001; 1-way ANOVA with 
Bonferroni’s post-test correction) 
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The influence of the supernatants on the migration of MDSC was studied using a transwell 
migration system.  The influence of the supernatants on cell proliferation was studied using 
a cell count method.  In order to control for serum proteins both the migration and 
proliferation experimental results were calculated relative to human serum-containing 
media.  In order to ensure that the results from these experiments were attributed to 
factors in the supernatant it was confirmed that serum-free media did not result in cell 
migration, differentiation or proliferation.  Moreover, human serum-containing media did 
not stimulate expression of ALP by MDSC (not shown).   
 
The fracture supernatants (coloured bars) uniformly stimulated expression of ALP by MDSC 
as shown in Figure 3.8A.  None of the surgically cut supernatants (open bars) stimulated ALP 
expression by MDSC.  Additionally, all of the fracture supernatants stimulated migration of 
MDSC in excess of the migration produced by human serum-containing media (Figure 3.8B).  
However, unlike the differentiation assay the fracture supernatants exhibited variability in 
their ability to promote cell migration.  None of the surgically cut supernatants promoted 
cell migration in excess of that produced by serum-containing media.   By contrast all of the 
supernatants promoted cell migration in excess of that produced by serum-containing 
media (Figure 3.8C).  However, the ability of the supernatants to stimulate proliferation of 
MDSC was widely variable and was unrelated to the fate of the bone (fracture or surgical 
cut).  These data suggested that fractured bone fragments contained a soluble factor or 
factors that promoted the migration and osteogenic differentiation of MDSC.  Moreover, 
bone contained a factor or factors that promoted proliferation of MDSC and this factor was 
not a function of the fate of the bone.     
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Figure 3.8 Fracture-derived supernatants promote osteogenic differentiation and migration 
of MDSC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 A: 1x104 MDSC were cultured in supernatant for 7 days, then ALP expression was quantified as 
before.  B: 1x104 MDSC were seeded onto an 8µm pore membrane mounted on a transwell.  Supernatant 
was placed in the lower chamber and cells incubated for 36 hours.  The membrane was then fixed and 
stained and 3 random-field counts performed per membrane, at x20 magnification.  The fold-increase in 
migration was calculated relative to 10% human serum-containing media C: 2.5x103 MDSC were cultured in 
supernatant for 5 days in a 96-well plate.  On day 5 the cells were trypsinized and counted using a 
haemocytometer.  The fold-increase in proliferation was calculated relative to 10% human serum-
containing media. “Fracture” 1, 2 and 3 are fracture supernatants from 3 donors.  “Surgical cut” 4, 5 and 6 
are non-fracture supernatants from 3 different donors.  Each figure part combines 3 experiments (n=3, 
each performed in triplicate), using MDSC from different donors, with the same 6 supernatants, ± SEM. *: 
P< 0.05; **: P< 0.01; ***: P< 0.001; 1-way ANOVA with Bonferroni’s post-test correction. 
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3.4 Proteomic approach to identification of the osteogenic stimulus in 
fracture supernatant 
 
 
Soluble factors derived from fractured bone fragments promoted the migration and 
osteogenic differentiation of MDSC.  While the fracture supernatants promoted cell 
migration variably, the osteogenic stimulus was entirely consistent.   In addition, while cell 
migration and proliferation may be permitted to exhibit variability, the osteogenic stimulus 
is vital to promoting new bone formation.  Hence, identification of the osteogenic stimulus 
became the focus of the next part of the study.  A proteomic approach was used. 
 
3.4.1 The osteogenic activity of supernatant declined with exposure to heat and 
trypsin 
 
Aliquots of fracture-derived supernatants were heated in order to denature the protein 
constituents.  The heat-denatured supernatants were then used to culture MDSC.  ALP 
expression at day 7 was quantified as before.   
 
After heating the supernatant to 95°C for 1 minute, the osteogenic effect of the supernatant 
on MDSC was halved (Figure 3.9A).  Thereafter, continued exposure to heat gradually 
reduced the osteogenic effect yet further.  Maintaining the supernatant at 4°C had no effect 
on the osteogenic effect of supernatant over 20 minutes. 
 
As glycoproteins and polysaccharides are also denatured by exposure to heat the protein 
content of supernatant was digested by agitating with agarose bead-bound trypsin for up to 
48 hours.  After agitating the supernatant with trypsin-coated beads for 6 hours the 
osteogenic effect of the supernatant on MDSC was halved (Figure 3.9B).  Thereafter 
continued exposure to trypsin reduced the osteogenic effect yet further, until a baseline 
was reached at around 48 hours.  This corresponded to heating the supernatant at 95°C for 
20 minutes.  Agitating the supernatant in agarose beads alone did not inhibit the osteogenic 
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effect of the supernatant significantly.  Hence, the osteogenic stimulus was impaired by 
heat denaturing and by trypsin digestion.   
 
 
Figure 3.9 Attenuation of the osteogenic stimulus in fracture supernatant by heat and 
enzymatic digestion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 The osteogenic effect of supernatant was localised to the negatively charged 
protein fraction 
 
 
The osteogenic stimulus appeared to be proteinaceous in nature.  The next series of 
experiments utilised chromatographic purification techniques in an attempt to isolate and 
Figure 3.9 A: Aliquots of supernatant were heated at 95°C or refrigerated at 4°C for the time-course 
shown, before normalising to room temperature.  The supernatants were then mixed with serum-free 
media at a concentration of 1:1 to replace heat-denatured glutamine (GlutaMAX™) in the culture media.  
The cooled mixture was then added to 1x104 MDSC in culture.  At 7 days ALP expression was quantified as 
previously.   B: 10ml aliquots of supernatant were agitated gently with 2ml 4% agarose or trypsin-coated 
agarose beads at 4°C for the time-course shown.  The suspension was then centrifuged to pellet the beads 
and the supernatant extracted. The supernatant was added to 1x104 MDSC in culture.  At 7 days ALP 
expression was quantified as previously.  Both figures combine 3 experiments (n=3), using MDSC from the 
same donor and 3 different supernatants, ± SEM. *: P< 0.05; **: P< 0.01; ***: P< 0.001; 1-way ANOVA with 
Bonferroni's post-test correction. 
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identify the osteogenic stimulus.  Supernatant proteins were first separated by molecular 
charge.  
 
Most proteins are constitutively negatively charged.  However, electrical charge is 
dependent on the conformation of the protein and characteristics of the media in which 
they are suspended.  The principle of the SP and Q columns are described in section 2.2.12.  
As the supernatant traverses the column, electrically charged proteins either bind to the 
column or are repelled by the column.  Hence, as supernatant transverses the positively 
charged (cation seeking) Q column, the flow through (FT) will contain neutrally charged and 
positively charged molecules. Elution of the column to disassociate the bound, charged 
molecules yields a suspension of negatively charged molecules (EL).  At each stage, the 
column is washed through, to ensure that unbound, then bound molecules are removed 
(FT-W, EL-W).  Conversely, the flow-through of the SP column will contain negatively 
charged molecules, and the elution will contain positively charged molecules.  As a buffer of 
high salt concentration was used to elute the columns, all fractions underwent a further 
desalination step, described in section 2.2.13. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was performed to 
visualise the constituent proteins of whole supernatant and the separated fractions.  Two 
examples are shown in Figures 3.10A and B.   The elution fraction from the Q column, 
(equivalent to the flow-through fraction from the SP column) included most of the proteins 
present in supernatant.  A comparison of the electrophoresis bands from 4 whole 
supernatants and from the corresponding Q column elution fractions confirmed this (Figure 
3.10C).   
 
The Q and SP column elution fractions were then reconstituted in serum-free media at a 
calculated concentration of 1:1 with the whole supernatant prior to column separation.  The 
reconstituted fractions were then used to culture MDSC and the ALP expression quantified 
at 7 days as before.  The result is shown in figure 3.10D.  The experiment demonstrated that 
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the osteogenic stimulus in supernatant is present within the Q column elution fraction and 
is, therefore, a negatively charged protein (or bound to a negatively charged protein).       
 
 
Figure 3.10 Ion column separation of supernatant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Aliquots of fracture supernatant from 2 donors were run through the HiTRAP™ SP HP cation 
exchange column and HiTRAP™ Q HP anion exchange column (GE Healthcare).  The flow through was 
collected and the column washed through.  Bound proteins were then eluted and the column washed 
through again.  All fractions were desalinated prior to cell culture.  A: SDS PAGE of supernatant SM2855, 
with the associated column fractions.  B: SDS PAGE of supernatant SM2958 with the associated column 
fractions.  C: Comparison of 4 whole supernatants with their corresponding Q-column elution fractions.  D: 
ALP expression of MDSC cultured in whole (W), Q-column elution (Q), and SP column elution (S) fractions.  
Cell culture was performed 3 times (n=3), using MDSC from the same donor, ± SEM. ***: P< 0.001, 1-way 
ANOVA with Dunnett’s post-test comparison, using the result from the whole supernatant as the control. 
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3.4.3 Mass spectrometry of the negatively charged protein fraction revealed mainly 
serum proteins 
 
To establish the identity of the protein bands in the Q column elution fraction tryptic 
digestion and spectrophotometric analysis of each band was performed as detailed in 
section 2.2.19.   
 
The proteins identified in the active Q column elution fraction were mostly serum proteins 
and proteins derived from red blood cell breakdown (Figure 3.11).  Albumin was by far the 
most abundant protein identified.  This was not surprising considering that the fractured 
and surgically cut bone fragments contained marrow, and in the case of the fracture 
fragments were derived from a traumatic disruption to the cortex.  Additionally the 
presence of red cell breakdown products alluded to the traumatic origin of the fracture 
fragments.  This technique identified only high abundance proteins when it was reasoned 
that growth factors were likely to be present at very low concentrations.  To further 
complicate analyses albumin is known to bind small molecules (Zunszain et al., 2003).   
Hence, these proteins may have been obscured by the greater abundance of serum and red 
blood cell proteins present.  
 
 
3.4.4 The osteogenic effect of supernatant was attributed to the non-serum protein 
fraction 
 
In order to surmount the problem of the abundant serum proteins, a method of selective 
serum protein extraction was sought.  The method used was an IgY-12 high capacity LC10 
proteome partitioning kit (Beckman Coulter Inc., Fullerton, CA).  The principle of the system 
was to selectively bind serum proteins to the column using immunoglobulins specific for the 
12 most abundant serum proteins.  The methodology is described in detail in section 2.2.14.   
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 Figure 3.11 Spectrophotometric analysis of the Q-column elution fraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this case, the flow-through (FT) fraction contained unbound (non serum) proteins, while 
the eluted (EL) fraction contained the bound serum proteins.  It was speculated that if the 
Figure 3.11 The Q-column elution fracture was separated using SDS PAGE.  Digestion of the gel was 
performed using trypsin with an investigator progest robotic digestion system (Genomic solutions, 
Huntingdon, UK). Spectrophotometric analysis was performed using a Q-Tof hybrid quadrupole/orthogonal 
acceleration time-of-flight spectrometer (Micromass, Manchester, UK) with a Micromass CapLC 
chromatograph. Proteins were identified by comparison with entries in the SwissProt/TrEMBL using 
ProteinLynx Global Server (Spectrophotometric analysis was performed courtesy of Dr. Robin Wait, 
lecturer in proteomics, Kennedy Institute of rheumatology).    
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osteogenic stimuli were non serum proteins the flow-through fraction would promote ALP 
expression in MDSC, while the serum protein-rich elution fraction would not.  Moreover, it 
was reasoned that since the process of fraction separation required the supernatant to 
traverse the FPLC and that reconstitution to an end concentration equivalent to the start 
concentration required centrifugation (see section 2.2.16); active proteins may have been 
lost to the tubing or filters.  Hence, in addition to using whole supernatant as a positive 
control, the flow-through fraction was added back to the elution fraction to make a 
reconstituted whole supernatant (FT+EL) at a concentration equivalent to the whole, un 
processed supernatant (W).   
 
Once more, the supernatant fractions were used to culture MDSC.  ALP expression at day 7 
was quantified as before.  ALP expression by MDSC cultured in the non-serum FT fraction (in 
blue) was approximately 50% that of the whole fracture supernatant (W, in pink) (Figure 
3.12).  However, osteogenic activity of the serum-abundant EL fraction (in purple) was 
approximately 50% of the FT fraction.  Additionally, when the EL fraction was added back to 
the FT fraction to form a reconstituted whole fracture supernatant (in azure) osteogenic 
activity was similar to the FT only fraction.  These data suggested that the osteogenic 
factor(s) were present in the non serum (FT) fraction, but that, in traversing the FPLC and 
following spin concentration, the potency of the osteogenic stimulus was diminished. 
 
 
3.4.5 Separation of the non-serum protein fraction by molecular size was associated 
with loss of osteogenic activity 
 
To aid the isolation of the osteogenic stimulus, further sub-division of the non-serum 
protein fraction was planned.   A pool of non-serum protein fractions was obtained using 
the serum-extraction column as detailed above.  These fractions were then further 
separated on the basis of the size of the constituent proteins by a process of gel filtration 
chromatography.  
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Figure 3.12 The influence of serum protein extraction on the osteogenic stimulus of fracture 
supernatant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This technique acts as a molecular sieve, utilising porous gel beads made from highly cross-
linked polymers that permit entry of small molecules.  These molecules therefore traverse 
the column slowly.  Large molecules, excluded from entry into the beads, pass around and 
exit the column first.  This process is detailed in section 2.2.15 and Figure 2.5.   
 
Figure 3.12 Aliquots of fracture supernatant from 3 donors were run through the IgY-12 high capacity LC10 
proteome partitioning column (Beckman Coulter Inc.) using the FPLC (see section 2.2.14).  The flow-
through (FT) was collected. Bound proteins were then eluted (EL).  The FT and EL fractions were then 
concentrated and reconstituted in serum-free media to produce a reconstituted supernatant fraction with 
a concentration of 1:1 with the whole (unprocessed) supernatant.  The fractions were used to culture 
1x104 MDSC and ALP expression was measured at day 7. W: whole supernatant; FT: flow-through fraction, 
containing non-bound (non serum) proteins; EL: elution fraction, containing bound (serum) proteins; 
FT+EL: reconstituted whole supernatant by the addition of 2x concentrated flow-through fraction and 
elution fraction.  The experiment was repeated 3 times for each supernatant (n=3), using MDSC from 
different donors. Figures represent the means from all 3 experiments ± SEM. *: P< 0.05; **: P< 0.01; ***: 
P< 0.001, 1-way ANOVA with Bonferroni’s post-test correction. 
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As the proteins exit the column, they are detected by a spectrophotometer, which registers 
the presence of the protein on a trace.  The flow-through is collected in 1ml aliquots 
labelled on the trace.   
 
The flow-through was divided into arbitrary sub-fractions using the trace (Figure 3.13A), 
concentrated and reconstituted in serum-free media to generate sub fractions at a 
concentration of 1:1 with the whole supernatant from which they were derived.  The sub-
fractions were tested by culture of MDSC and quantification of ALP expression as before.   
 
Aliquots of the flow-through (FT, in blue) and the serum-protein containing elution (EL, in 
purple) were tested again.  Once more, the osteogenic effect of the FT fraction was around 
twice that of the EL fraction (Figure 3.13B).  Again, ALP expression in MDSC cultured in the 
combined FT and EL fractions (FT+EL) confirmed that the osteogenic effect was similar to 
the FT fraction alone.   However, none of the sub-fractions of the FT fraction (#1, #2, #3, #4 
and #5) promoted expression of ALP by MDSC.  Moreover, when the sub-fractions were 
added together to reconstitute the FT fraction (#1-5), the reconstituted FT fraction was 
similarly inert.  This suggested that the osteogenic substance remained bound to the 
columns and FPLC or that it was denatured by the process of gel filtration.   
 
It was reasoned that as the osteogenic substance was a non serum protein present in 
fracture supernatant but not surgically cut supernatant, a comparison of the 
spectrophotometric waves produced by passage of the FT fractions through the gel 
filtration column may have enabled identification of candidate osteogenic proteins.    
Hence, the spectrophotometric wave for the FT fraction of fracture supernatant was 
compared with the corresponding wave for the FT fraction of surgically cut supernatant.  
However, the wave patterns were indistinguishable suggesting that the osteogenic factor 
had, as suspected, been removed by the processing steps or else the protein spike 
corresponding to this protein was masked by the larger spikes, all of which were identified 
as residual serum proteins.       
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Figure 3.13 Separation of the non-serum protein fraction of supernatant by gel filtration 
chromatography resulted in loss of activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Aliquots of fracture supernatant were run through the LC10 proteome partitioning column 
using the FPLC as before.  The flow-through (FT) and eluted (EL) fractions were again concentrated and 
reconstituted in serum-free media and used to culture 1x104 MDSC.  ALP expression was measured at day 
7 as before.  The FT fraction was then run through the gel filtration column as described in section 2.2.15. 
Sub-fractions were collected and reconstituted for cell culture.  A: A typical spectrophotometric wave of 
the gel filtration flow-through.  The flow-through was divided into 5 sub-fractions. B: ALP expression of 
MDSC cultured in whole supernatant (W), the FT and EL fractions and sub-fractions (#1, #2, #3, #4, #5) of 
the FT fraction. The experiment was repeated 6 times (n=6) using 3 supernatants and MDSC from different 
donors.  **: P< 0.01; ***: P< 0.001, 1-way ANOVA with Dunnett’s post test comparison, using FT as the 
control. 
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In summary, the attempt to isolate the osteogenic substance by chromatographic 
purification established only that the osteogenic substance was a non-serum protein.  
Further attempts to purify the substance led to loss of activity of the supernatant sub-
fractions.  Hence, this approach was found not to be suitable for identification of the 
osteogenic substance.    
  
 
 
CHAPTER THREE                                                                                                           MUSCLE-DERIVED STROMAL CELLS 
 177 
 
3.5 An antibody approach to identification of the osteogenic stimulus 
in fracture supernatant 
 
 
Chromatographic purification techniques failed to identify the osteogenic substance in 
supernatant.  A different strategy was employed.  Known osteogenic factors were 
quantified in fracture and surgically cut supernatant, using enzyme-linked immunosorbent 
assays (ELISA).  Candidate factors were tested by comparing ALP expression by MDSC 
cultured in antibody-inhibited supernatant or recombinant protein enriched media.   
 
3.5.1 ELISAs for TGF-β superfamily members revealed that supernatant contained 
very low concentrations of BMPs 2, 4 and 7 
 
As BMPs have been studied extensively in relation to osteogenic differentiation of 
mesenchymal cells, identification of the BMP content of supernatants was a starting point 
for this branch of investigation.  BMPs 2, 4 and 7 are most commonly studied pro-
osteogenic BMPs in vitro and in vivo.  BMPs are members of the TGF-β superfamily.  Hence, 
supernatants were tested for the presence of BMP-2, BMP-4, BMP-7 and TGF-β using 
commercially available enzyme-linked immunosorbent assays (ELISAs) (all R+D systems, 
Abington, UK) according to the manufacturer’s instructions.  As not all fracture-derived 
supernatants promoted osteogenic differentiation of MDSC, and none of the surgically cut 
supernatant did, this finding was used to aid comparison of the active with inactive 
supernatants. 
 
 The concentrations are shown in Table 3.4.  There was no significant difference in 
concentration of BMP-2 between osteogenically active and inactive supernatants or 
between fracture and surgically cut supernatants (21.0 ±2.8, 1SD vs. 17.6 ±1.3, 1SD; P=0.21 
Mann-Whitney test) and (19.6 ±2.8 vs. 17.5 ±1.2; P=0.36).  While the concentration of BMP-
4 was significantly greater in fracture than control supernatant (6.58 ± 1.8, 1SD vs. 2.83 ± 
0.6, 1SD; P=0.036) there was no correlation with activity, as active and inactive 
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supernatants exhibited similar mean concentrations (6.23 ± 1.8 vs. 6.58 ± 1.8; P=0.88). 
Similarly, where was no correlation between TGF-β concentration and supernatant activity. 
 
Table 3.4 BMP concentrations in fracture and surgically cut bone supernatants 
 
 Number BMP2 
(pg/ml) 
BMP4 
(pg/ml) 
 
BMP7 
(pg/ml) 
TGF-β 
(pg/ml) 
Fracture 
supernatant 
(active) 
SM3250 21.9 +/- 2.3 
 
5.7 +/- 0.3 <5 1092 +/- 6 
SM3311 23.2 +/- 0.5 
 
4.8 +/- 0.7 <5 486 +/- 39 
SM2801 17.8 +/- 2.3 8.2 +/- 1.3 <5 3644 +/- 298 
 
Fracture 
supernatant 
(inactive) 
     
SM2795 16.5 +/- 2.1 5.3 +/- 1.1 <5 3693 +/- 182 
 
SM2943 18.8 +/- 2.8 
 
8.9 +/- 2.2 <5 654 +/- 49 
Surgically cut 
supernatant 
(inactive) 
     
SM3310 5.9 +/- 1.8 2.3 +/- 0.1 
 
<5 1224 +/- 42 
SM3333 4.4 +/- 0.3 
 
2.7 +/- 0.1 <5 313 +/- 27 
SM3285 17.3 +/- 12.6 3.5 +/- 0.1 
 
<5 783 +/- 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The concentrations of BMP-7 in all supernatants were so low as to lie outwith the limits of 
the assay.  Concentrations of TGF-β were much higher, of the order of ng/ml in most cases, 
Table 3.4 Both active and inactive fractured-derived supernatants, and surgically cut (control) 
supernatants were tested for the presence of BMP-2, BMP-4, BMP-7 and TGF-β using individual, 
commercially available enzyme-linked immunosorbent assays (all R+D systems, Abington, UK) according to 
the manufacturer’s instructions.  Active fracture supernatants were defined as those that stimulated 
osteogenic differentiation of MDSC (determined by ALP assay) in culture at 7 days.  Supernatants were 
numbered arbitrarily.  All samples were run in triplicate, with the result represented as the mean ± SD. The 
limits of assay sensitivity were defined by each standard curve and expressed as a “less than” value at, or 
beyond the limit of sensitivity.        
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but varied widely.  There was no discernible pattern between fractured and surgically cut 
supernatants and between active and inactive supernatants.   
 
 
3.5.2 BMPs did not, in isolation, account for the osteogenic activity of supernatant 
 
The significance of the quantification results for BMP-2 and BMP-4 was unclear. Hence, a 
dose-response antibody inhibition of BMPs in fracture supernatant was performed, in order 
to determine whether slight differences in levels of BMPs 2 and 4 were significant in terms 
of their osteogenic effects on MDSC in vitro. Antibody inhibition of BMP-7 and TGF-β were 
also performed.  As antibodies to BMP-2 and BMP-4 cross-react, a single antibody was used. 
 
ALP expression by MDSC cultured in fracture supernatant was not inhibited by the addition 
of antibodies to BMP-2/4 across the dose range tested (Figure 3.14A).  Moreover, ALP 
expression was similar to culture in supernatant with the addition of the immunoglobulin 
isotype control.  These data suggested neither BMP-2 nor BMP-4 alone, or in combination, 
were responsible for the osteogenic effect of fracture supernatant.  Similarly, the addition 
of antibodies to BMP-7 and TGF-β did not appear to influence ALP expression by MDSC.    
 
While antibody inhibition of the BMPs 2, 4 and 7 did not appear to inhibit the osteogenic 
stimulus from fracture supernatant the isolated influence of BMPs on MDSC was still 
unclear.  Hence, MDSC were cultured in human serum-containing media with the addition 
of recombinant BMPs.  As supra-physiological concentrations of BMPs were used in clinical 
trials, it was hypothesised that high concentrations of BMPs would be required to stimulate 
osteogenic differentiation of MDSC and the dose range chosen reflected this.     
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Figure 3.14 The influence of BMPs and TGF-β on osteogenic differentiation of MDSC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recombinant human BMP-2, 4, 7 and TGF-β did not stimulate expression of ALP by MDSC 
within the dose range used (Figure 3.14B).  The highest dose investigated (1µg/ml) was the 
highest concentration that could reasonably be produced from the lyophilised aliquot.  
Figure 3.14 A: Antibody inhibition of BMPs 2/4 7 and TGF-β in fracture supernatant.  Antibodies were added 
to aliquots of supernatant and incubated at 4°C for one hour. The immunoglobulin isotype controls used 
included IgG1 for AbBMP-2/4 and AbTGF-β, and IgG2B for Ab-BMP-7.  The supernatant was then added to 
1x104 MDSC and cultured for 7 days.   ALP assay was performed on day 7 as before.    B: The addition of 
rhBMPs to human serum-containing media. To culture medium containing 10% human serum, recombinant 
human BMPs 2, 4, 7 and TGF-β were added.  The media were then added to 1x104 MDSC and cultured for 7 
days.   ALP assay was performed on day 7 as before.    Both A and B combine 3 experiments (n=3) using 
MDSC from 2 different donors (and 3 fracture supernatants in A). Values represent mean ± SEM. All values 
non-significant, 1-way ANOVA with Bonferroni’s post test correction in A, and Dunnett’s post test 
comparison against the media only control in B. 
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However, results from the clinical trial by Govender et al demonstrated an osteogenic effect 
in vivo at a concentration of 1.5mg/ml (1500 times higher) than the maximal in vitro dose 
used in this experiment (Govender et al., 2002).  Together, these data suggest that the 
BMPs 2, 4 and 7 were not responsible for the osteogenic effect of the supernatant on MDSC 
and that these cells were unresponsive to rhBMPs even at concentrations 105 higher than 
found in supernatant. 
 
 
3.5.3 ELISAs isolated PTH and IGF-1 in supernatant but not PTHrP  
 
A number of other growth factors are known to be important in osteogenic differentiation 
and in fracture healing.   These include parathyroid hormone (PTH) (with related peptide, 
PTHrP) and insulin-like growth factor-1 (IGF-1).  Hence, ELISAs for parathyroid hormone 
(fraction 1-34 and 1-84), PTH-related peptide and IGF-1 were performed using active and 
inactive fracture supernatants and surgically cut supernatants as before. 
 
PTH was detected in all fracture supernatants at a concentration of between around 150-
600pg/ml (Table 3.5).  PTH was not detected in any of the surgically cut supernatants or in 
culture media containing 10% human serum.  Active supernatants contained more PTH but 
the result was not significant (390 ± 127 vs. 225 ± 41; P=0.08, Mann-Whitney test).  The 
levels of PTHrP were beyond the limits of detection in all specimens.   By contrast IGF-1 was 
detected in all supernatants, but the levels varied between 20 and 1200pg/ml.  Additionally, 
there was no relationship between the concentration of IGF-1 and the osteogenic activity of 
the supernatant (329 ± 291 vs. 378 ± 425; P=0.60, Mann-Whitney test).   
 
These data suggested that fracture supernatants contained many growth factors but 
attributing concentrations of individual factors to the osteogenic effect of the supernatant 
was complicated by the complexity of the supernatant.   The osteogenic substance in 
fracture supernatant appeared not to be BMP-2, 4, 7, PTH or IGF-1. 
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Table 3.5 The concentrations of parathyroid hormone (PTH), parathyroid hormone-related 
peptide (PTHrP), and insulin-like growth factor-1 (IGF-1) in supernatant 
 
 Number PTH 
(pg/ml) 
PTHrP 
(pg/ml) 
 
IGF-1 
(pg/ml) 
Fracture 
supernatant 
(active) 
SM3250 
 
213 ± 47.2 <10 147 ± 15.3  
SM3311 
 
427 ± 16.6   <10 260 ± 20.0 
SM2801 
 
383 ± 35.1 <10 227 ± 15.3 
SM3334 
 
363 ± 85.1  <10 843 ± 30.6 
SM3497 
 
567 ± 10.6 <10 167 ±  5.8  
Fracture 
supernatant 
(inactive) 
SM2795 
 
167 ± 15.3 <10 37 ± 11.5 
SM2943 
 
220 ± 52.0 <10 117 ± 35.1 
SM3062 
 
213 ± 40.4 <10 80 ± 17.3 
SM3285 
 
257 ± 25.2 <10 453 ± 57.8 
SM3323 
 
270 ± 45.8 <10 20 ± 7.3 
Surgically cut 
supernatant 
(inactive) 
SM3310 
 
<10 <10 1200 ± 60.8 
SM3333 
 
<10 <10 863 ± 41.6 
SM3285 
 
<10 <10 563 ± 41.7 
SM3389 
 
<10 <10 73 ± 5.7  
  
Human serum 
supernatant 
 
 
<10 
 
<10 
 
4643 ± 66.6 
 
 
 Table 3.5 Parathyroid hormone (PTH) and Parathyroid hormone-related peptide (PTHrP) levels were 
measured using commercially available enzyme-linked immunosorbent assays (ELISA- both Bachem AG, 
Bubendorf, SW) according to the manufacturer’s instructions.  Insulin-like growth factor was measured using 
a commercially available ELISA (R+D systems, Abington, UK) according to the manufacturer’s instructions.  All 
samples were run in triplicate, with the result represented as the mean ± SD. As before, the sensitivity of 
each assay was determined by the standard curve and expressed as “less than” at, or beyond the limit of 
sensitivity.        
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3.6 Discussion 
 
 
This chapter investigated the contribution of muscle to fracture healing.  The nature of an 
osteoprogenitor population of cells isolated from human skeletal muscle was explored.  The 
nature of the osteogenic stimulus from fractured bone fragments was also investigated.  
 
The results demonstrated that cells from muscle were important for fracture healing.  These 
muscle-derived cells: 
 
1. Were mesenchymal stromal cells 
2. Exhibited tri-lineage differentiation potential 
3. Underwent osteogenic differentiation in proximity to the fracture site in vivo 
4. Localised to the callus following ex vivo transplantation around a healing fracture 
 
The osteogenic stimulus was a not a BMP commonly implicated in bone formation although 
chromatographic purification was unable to identify candidates. 
 
The first demonstration of the presence of bone forming cells in muscle came from Urist in 
1965 (Urist, 1965).  At present, phenotypic identification of muscle-derived cells is still 
hampered by the lack of specific markers for stromal cell sub-populations (Alhadlaq and 
Mao, 2004; Pittenger et al., 1999).  The muscle-derived cells isolated from human skeletal 
muscle on which the in vitro work detailed in this chapter is based, expressed the markers 
CD73, CD90, CD105 and HLA-ABC.  All non-antigen presenting cells would be expected to be 
positive for HLA-ABC (MHC class 1).  The presence of CD73, CD90 and CD105, together with 
the absence of the haematopoetic markers CD45 and CD117, and the endothelial markers 
CD31 and CD106 confirms these cells as mesenchymal stromal cells (Jones et al., 2007). The 
phenotypic characterisation of murine muscle-derived cells was less straightforward. 
Around 90% of murine MDSC expressed sca-1 (stem cell antigen-1), which is a 
haematopoetic stem cell marker (van de Rijn et al., 1989).  However, this marker is 
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consistently expressed in high percentages of heterogeneous MDSC (Deasy et al., 2007; 
Jankowski et al., 2001).   Additionally, around 3% of cells derived from murine muscle 
expressed CD34.  Again, while CD34 is a haematopoetic marker, variable expression of CD34 
in MDSC populations has been reported (Deasy et al., 2007; Jankowski et al., 2001).  To add 
to the difficulty, cells gain and lose markers as they differentiate, so a heterogeneous cell 
population may vary both in terms of the lineage of the cells and their degree of maturity of 
cells of the same lineage.  For example, while debate exists over whether MDSC express 
CD34 (Beauchamp et al., 2000; Lee et al., 2000), quiescent satellite cells (myogenic 
precursor cells with stem-like potential) express CD34 (Beauchamp et al., 2000; Montarras 
et al., 2005).  Expression is lost as the cells mature (Beauchamp et al., 2000). Using a process 
of pre-plating, where cell sub-populations were isolated on the basis of their cell adhesion 
characteristics (Qu-Petersen et al., 2002), Jankowski et al demonstrated the presence of one 
such sub-population from the MDSC pool which expressed CD34 (Jankowski et al., 2001).  
Thus, it seems likely that one of the sub-populations of MDSC is the quiescent satellite cell.  
Pre-plate sub-division of the MDSC was not performed as part of this study as the whole cell 
population better reflects the cells available to the fracture in vivo.   
 
Satellite cells are, themselves, heterogeneous in nature, comprising both cells with stem-
like potential and cells committed to myogenic differentiation (Kuang et al., 2007; Zammit 
et al., 2006).  Satellite cells express paired-box transcription factor-7 (PAX7) (Seale et al., 
2000), with committed satellite cells also expressing myogenic regulatory factor-5 (Myf5) 
(Kuang et al., 2007).   Myf5 expression is regulated by PAX7 (McKinnell et al., 2008; Zammit 
et al., 2006).   The osteogenic potential of satellite cells has been established (Asakura et al., 
2001; Lee et al., 2000) and has been attributed to the non Myf5-expressing stem-like 
satellite cells. While the satellite cell sub-population of MDSC used in this study was not 
defined, it is likely that at least some of the osteogenic potential of the heterogeneous 
MDSC used were uncommitted quiescent satellite cells, stimulated to differentiate down an 
osteogenic lineage.  Importantly, satellite cells are not solely responsible for the tri-lineage 
differentiation potential of MDSC.  Mastrogiacomo et al reported that CD34 negative cells 
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from the MDSC population also exhibit tri-lineage differentiation potential (Mastrogiacomo 
et al., 2005a).  
 
Another candidate sub-population was the pericyte. While satellite cells arise from beneath 
the basal lamina and are closely associated with muscle fibres, pericytes arise from the 
microvasculature of skeletal muscle.  Pericytes express the markers CD13 and CD44 and are 
weakly positive for CD90, CD105 and CD146 (Dellavalle et al., 2007).  The osteogenic 
potential of the vascular pericyte has been established in vivo (Doherty et al., 1998).  As part 
of the characterisation of the MDSC population, the presence of vascular pericytes was 
sought by FACS for CD13, but the result was indistinguishable from the isotype control 
(result not shown).  The reason for this is that pericytes are probably a very small sub-
population of MDSC.     
 
Muscle-derived stromal cells must not be confused with marrow-derived stromal cells 
(BMSC).  While these two cell types exhibit similarities in lineage and differentiation 
potential, Pittenger et al reported that marrow-derived stromal cells were uniformly 
positive for CD29, CD44, CD71, CD90, CD106, CD120a and CD124 (Pittenger et al., 1999) 
making them phenotypically distinct from the CD106-negative MDSC (Jankowski et al., 
2002).  Around 9% of the murine MDSC expressed CD45 (a haematopoetic marker) while 
human MDSC did not.  Stromal cells are CD45 negative (Young et al., 1999).   It is likely that 
contamination of murine muscle samples by marrow or circulating cells accounted for this 
finding, as murine skeletal muscle was harvested adjacent to fracture.    
 
Cell sex was a variable that was not considered, but that may have influenced the 
expression of ALP by MDSC cultured in fracture-derived supernatant.  Deasy et al have 
reported that MDSC from female donors resulted in significantly higher skeletal muscle 
regeneration when implanted into dystrophic mice, and attributed these findings to innate 
differences in stress response (Deasy et al., 2007).    
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Following injection into the leg muscles posteriorly, eGFP expressing MDSC localised to the 
cartilaginous callus at the junction with the centrally situated inflammatory infiltrate and to 
the overlying skin wound in both fracture and sham fracture controls.  Importantly the cells 
did not localise to the periosteally stripped soft tissue interface.  Hence the cells localised to 
the two sites of tissue injury.  The concept of stromal cell recruitment in response to tissue 
injury is attractive, as it implies that cells are capable of migrating and differentiating to 
chemical signals released in response to tissue injury.  Identification of these signals holds 
the key to accelerating fracture healing.  However, the study of cell recruitment in vivo is 
complicated by limitations in the methods used to track cells.  Fluorescent in situ 
hybridization (FISH) to detect the Y-chromosome is an alternative to using GFP-expressing 
cells (Granero-Molto et al., 2008).  Additionally, the study of cell recruitment does not 
reveal the function of the cells at the site of localisation.  In this case, it does not reveal 
whether the cells were involved in the regulation of callus formation or whether the cells 
were undergoing cartilaginous or osteogenic differentiation as part of endochondral 
fracture healing.  This highlights the common problem with the study of mesenchymal 
stromal cells in tissue repair.  While tissue repair has been demonstrated following the 
addition of stem-like cells with differentiation potential encompassing the damaged tissue, 
detection of those cells within the repair has often been elusive (Granero-Molto et al., 
2008).  Moreover, paracrine signalling from stem-like cells has been attributed to secondary 
recruitment and differentiation of progenitor cells for tissue repair (Kinnaird et al., 2004; 
Parekkadan et al., 2007).  Thus the results presented in this chapter have demonstrated 
recruitment and osteogenic differentiation of MDSC by fracture-derived signals in vitro and 
in vivo.  The paracrine actions of MDSC on other cells were not investigated.   
 
Comparison of the osteogenic potential of MDSC with stromal cells from marrow (BMSC), 
fat (ADSC) and skin (SF) was interesting from a clinical perspective as these cells are also 
available to fractures following cover by fasciocutaneous flaps or skin grafts.   The bone 
nodule-forming superiority of MDSC over SF supported the findings of Shemitsch et al, who 
observed improved tibial cortical healing when the anterior third of a devascularised section 
of tibial was in contact with muscle over skin (with the deep fascia removed) (Schemitsch et 
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al., 1997).  The finding also support the work of Harry et al who observed that a periosteally-
stripped open tibial fracture model, covered exclusively with muscle healed better than 
when covered exclusively with fasciocutaneous tissue (fat and skin) (Harry et al., 2008).    
 
Both fracture and surgically cut supernatants were derived from patients who had suffered 
major limb trauma and therefore the systemic response to injury was sampled.  Fracture-
derived supernatants, in addition sampled the local response to injury.  Yet only fracture-
derived supernatants promoted osteogenic differentiation and migration of MDSC.  Hence, 
the observed differences in cell differentiation and migration arose as result of local, not 
systemic factors.  As supernatants were representative of the fracture environment at the 
moment of harvest variability in the concentrations of the factors present was inevitable 
and was dependent on the time from injury, the severity of injury and degree of 
comminution, previous fracture washout and pre-morbid condition.  These factors were 
likely to have accounted for the differences between fracture supernatants in terms of their 
effects on MDSC. 
 
Fracture supernatants promoted cell proliferation between three and nine-fold greater than 
human serum-containing media alone.  Non-fracture supernatants promoted cell 
proliferation between four and seven-fold greater than human serum-containing media 
alone.  These data suggested that proliferative factors were present in both fracture and 
surgically cut supernatants but that they were not related to the fracture. Alternatively 
these factors may have been particularly labile in media and thus not suited to sampling and 
testing using the in vitro model.   
 
The comparison of fracture and surgically cut supernatants also suggested that the 
osteogenic stimulus arose as a consequence of bone trauma and was not an inherent 
property of bone.  This explained why BMPs 2 and 4, present in cortical bone and released 
by the fractured cortex, were slightly higher in fracture supernatant than surgically cut 
supernatant but did not account for osteogenic differentiation of MDSC despite their 
established bone inducing ability (Kain and Einhorn, 2005; Lieberman et al., 2002).   
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Similarly, the failure of isolated BMPs to induce ALP expression in MDSC is consistent with 
the hypothesis that the BMPs act downstream of a regulatory system for skeletal repair that 
involves priming cells for receptiveness to BMPs by the expression of BMP receptors 
(Singhatanadgit et al., 2006).  Additionally, the non-physiological manner of cell stimulation 
by BMPs, including the use of supra-physiological doses (Lieberman et al., 2002) and lack of 
temporal and spatial appreciation in BMP delivery (Gerstenfeld et al., 2003b) may also have 
influenced in vitro bone formation by MDSC.   
 
While parathyroid hormone (PTH) was elevated in fracture-derived, but not surgically cut 
supernatants this finding did not correlate with the osteogenic effect of the supernatant.  
The reason for this is that while PTH influences bone healing, it does so by influencing the 
balance between osteoblast and osteoclast stimulation and thus the anticipated effect on 
an individual precursor population is unclear (Alkhiary et al., 2005; Andreassen et al., 1999; 
Komarova, 2005).  The osteogenic effect of recombinant PTH on MDSC was not tested 
directly but this is certainly another approach that may be considered.   
 
While it was established that the osteogenic stimulus from fracture-derived supernatant 
was heat-labile and digested by trypsin (both of which suggested that the factor was a 
protein), chromatographic purification was otherwise unsuccessful.  The reason for this was 
partly on account of the very low concentrations at which the factor seemed to be present 
and was thus obscured by the abundance of serum proteins in the supernatants.   
Moreover, the methods used to purify and concentrate sub-fractions seemed to have a 
deleterious effect on the osteogenic factor(s).  Hence, another approach was considered, 
and will be discussed in the following chapter.   
 
In summary, the results presented in this chapter demonstrated that muscle-derived 
stromal cells are a potentially important osteoprogenitor population recruited to aid 
fracture healing.  The recruitment by means of migration and differentiation of these cells is 
mediated by soluble factor(s) released locally in the post-fracture environment.  The factor 
implicated in osteogenic differentiation was a protein, but not a BMP commonly associated 
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with osteogenic differentiation (BMP2, 4 or 7).  Neither ELISA nor chromatographic 
purification strategies yielded candidate osteogenic factors. 
 
Hence, the next chapter focussed on the pursuit of factors anticipated to be active at very 
low concentrations and only released in response to tissue trauma in vivo.   
  
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
The role of cytokines in bone formation by muscle-
derived stromal cells  
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4.1 Introduction 
 
Not all fracture supernatants promoted ALP expression by MDSC,  however the 
characteristics of those that did were that they arose from a recent (within 72 hours) 
fracture site, had not been subjected to multiple washout procedures, were associated with 
significant surrounding soft tissue injury and were harvested from young (<50 years old) 
patients.  It was reasoned that the principle difference between the environment that 
generated active fracture supernatant and the environment that did not was the highly 
inflammatory nature of the surrounding milieu.  If the osteogenic stimulus was a cytokine, 
this may have accounted for the failure of the chromatographic approach, as cytokines may 
be present at concentrations below the threshold for detection by chromatography. 
 
Hence the next part of the study aimed at re-evaluating supernatants for the presence of 
pro (and anti) inflammatory cytokines, cytokine receptors and chemoattractant factors and 
to define the influence of these factors on the migration, proliferation and osteogenic 
differentiation of MDSC in vitro. 
 
In this section, the constitutive level of pro- and anti-inflammatory cytokines and cytokine 
receptors in fracture and surgically cut supernatants was established. The importance of the 
pro-inflammatory cytokines TNF-α, IL-1β and IL-6 on both migration and osteogenic 
differentiation by supernatant was explored using antibody inhibition.  The direct effect of 
human TNF-α, IL-1β and IL-6 on the migration, osteogenic differentiation and proliferation 
of MDSC was observed.  Lastly, the supernatants were evaluated for the presence of 
chemoattractant factors and these investigations formed the basis for a study of the 
responsiveness of MDSC to candidate chemoattractant factors.  
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4.2 Cytokines in supernatant  
 
 
Fractured bone is exposed to the inflammatory milieu following injury.  Hence, it was 
reasoned that whilst fragments of bone debrided from the fracture site contained BMPs and 
osteogenic growth factors as shown in chapter 3, they also sampled the inflammatory 
milieu. By comparing the cytokine constituents of these supernatants with their osteogenic 
activity, candidate factors mediating recruitment and differentiation in vivo were sought.    
 
4.2.1 The constitutive levels of TNF-α, IL-1β and IFN-γ in fracture and surgically cut 
supernatant are low 
 
The pro-inflammatory cytokine profile of active (and inactive) and surgically cut 
supernatants were evaluated using a 30-plex immuno-assay read using the Luminex xMAP® 
system, as detailed in section 2.2.10. The cytokines tested include: 
 
 IL-1β  IL-12 (p40⁄p70)  IP-10 
 IL-1RA  IL13  MIG 
 IL-2  IL-15  Eotaxin 
 IL-2R  IL-17  RANTES 
 IL-4  TNF-α  MCP-1 
 IL-5  IFN-α  VEGF 
 IL-6  IFN-γ  G-CSF 
 IL-7  GM-CSF  EGF 
 IL-8  MIP-1α  FGF-basic 
 IL-10  MIP-1β  HGF 
 
 
This system provides a means of rapidly assaying several cytokines simultaneously.  All 
supernatant samples were read once, in triplicate.   
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Table 4.1 Pro-inflammatory cytokines from fractured and surgically cut bone 
 
 Sup’tant 
number 
TNF-α  
(pg/ml) 
IL-1β 
(pg/ml) 
IL-6 
(pg/ml) 
IFN-γ 
(pg/ml) 
Fracture 
supernatant 
(active) 
SM3250 (1) <15 
 
<1 1841 ± 92 <50 
 
SM3311 (2) 
 
<15 <1 9522 ± 476 <50 
 
SM2936 (3) 
 
<15 <1 17671 ± 283 <50 
 
SM2801 
 
<15 <1 1673 ± 903 <50 
 
SM3334 
 
<15 <1 1164 ± 524 <50 
 
Fracture 
supernatant 
(inactive) 
SM2795 <15 
 
<1 3205 ± 250 <50 
 
SM2943 
 
<15 <1 4636 ± 603 <50 
 
SM3062 
 
17 ± 1 103 ± 24 <1 62 ± 14 
SM3285 
 
16 ± 1 <1 1864 ± 30 56 ± 3 
SM3323 
 
<15 <1 2137 ± 94 <50 
 
Surgically cut 
supernatant 
(inactive) 
SM3310 (4) 
 
<15 
 
<1 11414 ± 171 <50 
 
SM3333 (5) 
 
<15 <1 580 ± 52 <50 
 
SM3285 (6) 
 
<15 <1 764 ± 82 <50 
 
SM3389 
 
<15 <1 898 ± 391 <50 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Supernatant or standard (50µl) was added to wells of a 96-well micro plate in triplicate.  
Polystyrene microspheres pre-coated with antibodies specific to the proteins (antigens) being tested were 
then added and incubated for 2 hours.  After washing, a solution containing a mixture of biotinylated, 
analyte-specific antibodies was added and incubated for a further 1 hour.  After further washing, 
streptavidin, conjugated to R-Phycoerythrin was added and incubated for a further 30 minutes.  After 
repeated washing the plate was read using a Luminex 100™ instrument.  This system permitted beads to be 
read individually and a mean value was generated using the Luminex software.  All values represent the 
mean ± SD.  The limits of assay sensitivity were defined by the standard curve and expressed as a “less than” 
value where the limit of sensitivity was reached.   The limit of sensitivity of the assay varied between factors 
tested.   
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In all but two supernatants the concentration of TNF-α was below the limit of detection of 
15pg/ml (Table 4.1).  In the remaining two (both inactive fracture supernatants) 
concentration was just above the limit of detection.  The concentrations of IL-1β were 
below the limit of detection of 1pg/ml for all but one supernatant.  The mean concentration 
in this supernatant was 103pg/ml.  This supernatant was osteogenically inactive.  The 
concentrations of IFN-γ were below the limit of detection of 50pg/ml in all but two 
supernatants.  These supernatants (SM3062 and SM3285) were the same osteogenically 
inactive fracture supernatants with levels of TNF-α above the level of detection.  The 
concentrations of IL-6 were much higher (of the order of ng/ml in most cases).  The highest 
concentration (17ng/ml) was found in an active fracture supernatant.  The lowest 
concentration (less than 1pg/ml) was found in an inactive fracture supernatant.  However, 
the pattern of IL-6 concentration did not reflect osteogenic activity.  Moreover, there was 
no statistically significant difference in concentration between active and inactive 
supernatant or between fracture and surgically cut supernatant (P=0.44, P=0.30 
respectively, Mann-Whitney test).      
 
 
4.2.2 Fracture and surgically cut supernatant also contain the cytokine and 
receptors IL-1Ra, IL-2R and IL-12 
 
In addition to TNF-α, IL-1β, IL-6 and IFN-γ, a number of other cytokines influence 
inflammatory signalling.  The IL-1 receptor antagonist (IL-1Ra) inhibits IL-1 mediated 
inflammatory signalling.  IL-2 receptor (IL-2R) promotes IL-2 mediated T cell proliferation, 
and thus, indirectly, TNF-α synthesis.  IL-4 induces proliferation of naïve T cells and 
suppresses IFN-γ.    IL-12 stimulates synthesis of TNF-α and IFN-γ by T cells and inhibits IL-4-
mediated suppression of IFN-γ.  IL-10 is the principal anti-inflammatory cytokine.  Hence, 
these cytokines and receptors were also tested for their presence in supernatants.   
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Table 4.2 Other cytokines and soluble receptors from fractured and surgically cut bone 
 
 Sup’tant 
number 
IL-1Ra 
(pg/ml) 
 
IL-2R 
(pg/ml) 
 
IL-4 
(pg/ml) 
 
IL-10 
(pg/ml) 
 
IL-12 
(pg/ml) 
 
Fracture 
supernatant 
(active) 
SM3250 (1) 
 
946 ± 350 132 ± 1 <30 <1 75 ± 1 
SM3311 (2) 
 
1817 ± 309 160 ± 40 <30 <1 80 ± 6 
SM2936 (3) 
 
1977 ± 277 123 ± 14 <30 <1 85 ± 13 
SM2801 
 
1425 ± 328 113 ± 1 <30 <1 80 ± 5 
SM3334 
 
1716 ± 549 142 ± 14 <30 <1 109 ± 38 
Fracture 
supernatant 
(inactive) 
SM2795 
 
1851 ± 91 123 ± 13 36 ± 3 <1 96 ± 1 
SM2943 
 
2446 ± 482 179 ± 13 44 ± 5 <1 126 ± 5 
SM3062 
 
2167 ± 267 290 ± 64 92 ± 4 <1 212 ± 15 
SM3285 
 
2230 ± 265 244 ± 1 78 ± 16 <1 182 ± 11 
SM3323 
 
2008 ± 402 123 ± 13 35 ± 5 <1 100 ± 9 
Surgically cut 
supernatant 
(inactive) 
SM3310 (4) 
 
1978 ±  89 122 ± 13 <30 <1 89 ± 4 
SM3333 (5) 
 
1327 ±  93 103 ± 40 34 ± 3 <1 61 ± 5 
SM3285 (6) 
 
982 ± 295 142 ± 40 <30 <1 118 ± 19 
SM3389 
 
1941 ± 78 123 ± 13 35 ± 5 <1 87 ± 18 
 
 
 
 
 
 
 
The concentrations of IL-1Ra were roughly between 1 and 2ng/ml (Table 4.2).  There was no 
significant difference in concentration of IL-1Ra between osteogenically active and inactive 
supernatants or between fracture and surgically cut supernatants (P=0.11, P=0.38 
respectively, Mann-Whitney test).  The concentrations of IL-2R were between around 100 to 
Table 4.2 The Luminex xMAP methodology was performed as described for table 4.1. All values represent 
the mean ± SD.  The limits of assay sensitivity were defined by the standard curve and expressed as a “less 
than” value where the limit of sensitivity was reached.   The limit of sensitivity of the assay varied between 
factors tested.   
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300pg/ml.  Again, there were no statistically significant differences between osteogenically 
active and inactive supernatants or between fracture and surgically cut supernatants in 
terms of IL-2R concentrations (P=0.89, P=0.13 respectively, Mann-Whitney test). The 
concentrations of IL-4, (a cytokine with anti-inflammatory activity) were higher in the 
inactive fracture supernatants than in the active supernatants, where the concentrations 
were invariably below the limit of detection.  The concentrations of IL-4 were also higher in 
the inactive fracture supernatants than in the surgically cut supernatants.  IL-10 
concentrations (the principal anti-inflammatory cytokine) were invariably below the limit of 
detection regardless of activity. IL-12 concentration varied between around 60 and 
200pg/ml.  Again, no significant differences were observed in IL-12 concentrations based on 
activity or aetiology (fracture or surgical cut) (P=0.08, P=0.52 respectively, Mann-Whitney 
test) although the active supernatants tended towards a lower IL-12 concentration.   
 
 
4.2.3 Granulocyte and Granulocyte-Macrophage colony stimulating factors (G-CSF, 
GM-CSF), Hepatocyte-stimulating factor (HSF) and Stem cell factor-1 (SCF-1) 
were all detected in supernatant  
 
It is probable that the fracture environment also influences tissues other than skeletal 
muscle.  Responses from these tissues may, in turn influence MDSC indirectly.  For example 
bone marrow responds to fracture by producing monocytes and macrophages (Colnot et al., 
2006).  These cells are major sources of TNF-α (Belge et al., 2002).   
 
Factors known to promote cells of innate immunity such as monocytes and macrophages 
include granulocyte-colony stimulating factor (G-CSF), that promotes maturation of the 
granulocytes including neutrophils (with basophils and eosinophils) and 
granulocyte/macrophage-colony stimulating factor (GM-CSF) that promotes maturation of 
cells of both the monocyte and granulocyte lineages.  Hepatocyte-stimulating factor (HSF) is 
a monocyte-derived protein that stimulates the liver to systhesise acute phase proteins in 
response to infection (Gabay and Kushner, 1999).  HSF is thus an indirect measure of 
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monocyte activity in response to an inflammatory process. Stem cell factor-1 (SCF-1) is a 
haematopoetic growth factor known to augment CSF- mediated haematopoetic and stromal 
cell growth (Gabrilove et al., 1994).    
 
The concentrations of G-CSF were roughly between 50 and 1200pg/ml (Table 4.3).  There 
was no significant difference in concentration of G-CSF between osteogenically active and 
inactive supernatants or between fracture and surgically cut supernatants (P=0.69, P=0.36 
respectively, Mann-Whitney test).  The concentrations of GM-CSF were all less than 
135pg/ml.  Many were below the limit of detection of 100pg/ml.  The concentrations of HSF 
varied from less than 50pg/ml to around 260pg/ml.  One high mean concentration of 
833pg/ml (SM2801) was dubious as the standard deviation was also very high.  Again, there 
appeared to be no pattern to the concentrations based on activity or aetiology (fracture or 
surgical cut).   SCF-1 was detected in only 3 of the 14 supernatants tested.   
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Table 4.3 Stem cell growth factors from fractured and surgically cut bone 
 
 Sup’tant 
number 
G-CSF 
(pg/ml) 
GM-CSF 
(pg/ml) 
 
HSF 
(pg/ml) 
SCF-1 
(pg/ml) 
Fracture 
supernatant 
(active) 
SM3250 (1) 
 
115 ± 21 <100 <50 <1 
SM3311 (2) 
 
290 ± 128 131 ± 2 <50 <1 
SM2936 (3) 
 
107 ± 11 <100 109 ± 36 <1 
SM2801 
 
88 ± 6 123 ± 2 833 ± 526 <1 
SM3334 
 
115 ± 21 <100 <50 <1 
Fracture 
supernatant 
(inactive) 
SM2795 
 
327 ± 31 <100 <50 <1 
SM2943 
 
200 ± 1 <100 <50 6.0 ± 3.9 
SM3062 
 
1233 ± 592 132 ± 4 260 ± 34 12.5 ± 3.4 
SM3285 
 
<50 127 ± 4 201 ± 29 <1 
SM3323 
 
176 ± 25 <100 109 ± 36 <1 
Surgically cut 
supernatant 
(inactive) 
SM3310 (4) 
 
197 ± 34 128 ± 2 <50 60.2 ± 8.2 
SM3333 (5) 
 
63 ± 6 <100 <50 <1 
SM3285 (6) 
 
72 ± 6 <100 <50 <1 
SM3389 
 
155 ± 35 <100 83 ± 11 <1 
 
 
 
 
 
 
 
 
 
 
Table 4.3 To obtain values for G-CSF, GM-CSF and HSF the Luminex xMAP methodology was performed as 
described for table 4.1. All values represent the mean ± SD.  The limits of assay sensitivity were defined by 
the standard curve and expressed as a “less than” value where the limit of sensitivity was reached.   The 
limit of sensitivity of the assay varied between factors tested.  SCF-1 was measured using a commercially 
available ELISA (R+D systems, Abington, UK).  Briefly, 50µl supernatant or standard was added to well of a 
96-well micro plate that had been pre-coated with antibody and incubated at room temperature for 2 
hours.   After washing, an enzyme linked polyclonal antibody specific for the antigen was added to the wells 
and incubated for 1 hour. After washing to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to the wells.  Colour development was stopped at 30 minutes and the colour change 
quantified spectrophotometrically at 540nm absorbance.  All samples were run in triplicate, with the result 
represented as the mean ± SD.  
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4.3 The influence of cytokines on MDSC in culture 
 
All supernatants were found to contain IL-6 at ng/ml concentrations.  Moreover, while 
concentrations of TNF-α and IL-1β were (in most cases) lower than the detectable limits of 
the human cytokine 30 plex assay,  these cytokines are known to be active at very low 
concentrations and thus were likely to be present (Einhorn et al., 1995; Gerstenfeld et al., 
2003b).  Therefore the influence of these pro-inflammatory cytokines on both the 
osteogenic differentiation and migration of MDSC was evaluated, both in fracture 
supernatant and in isolation using recombinant proteins.  Additionally, the influence of 
isolated TNF-α, IL-1β and IL-6 on MDSC proliferation was investigated.  The influence of 
these cytokines on MDSC proliferation in supernatant was not investigated as proliferation 
by supernatant was so variable (See figure 3.7).   
 
 
4.3.1 Antibody inhibition of TNF-α and IL-6 diminished the osteogenic effect of 
supernatant 
 
The role of TNF-α in the differentiation of osteoprogenitor cells (in vitro) and bone 
formation (in vivo) remains unclear (see section 1.4.10).  While the concentrations of TNF-α 
in supernatant were so low as to be undetectable by the assay used, it is still conceivable 
that concentrations of the order of pg/ml were biologically active.   Indeed, it is likely that 
the concentrations encountered physiologically are of this magnitude (Gerstenfeld et al., 
2003b).  Hence, in order to ensure that the very low concentrations of TNF-α present in 
supernatant were not responsible for osteogenic differentiation, dose response antibody 
inhibition of TNF-α in supernatant was performed.  As IL-1β is active at similarly low 
concentrations (Fukui et al., 2003), dose response antibody inhibition of IL-1β in 
supernatant was also performed using the same methodological approach.  IL-6 in 
supernatant was also tested by antibody inhibition.  
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Figure 4.1 Antibody inhibition of TNF-α and IL-6 diminishes the osteogenic activity of 
fracture supernatant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 ALP quantification assay after culture of 1x104 MDSC in fracture supernatant with the addition 
of A: AbTNF-α; B: AbIL-6 and C: AbIL-1β. Antibody or isotype control (added to produce the 
concentrations shown) was added to 2ml aliquots of supernatant and incubated for 1 hour at 4°C.  The 
supernatant was then added to 1x104 MDSC, plated in triplicate in a 96-well plate as before.   ALP 
expression was quantified on day 7.  Values represent a mean from 3 experiments ±SEM (n=3), using 
MDSC from 2 donors and supernatant from 3 donors. *: P< 0.05; **: P< 0.01; ***: P< 0.001; 1-way 
ANOVA with Bonferroni’s multiple comparison test. 
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Antibody inhibition of TNF-α in fracture supernatant dose-dependently inhibited the 
osteogenic effect of supernatant on MDSC (Figure 4.1A).  However, the effect was not 
abolished completely.  At the highest concentration of antibody used (104ng/ml) ALP 
expression was inhibited to less than 50% of the ALP expression by MDSC cultured in 
supernatant alone.  Antibody inhibition of IL-6 in fracture supernatant also dose-
dependently inhibited the osteogenic effect of the supernatant on MDSC (Figure 4.1B).  
Again, ALP expression was not abolished completely and again, ALP expression by MDSC fell 
to less than 50% at an antibody concentration of 104ng/ml. There was no clear association 
between antibody inhibition of IL-1β in supernatant and ALP expression by MDSC.  
Moreover, at the highest concentration of antibody tested (104ng/ml) there was no 
significant difference in ALP expression by MDSC compared with the isotype only control 
(Figure 4.1C).   
 
 
4.3.2 TNF-α and IL-6 promoted bone nodule formation by MDSC 
 
As antibody inhibition of TNF-α and IL-6 in appeared to influence the osteogenic activity of 
supernatant on MDSC, the cytokines were tested directly using the in vitro culture system.  
While antibody inhibition of IL-1β did not appear to influence the osteogenic activity of 
supernatant on MDSC this cytokine was also tested directly, to confirm a lack of effect.  
Once more, the in vitro culture system was used.  Additionally, MDSC were cultured in the 
optimised concentrations of cytokines determined by the in vitro culture system in order to 
confirm bone nodule formation.   
 
The results are shown in Figure 4.2A, B and C.  Recombinant human TNF-α stimulated ALP 
expression by MDSC.  The optimal concentration was 1ng/ml.  ALP expression fell sharply at 
a TNF-α concentration of greater than 1ng/ml and was (non-significantly) less than the 
negative control at 100ng/ml.   By contrast, expression of ALP by IL-6 increased with the 
dose through the range tested.  The highest concentration tested, 1000ng/ml was the 
highest concentration that could reasonably be achieved with the recombinant protein.  
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While IL-1β did produce a rise in ALP expression (peaking at 100pg/ml), the response was 
less consistent than that observed for either rhTNF-α or rhIL-6 and the magnitude of the 
increase was also reduced.  
 
The result following culture of MDSC for bone nodules, using the cytokine concentrations 
optimised by the dose response ALP expression, is shown in Figure 4.2D, E and F.    RhTNF-
α, at a concentration in media of 1ng/ml stimulated the formation of bone nodule 
formation as shown in Figure 4.2D.  RhIL-6 at a concentration in media of 100ng/ml also 
stimulated the formation of bone nodule formation as shown in Figure 4.2E, although the 
nodules were smaller and less confluent.  Interestingly, rhIL-1β at a concentration of 
100pg/ml did not stimulate bone formation in any of the wells, as shown in Figure 4.2F.  
These data suggested that ALP expression at 1 week, stimulated by both rhTNF-α and IL-6 
were consistent with the development of bone nodules at 4 weeks.  IL-1β, by contrast, 
promoted ALP expression by MDSC weakly.  Furthermore, this process did not result in the 
completion of osteogenic differentiation into bone-forming osteoblasts.   
 
 
4.3.3 Antibody inhibition of TNF-α and IL-6 diminished the chemoattractant effect 
of supernatant 
 
The previous experiments identified the influence of TNF-α and IL-6 on osteogenic 
differentiation of MDSC.  However, recruitment of these cells for osteogenic differentiation 
in vivo requires that the cells respond to chemoattractant signals by migration.  Hence, the 
role of the pro-inflammatory cytokines on cell migration was investigated.  This was done 
using an in vitro transwell system, where cells migrating through an 8µm pore in response 
to a chemoattractant gradient were counted.   A pore size of 8µm has previously been 
demonstrated to permit the migration of stromal cells in response to the presence of a 
chemoattractant gradient across the membrane (Ponte et al., 2007; Ringe et al., 2007).  The 
experimental set up is shown in Figure 2.2, and described in detail in section 2.2.6.   
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Figure 4.2 Dose-response osteogenic differentiation and bone nodule formation by MDSC 
cultured in TNF-α, IL-1β and IL-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 A, B and C: 1x104 MDSC were cultured in human serum-containing media ± recombinant 
cytokine A: rhTNF-α; B: rhIL-6 and C: rhIL-1β at the concentrations stated.  The media was changed at 
day 4 and ALP expression quantified using an ALP quantification assay at day 7.  The values represent a 
mean value from 3 experiments (n=3), using MDSC from 3 donors, ± SEM. *: P< 0.05; **: P< 0.01; ***: 
P< 0.001; 1-way ANOVA with Bonferroni’s post test correction. D, E and F: 1x104 MDSC were cultured in 
24 well plates using human serum-containing media ± recombinant cytokine at the concentration 
optimised for osteogenic activity by the dose response curves. The media was changed every 4 days and 
the plate fixed and stained using alizarin red at 28 days.  The experiment was performed in triplicate 
using MDSC from 3 donors (n=3).  Each image, observed at 10x magnification, is a representative area of 
a single well, which, in turn is representative of all wells.    
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Figure 4.3 Antibody inhibition of TNF-α, but not IL-1β diminished the chemo attractant 
effect of supernatant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Migration of MDSC through an 8µm pore transwell membrane in response to fracture 
supernatant with the addition of A: AbTNF-α; B: AbIL-6 and C: AbIL-1β. 1x104 MDSC were seeded onto 
an 8µm pore membrane and left overnight.  Antibody or IgG1 immunoglobulin control (added to 
produce the concentrations shown) were added to aliquots of supernatant and incubated for 1 hour at 
4°C.  The supernatant was then added to the lower chamber and incubated for 36 hours.  The upper 
chamber of the membrane was then cleared of cells, then fixed and stained.  Adherent cells on the 
underside of the membrane were counted at 20x magnification (3 random fields per membrane) in 
triplicate.  The experiment was performed 3 times (n=3) using 3 fracture supernatants.  Results are 
given as percentage migration relative to the supernatant only control and represent a mean of 3 
experiments ±SEM. **: P< 0.01; ***: P< 0.001; 1-way ANOVA with Bonferroni’s post test correction.   
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 As shown in Figure 4.3A, antibody inhibition of TNF-α in supernatant diminished the 
chemoattractant effect of the supernatant within the dose-range tested.  Above 102ng/ml 
AbTNF-α, cell migration levelled at around 50% of that observed in the supernatant and 
supernatant plus immunoglobulin isotype control.  Hence, this suggested that while TNF-α 
in supernatant did promote cell migration, other factors were also involved.   Antibody 
inhibition of IL-6 also demonstrated some diminution of the chemoattractant effect, 
levelling at around 80% of the supernatant only control.  However, in this case while AbIL-6 
at a concentration of 103ng/ml resulted in a significant reduction in migration relative to the 
supernatant with immunoglobulin isotype control, at 104ng/ml there was no significant 
difference in cell migration (Figure 4.3B).  Inhibition of IL-1β did not appear to influence 
chemoattraction (Figure 4.3C).   
 
 
4.3.4 TNF-α and IL-6 stimulated migration of MDSC  
 
While inhibition of the chemoattractant effect of supernatant using antibodies for TNF-α 
provided indirect evidence for the role of TNF-α as a chemoattractant factor for MDSC, TNF-
α, IL-6 and IL-1β were tested directly, using recombinant cytokines in human serum 
containing media.  Again, an in vitro approach using an 8µm pore membrane was used. 
 
The results are shown in Figure 4.4.  Both TNF-α and IL-6 were chemoattractant for MDSC 
within the dose-range tested.  Interestingly, the optimal concentration of rhTNF-α for MDSC 
migration was 1pg/ml, which was 1000-fold less than the optimal concentration for 
osteogenic differentiation determined by ALP expression (Figure 4.4A).  TNF-α, at a 
concentration of 1pg/ml resulted in a greater than 3-fold increase in cell migration relative 
to the human serum-containing media alone.  The optimal concentration for IL-6 was 
1ng/ml, which was also 1000-fold less than the optimal concentration for osteogenic 
differentiation determined by ALP expression in figure 4.2 (Figure 4.4B).  IL-6, at a 
concentration of 1ng/ml also resulted in a greater than 3-fold increase in cell migration 
relative to the human serum-containing media alone.  
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Figure 4.4 TNF-α and IL-6 are chemoattractants for MDSC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Migration of MDSC through an 8µm pore transwell membrane in response to A: rhTNF-α; B: 
rhIL-6 and C: rhIL-1β in human serum-containing media at the dose range indicated.  1x104 MDSC were 
seeded onto an 8µm pore membrane and left overnight.  Recombinant human cytokine was added to 
human serum-containing media at the concentrations indicated then added to the lower chamber and 
incubated for 36 hours.  The upper chamber of the membrane was then cleared of cells, then fixed and 
stained.  Adherent cells on the underside of the membrane were counted at 20x magnification (3 random 
fields per membrane) in triplicate.  Experiment performed 3 times (n=3) with MDSC from 2 donors.  
Results represent mean of 3 experiments ±SEM. *: P< 0.05; **: P< 0.01; ***: P< 0.001; 1-way ANOVA 
with Dunnett’s post test comparison against the media only control.   
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IL-1β did not significantly promote or suppress MDSC migration at any of the concentrations 
tested (Figure 4.4C). 
 
 
4.3.5 TNF-α, IL-6 and IL-1β did not stimulate proliferation of MDSC 
 
If the osteogenic activity of fracture supernatant was attributed to the pro-inflammatory 
cytokine content of the supernatant (see section 3.3.5), then it was hypothesised that given 
the random pattern of cellular proliferation when cultured in fracture and surgically cut 
supernatants, these cytokines were not responsible for the pattern of cellular proliferation 
seen.  In order to test this hypothesis, proliferation of MDSC cultured in human serum-
containing media with or without recombinant human TNF-α, IL-6 and IL-1β was assessed 
using a luminescent cell viability assay.  This method assays the number of viable cells in 
culture, by measuring adenosine triphosphate (ATP), where the luminescent signal is 
directly proportional to the number of ATP present.   
 
The results are shown in Figure 4.5.    None of the cytokines resulted in cellular proliferation 
in excess of that observed using human serum-containing media alone at the 
concentrations used.  In addition, none of the cytokines resulted in a pattern of cellular 
proliferation which differed from the control media.  Proliferation was not dose-
dependently-linked to the presence of pro-inflammatory cytokines TNF-α, IL-1β or IL-6.   
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Figure 4.5 Pro-inflammatory cytokines TNF-α, IL-1β and IL-6 do not promote MDSC 
proliferation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CellTiter-Glo® luminescent cell viability assay (Promega Corp., Madison, WI)  for MDSC in 
culture with A: rhTNF-α, B: rhIL-1β and C: rhIL-6.  2.5x103 cells were cultured in an opaque-bottomed 96-
well plate in triplicate for 1, 3 and 5 days in human serum-containing media ± recombinant human 
cytokine at the concentration indicated.  A control plate was also tested at day 0.  Serum-free media was 
used as the negative control.  The luminescent assay media was added to each well and the plate read 
using a fluorescence spectrometer.  The luminescence signal was directly proportional to the 
concentration of ATP from viable cells.  Results indicate mean ± SEM (n=3) from 3 donors, with Dunnett’s 
post-test comparison against the serum-containing media control. *: P<0.05. 
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4.4 Chemokines in supernatant 
 
 
While AbTNF-α, and to a lesser extent AbIL-6 diminished the chemoattractant effect of 
supernatant on MDSC, they did not wholly suppress it.  This suggested that either more 
than one factor present in supernatant was responsible for chemoattraction of MDSC, or 
that TNF-α promoted the responsiveness of MDSC to migration in response to other factors 
present in supernatant.  The chemoattractant molecules collectively known as chemokines 
(of which the CCL and CXCL classes are most abundant) have previously been implicated in 
promoting migration of stromal cells (Ringe et al., 2007; Yoshimura and Leonard, 1992; 
Zhang et al., 2009).  Candidates for stromal cell migration include CCL-2 (Yoshimura and 
Leonard, 1992; Zhang et al., 2009) and CXCL-8 (Ringe et al., 2007). 
 
In this section, the concentration of these and other chemokines were first established in 
supernatant.  Using a similar approach to the study of cytokines in section 4.3, the influence 
of candidate chemokines on migration of MDSC by fracture supernatant was tested.  The 
isolated role of candidate chemokines was then tested using recombinant human 
chemokines using the in vitro migration system.  As platelet-derived growth factor is 
another candidate chamoattractant molecule (Hollinger et al., 2008, Ponte, 2007 #402) this 
was also tested in isolation.   
 
 
4.4.1 Fracture and surgically cut supernatants contain the chemokines CCL-2 and 
CXCL-8 
 
Fracture and surgically cut supernatants were investigated for the presence of the common 
chemokines CCL-2 to CCL-5 and CXCL-8 to CXCL-10 using the 30-plex immuno-assay 
(Invitrogen Corp., Carlsbad, CA). As “active” and “inactive” supernatant referred to the 
ability of the supernatant to stimulate osteogenic differentiation of MDSC and not to the 
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ability of the supernatant to promote cell migration all fracture supernatants were analysed 
together and compared with surgically cut supernatants. 
 
 
Table 4.4 Chemokines from fractured and surgically cut bone 
 
 
Sup’tant 
number 
 
CCL2 
µg/ml 
CCL3 
pg/ml 
CCL4 
pg/ml 
CCL5 
pg/ml 
CXCL8 
µg/ml 
CXCL9 
pg/ml 
CXCL10 
pg/ml 
Fr
ac
tu
re
 su
pe
rn
at
an
t 
(a
ct
iv
e)
 
SM3250  
 
0.8 ±0.1 <5 38 ±1 108 ±1 2.7 ±0.2 <5 <5 
SM3311  
 
2.9 ±0.2 <5 46 ±3 34 ±1 87.7 ±5 <5 <5 
SM2936  
 
3.5 ±0.1 <5 38 ±3 28 ±1 >800 <5 <5 
SM2801 
 
1.3 ±0.3 <5 39 ±1 31 ±4 10.4 ±4 <5 28 ±14 
SM3334 
 
1.0 ±0.1 <5 38 ±2 107 ±34 13.1 ±4 <5 6 ±2 
Fr
ac
tu
re
 su
pe
rn
at
an
t 
(in
ac
tiv
e)
 
SM2795 
 
2.3 ±0.1 <5 89 ±7 128 ±12 20.8 ±1 <5 <5 
SM2943 
 
2.0 ±0.3 <5 52 ±3 171 ±41 91.2 ±11 <5 <5 
SM3062 
 
8.5 ±1 178 ±62 197 ±39 1131 ±226 519 ±15 42 ±8 5 ±1 
SM3285 
 
1.4 ±0.1 <5 59 ±1 739 ±126 19.3 ±10 <5 5 ±2 
SM3323 
 
1.8 ±0.1 <5 52 ±1 107 ±4 69.5 ±11 <5 <5 
Su
rg
ic
al
ly
 cu
t 
su
pe
rn
at
an
t 
(in
ac
tiv
e)
 
SM3310  
 
3.8 ±0.7 <5 <5 34 ±4 46.2 ±33 <5 <5 
SM3333  
 
0.6 ±0.01 <5 38 ±2 85 ±20 4.1 ±0.1 <5 <5 
SM3285  
 
0.5 ±0.01 <5 <5 407 ±44 1.5 ±0.2 <5 <5 
SM3389 
 
1.2 ±0.4 <5 42 ±5 87 ±12 14.7 ±0.7 <5 <5 
 
 
 
 
 
 
Table 4.4 The chemo attractant factors CCL-2 to CCL-5, and CXCL-8 to CXCL-10 were quantified in supernatant 
using the Luminex xMAP® system.  All samples were run in triplicate, with results expressed as a mean ± SD.   
The value was expressed as “less than” at the limit of assay sensitivity. 
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The results are shown in Table 4.4.   Of interest were the high levels of CCL-2 and CXCL-8 
found in most of the supernatants.  However, there was no significant difference in CCL-2 
concentration (P=0.24) or CXCL-8 concentration (P=0.14) between fracture and surgically cut 
supernatant (Mann-Whitney test).  Of the remaining chemokines tested, a comparison of 
fracture and surgically cut supernatants revealed a significant increase in CCL-4 (64.8 ± 49.0, 
1SD vs. 22.5 vs 20.3, 1SD; P=0.04, Mann-Whitney test) in fracture supernatant.  There was 
no significant difference in CCL-5 concentration (P=0.67) between fracture and surgically cut 
supernatant (Mann-Whitney test). 
 
 
4.4.2 Antibody inhibition of CXCL-8, but not CCL-2 diminished the chemoattractant 
effect of supernatant 
 
While there were no significant differences in the concentration of chemokines CCL-2 and 
CXCL-8 between fracture and surgically cut supernatant both were present at high 
concentrations.  Hence, in order to identify the role of CCL-2 and CXCL-8 on supernatant-
mediated cell migration the in vitro cell migration model was again used.  On this occasion 
cell migration was studied following culture in supernatants pre-incubated with antibodies 
to human CCL-2 (MCP-1) and CXCL-8 (IL-8).   
 
The results are shown in Figure 4.6.   Antibody inhibition of CXCL-8 in supernatant reduced 
MDSC migration in a dose-dependent manner.  Cell migration fell to around 60% of the 
supernatant control at an antibody concentration of 104ng/ml.  Antibody to CCL-2 in 
supernatant did not influence cell migration throughout the dose range tested.   
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Figure 4.6 Antibody inhibition of CXCL-8 impairs supernatant chemotaxis for MDSC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Neither recombinant human CXCL-8 nor CCL-2 stimulated migration of MDSC 
in vitro 
 
As antibody inhibition of CXCL-8 in supernatant impaired the chemoattractant effect of the 
supernatant, the direct influence of CXCL-8 (and other chemokines) on MDSC migration was 
tested.  Using the same approach used in section 4.3.4 the migration of MDSC through a 
transwell membrane in response to recombinant human CXCL-8 was tested.  The 
chemokines CCL-2, with CCL-3, CCL-4, CCL-5, CXCL-9 and CXCL-10 were also tested.  As 
 
Figure 4.6 Migration of MDSC through an 8µm pore transwell membrane in response to fracture 
supernatant with the addition of AbCCL-2 and AbCXCL-8. MDSC were seeded onto an 8µm pore membrane 
and left overnight.  Antibody or IgG1 immunoglobulin control (added to produce the concentrations 
shown) were added to aliquots of supernatant and incubated for 1 hour at 4°C.  The supernatant was then 
added to the lower chamber and incubated for 36 hours.  The upper chamber of the membrane was then 
cleared of cells, then fixed and stained.  Adherent cells on the underside of the membrane were counted at 
20x magnification (3 random fields per membrane) in triplicate.  The experiment was performed 3 times 
(n=3) using 3 fracture supernatants.  Results are given as percentage migration relative to the supernatant 
only control and represent a mean of 3 experiments ±SEM. **: P< 0.01; 1-way ANOVA with Bonferroni’s 
post test correction.   
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migration of marrow-derived stromal cells has been reported in response to platelet-
derived growth factor (PDGF-AB) (Ponte et al., 2007), this factor was also tested.   
 
The results are shown in Figure 4.7. Platelet-derived growth factor promoted migration of 
MDSC, resulting in a 7-fold increase in cell migration over the media only control at a 
concentration of 100ng/ml.   CXCL-8, by contrast, did not promote MDSC migration 
throughout the dose range tested.  Similarly, the other chemokines tested, including CCL-4 
(found in significantly increased concentrations in fracture supernatant) did not appear to 
influence MDSC migration.   The significance of this finding is discussed below. 
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Figure 4.7 Platelet-derived growth factor, but not CXCL-8 (or other chemokines tested) 
promotes the migration of quiescent MDSC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Migration of MDSC through an 8µm pore transwell membrane in response to human serum-
containing media ± PDGF, CCL-2 to CCL-5, and CXCL-8 to CXCL-10 at the dose range indicated.  1x104 
MDSC were seeded onto an 8µm pore membrane and left overnight.  Recombinant human chemokine 
was added to human serum-containing media at the concentrations indicated then added to the lower 
chamber and incubated for 36 hours.  The upper chamber of the membrane was then cleared of cells, 
then fixed and stained.  Adherent cells on the underside of the membrane were counted at 20x 
magnification (3 random fields per membrane) in triplicate.  Experiment performed 3 times (n=3) with 
MDSC from 1 donor.  Results represent mean of 3 experiments ±SEM. ***: P< 0.001; 1-way ANOVA with 
Dunnett’s post test comparison against the media only control.   
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4.5 Discussion 
 
Experiments described in this chapter investigated the direct and indirect influence of the 
pro-inflammatory cytokines TNF-α, IL-1β and IL-6 on the migration, proliferation and 
osteogenic differentiation of human MDSC using in vitro models.  TNF-α, and, to a lesser 
extent IL-6 was found to promote the migration and osteogenic differentiation of MDSC.  
TNF-α was found to be the most potent stimulator of differentiation.  The chemokine CXCL-
8, present in the post-fracture inflammatory environment also promoted MDSC migration in 
supernatant but was unable to promote migration in isolation.  By contrast, IL-1β initiated 
some osteogenic differentiation of MDSC but was unable to drive the differentiation to 
completion.  Moreover, IL-1β did not promote cell migration.  Neither TNF-α, IL-6 nor IL-1β 
promoted proliferation of MDSC.   
 
Interestingly, compositional analysis of the fracture and surgically cut supernatants did not 
yield any discernible pattern to aid in the identification of candidate factors for osteogenic 
differentiation.  On reflection, this was not surprising as supernatant variability was 
expected owing to the variables encountered in the clinical situation.  Factors which may 
have influenced the nature and composition of the fracture supernatant (and hence the 
result of compositional analyses) include the severity of the injury and associated local 
inflammatory response, the time since injury and any surgical and temporising procedures 
performed prior to debridement including wound washout and use of negative-pressure 
dressings, as well as pharmacological management of the patient including non-steroidal 
anti-inflammatory drugs.  Patient factors including gender, age and pre-morbid health were 
also likely to be relevant to the results obtained.  While all supernatants were produced 
using 5g bone per ml of media differences in the size and configuration of the debrided 
fracture fragments resulted in differences in the bone surface areas in contact with the 
media in culture. In turn, this may have influenced the concentrations of growth factors in 
the supernatant. 
 
CHAPTER FOUR                                                                                                                                                       CYTOKINES 
 216 
The surgically cut supernatants, by contrast were anticipated to be similar in composition.  
However, factors which may have resulted in the variability seen in these supernatants 
include differences in the systemic responses to major foot and ankle trauma, local 
variability in growth factor expression and the aforementioned patient factors.   
 
It was found that the concentrations of TNF-α and IL-1β in supernatant were mostly less 
than 15 pg/ml and 1pg/ml respectively, while IL-6 was present in ng/ml concentrations.  
These findings are consistent with data published by Einhorn et al in a closed rat femoral 
fracture model.  They identified high constitutive levels of IL-6 and low constitutive levels of 
IL-1 in early fracture callus (Einhorn et al., 1995).  As IL-6 is synthesised in response to IL-1 
(Elias and Lentz, 1990) and TNF-α (Heymann and Rousselle, 2000), we can assume that the 
high levels of IL-6 indicated that IL-1 and TNF-α were present at physiologically active 
concentrations.   The presence of G-CSF and GM-CSF may be similarly attributed to 
stimulation of expression induced by IL-1 and TNF-α (Broudy et al., 1986; Koeffler et al., 
1987; Zsebo et al., 1988).  Also of interest was the low constitutive level of IL-10 (which is 
predominantly anti-inflammatory in nature) in fracture supernatant.  This observation is 
consistent with the pro-inflammatory nature of the post-fracture environment  (Mosser and 
Zhang, 2008).   
 
The role of TNF-α in the osteogenic differentiation of MDSC by fracture supernatant was 
suggested by the finding that antibody inhibition of TNF-α in supernatant partly suppressed 
the osteogenic stimulus within the range tested.   Moreover, addition of recombinant TNF-α 
to MDSC in culture media demonstrated osteogenic differentiation in a dose-dependent 
manner.  Bone nodule formation was also demonstrated.  In these experiments human 
serum and recombinant proteins were used ensuring that the in vitro model system was 
representative of the human post-fracture environment.  These findings were consistent 
with the pro-osteogenic effect of TNF-α on human marrow stromal cells reported by Rifas, 
but unique in that TNF-α alone promoted osteogenic differentiation without the presence 
of co-factors including TGF-β and IFN-γ (Rifas, 2006).  The findings contradict those of 
Gilbert et al, who reported that TNF-α inhibited osteogenic differentiation of rat fetal 
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calvarial cells and murine clonal osteoblastic (MC3T3-E1-14) cells (Gilbert et al., 2000; 
Gilbert et al., 2005).  It is possible that these observations reflected properties of the non-
human cells used.  Interestingly as the concentration of TNF-α increased, the pro-osteogenic 
effect rapidly diminished and even dropped below the negative control at the highest 
concentration tested.  This observation was consistent with the findings of Hashimoto et al, 
who demonstrated impaired fracture healing following high, and prolonged doses of TNF-α 
(Hashimoto et al., 1989).  This suggests that TNF-α may exert differential effects on 
osteoprogenitor cells, depending on local concentration and has important translational 
implications if inflammatory modulation is considered as a means of promoting fracture 
healing.     
 
Similar to TNF-α, the role of IL-6 in the osteogenic differentiation of MDSC by fracture 
supernatant was suggested by the finding that antibody inhibition in supernatant partly 
suppressed the osteogenic stimulus within the range tested.   While fracture supernatant 
contained higher constitutive levels of IL-6 the same concentrations of IL-6 and TNF-α 
antibodies were required to produce similar suppression of ALP expression by MDSC.  This 
suggested that either IL-6 was less biologically active than TNF-α or that the binding 
efficacies of the antibodies were different.   
 
Addition of recombinant IL-6 to MDSC in culture media demonstrated osteogenic 
differentiation as evidenced by ALP expression.   However, osteogenic differentiation by IL-6 
followed a pattern distinct from TNF-α.   Firstly, ALP expression did not follow the same 
dose-response relationship as TNF-α, but instead ALP expression increased in direct 
proportion to concentration throughout the range tested.  At the highest concentration 
used (1000ng/ml) this was between 100 and 1000-fold higher than the concentrations 
found in fracture supernatant.   Secondly, the concentrations of TNF-α (1ng/ml) and IL-6 
(100ng/ml) used to culture bone nodules both resulted in a 2-fold increase in ALP 
expression on the ALP expression curve.  However, bone nodule formation was greater 
using TNF-α despite the fact that the concentration of rhIL-6 was 100-fold higher.  The 
similarities between TNF-α and IL-6 in osteogenic differentiation of MDSC suggest that IL-6 
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may act downstream of TNF-α as part of the same pathway (Franchimont et al., 2005; 
Kozawa et al., 1997).  A way of demonstrating this would be to demonstrate TNF-α-
mediated synthesis of IL-6 by ELISA of cell supernatant.   
 
The data suggested that IL-1β did not stimulate osteogenic differentiation of MDSC in 
supernatant.  Moreover, recombinant human IL-1β promoted modest expression of ALP by 
MDSC, a result which failed to translate to bone nodule formation when cultured at the 
optimised concentration.  These data suggest that, uniquely among the cytokines studied, 
IL-1β may initiate differentiation, but fails to continue to stimulate differentiation down an 
osteogenic lineage, or else fails to promote the synthesis of bone growth factors which, in 
turn, continue the process of osteogenic differentiation.  Alternatively, if TNF-α exerts its 
osteogenic effect by stimulating downstream synthesis of IL-6, then perhaps IL-1β fails to 
stimulate IL-6 expression by MDSC in the way that TNF-α can.  
 
Neither recombinant TNF-α, IL-1β or IL-6 induced the proliferation of MDSC in excess of the 
proliferative effect of the human serum-containing culture medium.  This finding was 
surprising as the proliferative effect of TNF-α on both stromal and epithelial cells has been 
reported (Iwabe et al., 2000; Rubio et al., 2006).  The reason may lie in inherent differences 
between MDSC and the endometrial and ductal epithelial cells described in these studies.  
These data suggest that MDSC are adapted for recruitment and osteogenic differentiation 
by the fracture environment but not for additional cell proliferation in their undifferentiated 
state.  This would seem to make physiological sense as the fracture environment needs first 
to recruit progenitor cells and then promote their osteogenic differentiation.  Proliferation 
of committed osteoprogenitors is more desirable than proliferation of uncommitted cells.  
To study this hypothesis in greater detail, a repeat of the proliferation experiment using a 
committed osteoprogenitor cell is necessary.   
 
The migration data is rather complex and may be summarised as follows: antibody 
inhibition of TNF-α in supernatant reduced subsequent supernatant-mediated migration of 
MDSC by around 50% at concentrations above 100ng/ml.  Moreover, recombinant human 
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TNF-α promoted migration of MDSC.  Recombinant human platelet-derived growth factor 
(PDGF) also promoted the dose-dependent migration of MDSC.    Hence, TNF-α and PDGF 
(likely to be present in supernatant but not quantified) promoted cell migration directly and 
PDGF may have accounted for at least some of the residual chemoattractant properties of 
supernatant following TNF-α inhibition.  This could be confirmed by dual antibody 
inhibition.  The expression of cell adhesion molecules such as selectins and VCAM-1 may 
account for direct cell migration was a result of stimulation by TNF-α.  This observation has 
also been reported for T-cells (von Andrian and Mackay, 2000).  Determining the 
mechanism by which TNF-α promoted MDSC migration directly is an important area for 
further investigation.   
 
Additionally, antibody inhibition of the chemoattractant molecule CXCL-8, present in high 
concentrations in fracture supernatant, also reduced supernatant-mediated migration 
MDSC by around 40% at a concentration of 10µg/ml.  Interestingly however, recombinant 
human CXCL-8 did not appear to promote migration of MDSC directly.  The fact that CXCL-8 
promoted migration in supernatant but was unable to promote migration directly, suggests 
that factor(s) in supernatant promoted cell responsiveness to CXCL-8.  CXCL-8 (IL-8) is 
synthesised principally by cells of the monocyte lineage and is chemotactic for neutrophils 
(Zhang et al., 1994).  Ringe et al demonstrated that human marrow-derived mesenchymal 
stromal cells have been shown to express the IL-8 receptors CXCR-1 and CXCR-2 and to 
migrate upon stimulation by IL-8 (Ringe et al., 2007).  Ponte et al reported that TNF-α 
primed stromal cells for migration by stimulating expression of chemokine receptors CCR-2, 
CCR-3 and CCR-4 (Ponte et al., 2007).  Ligands for these receptors include CCL-2 (MCP-1) 
and CCL-5 (RANTES). TNF-α has also been reported to stimulate expression of the 
chemokines CCL-2, CCL-3, CCL-4, CCL-5 and CXCL-8 by human marrow-derived stromal cells 
(Croitoru-Lamoury et al., 2007).  
 
As with differentiation, the small effect of IL-6 on cell migration in supernatant may occur as 
a consequence of indirect regulation by TNF-α.  The concentrations of both TNF-α and IL-6 
required to stimulate optimal cell migration in culture were 1000-fold less than the 
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concentrations required for osteogenic differentiation. One may speculate that as local 
concentrations of TNF-α and IL-6 rise within the fracture environment they stimulate cell 
migration then, as concentration rises further, the differentiation of recruited cells.    In 
contrast to TNF-α (and IL-6) antibody inhibition of IL-1β in supernatant did not influence 
subsequent supernatant-mediated migration of MDSC. Furthermore, recombinant human 
IL-1β did not promote migration of MDSC.   Similarly, Ponte et al reported that only TNF-α, 
and not IL-1β, influenced bone marrow stromal cell (BMSC) migration in culture.  
Specifically, IL-1β did not promote expression of chemokine receptors and, following pre-
stimulation with IL-1β, migration of BMSC in response to growth factors remained 
unchanged (Ponte et al., 2007).  Hence, IL-1β neither promotes MDSC migration directly, or 
indirectly.  In this respect, stromal cells behave differently from T cells, as IL-1 and TNF-α 
promote T-cell migration similarly (von Andrian and Mackay, 2000).   
 
Interestingly, the chemokine CCL-2 was also present in high concentrations in fracture 
supernatant.  CCL-2 is also known as monocyte chemotactic protein-1 (MCP-1).  It is 
synthesised by osteoblasts and osteoclasts and recruits cells of the monocyte lineage to 
tissue injury (Yoshimura and Leonard, 1992).  However, MCP-1 has been implicated in 
mesenchymal progenitor cell chemotaxis.  Zhang et al demonstrated that TGF-β mediated 
rat marrow-derived stromal cell chemotaxis occurred as a result of the downstream 
synthesis of MCP-1 (Zhang et al., 2009).  Ringe et al reported that marrow-derived stromal 
cells expressed the MCP-1 receptor CCR-2, but MCP-1 did not promote chemotaxis (Ringe et 
al., 2007).  In the experiments detailed here, MCP-1 (like IL-8) did not promote migration of 
quiescent MDSC in media.   These data provide further evidence that chemokine-mediated 
chemotaxis of stromal cells may require cell priming.  
 
In summary, the results presented in this chapter have demonstrated that TNF-α (with IL-6) 
in the post fracture inflammatory milieu is capable of recruiting muscle-derived stromal 
cells and stimulating differentiation down an osteogenic lineage to form bone.  By contrast 
IL-1β promoted neither cell migration nor bone nodule formation.  The chemoattractant 
molecule CXCL-8, present in high concentrations in fracture supernatant also promoted 
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supernatant-mediated migration of MDSC but did not promote MDSC in isolation. Having 
confirmed the importance of TNF-α and IL-6 in bone formation using an in vitro fracture 
model and human tissue, the next step is to confirm the importance of these cytokines in an 
in vivo model of high energy tibial fracture and to demonstrate how fracture healing might 
be enhanced by manipulating the inflammatory environment.   
 
 
  
 
 
 
 
 
 
 
CHAPTER FIVE 
 
The influence of inflammatory cytokines on fracture 
healing in vivo  
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5.1 Introduction 
 
 
The previous chapter explored the potential of pro-inflammatory cytokines to promote the 
recruitment of muscle stromal cells for fracture healing using an in vitro system and 
demonstrated that TNF-α (and IL-6) can promote cell migration and osteogenic 
differentiation. Hence, it was hypothesised that the administration of TNF-α and/or 
manipulation of the TNF-α pathway may influence fracture healing in vivo.   
 
While the in vitro model was developed using human tissue, supernatants and recombinant 
proteins to avoid non translatable, species-specific results in vivo proof of concept must be 
sought using an animal model. This does, however, constitute a different approach from the 
rodent models used to study BMPs as the proof of concept has already been established 
using primary human tissue in vitro.  Hence, for this final chapter, the murine fracture 
model was utilised once more.    
 
The murine model was favoured for several reasons.  Firstly, fracture healing can be 
prolonged, and thus a species must be chosen that can be expected to heal within a 
reasonable time frame to permit comparative analyses.  Secondly, a range of knockout 
strains exist to permit examination of the influence of a single cytokine or receptor.  Thirdly, 
fracture healing using this model is relatively easy to measure and observe, using both 
histological and radiographic approaches.   
 
The second question that arose from the work detailed in chapter 4 concerned the origin of 
TNF-α found in supernatants representative of the early fracture healing environment.  
While it was hypothesised that cells of the inflammatory infiltrate (particularly neutrophils 
and macrophages) were responsible for TNF-α synthesis, the spatial and temporal 
arrangement of inflammatory cell types remains poorly understood.  Hence the final part of 
this study concerned defining the spatial and temporal arrangement of cells of the post-
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fracture inflammatory infiltrate and determining whether the presence of cells of the 
adaptive immune response influence fracture healing in vivo.   
 
Hence, this section is divided in to two parts. In the first, the influence of TNF-α on fracture 
healing is investigated. In the second part, the cell-specific nature of the post-fracture 
inflammatory infiltrate and the influence of adaptive immunity on fracture healing are 
evaluated.   
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5.2 Fracture healing in pro-inflammatory cytokine knockout mice  
 
 
TNF-α and IL-6, present in fracture-derived supernatant, stimulate migration and osteogenic 
differentiation of stromal cells in vitro, while IL-1β promotes early osteogenic differentiation 
weakly and does not promote cell migration.  However, while these data, compiled using 
human samples, provide translationally compelling evidence for the relevance of TNF-α and 
IL-6 to early fracture healing, the evidence is merely circumstantial.  Direct evidence for the 
influence of TNF-α, IL-6 and IL-1β on fracture healing must be obtained using an in vivo 
fracture model.   By choosing a murine model, using knockout stains to study the absolute 
requirement of any one factor, such direct evidence can be obtained.  The cost of such 
direct data is the loss of species-specificity; however, this cost is minimised as these studies 
were directed by human in vitro data.  
 
 
5.2.1 Early inflammation is reduced in the P55-/- mouse but not in the P75-/- mouse 
 
To evaluate the absolute requirement for TNF-α in fracture healing, the murine in vivo 
model (described in detail in section 2.2.20) was performed using P55 (TNF-α receptor-1) 
and P75 (receptor-2) knockout mice.  These mice, on a background strain of C57Bl6, exhibit 
a normal phenotype.  Hence age, sex and sized-matched C57Bl6 mice were used as the 
controls.   Following fracture the mice were harvested at day 3, 7, 14 and 28 and histological 
sectioning of the fractured limb performed.  The sections were stained with Masson’s 
trichrome stain.  Mineralised callus and bone is stained blue/green, muscle and connective 
tissue is stained red and cells are stained black.   The sections were viewed under light 
microscopy and comparisons of callus maturation made.  
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Figure 5.1 P55-/- mouse exhibits a reduced inflammatory infiltrate in early fracture healing 
but exhibits later catch-up healing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results are shown in Figure 5.1.  The wild type mice exhibited fracture debris and 
cellular infiltration at day 3.  Cellular infiltration was extensive at day 7 and comprised 
Figure 5.1 The murine tibial fracture model was performed as described in section 2.2.20 on 12 week old, 
female P55 (TNF-α receptor 1) and P75 (TNF-α receptor 2) knockout mice, and on age, sex and weight-
matched C57Bl6 (wild type- WT mice).  Limbs (≥3 per time point) were harvested at day 3, 7, 14 and 28 
post fracture, fixed in 10% formalin, decalcified using 10% formic acid and bisected longitudinally.  
Histological sections were cut and stained using Masson’s trichrome.  A representative section of 1 of 3 
limbs is shown.  
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inflammatory cells centrally and organising cartilaginous callus marginally.  A front of 
ossification was seen on the muscle side at the margins of the callus.  At day 14 the callus on 
the muscle side had ossified all but centrally, where a residual margin of cartilaginous 
intermediary remained.  On the fasciocutaneous side, the margins of the ossifying callus 
were encroaching on the fracture line but bridging was incomplete.  By day 28 both cortices 
had bridged, and remodelling of the callus was in progress.  The callus was less mature on 
the fasciocutaneous side at all time points.   
 
In the P55-/- mice, the cellular infiltration was minimal at day 3 in comparison with the wild 
type control, but was extensive by day 7.   While a front of ossification was seen on the 
muscle side at the margins of the organising callus the cartilaginous intermediary was less 
voluminous or mature.  However, by day 14, this delay had reversed, as bone bridging was 
complete on the muscle side and almost complete on the fasciocutaneous side, in 
comparison with the wild type the callus was now more mature.  The appearance is similar 
to the wild type at day 28, with cortical bridging on both muscle and fasciocutaneous side 
and cortical remodelling in progress.  Unlike the histological profile of the P55-/- mice, the 
histological sections of the P75-/- mice revealed a pattern of fracture healing similar to the 
wild-type control at all time points.   
 
 
5.2.2 Callus mineralisation in the P55-/- and P75-/- mice are similar to the wild type 
controls at day 14 and day 28 
 
In order to evaluate maturation of the fracture callus quantitatively, the fracture model was 
repeated for all 3 strains and limbs harvested at day 14 and day 28 for computer 
tomography (CT) imaging.  Day 14 (when ossification of the cartilaginous intermediary was 
in progress) was considered to be the earliest time point that could be harvested for CT 
owing to the need for removal of the pin.  Day 28 was also chosen as this represented the 
phase of bone remodelling.  Using a reconstructed image of the callus, as described in 
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section 2.2.29, the callus volume was established and the mineralised portion of the callus 
calculated. 
 
 
Figure 5.2 At day 14 and day 28 fracture callus mineralisation is similar between the P55-/- 
and P75-/- mice and the wild type control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results are shown in Figure 5.2.  At day 14 the mean percentage callus mineralisation of 
the P55-/- group was higher than the wild type group (44.8 ±7.7%, 1SD vs. 38.4 ±7.6%, 1SD; 
P=0.116) but the result was not significant (Figure 5.2A).  At day 28 the mean percentage 
callus mineralisation of the P55-/- group was again higher than the wild type group (63.0 
±8.9%, 1SD vs. 57.8 ±6.4%, 1SD; P=0.211) but again the result was not significant (Figure 
5.2B).   Similarly, there were no significant differences between the P75-/- group and the 
Figure 5.2 The murine tibial fracture model was performed as described in section 2.2.20 on 10-12 week 
old, female P55, P75 and C57Bl6 (WT) mice (6-10 per strain).  At day 14 (A) and day 28 (B), the fractured 
tibiae were harvested, stripped of all soft tissue and the pin removed.  The bones were stored in 70% 
ethanol, and computer tomographic imaging (CT) was performed (courtesy of Mr Kevin Mackenzie, 
University of Aberdeen). Callus mineralisation, expressed as a percentage of the total callus volume, was 
calculated from the reconstructed CT image of the callus as described in section 2.2.29 (courtesy of Dr. 
Andrew Freidin, Imperial College).  Statistical analyses were performed using an unpaired t-test with 
Welch’s correction.  There were no statistically significant differences identified. 
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wild type group at day 14 (42.3 ±8.5%, 1SD vs. 38.4 ±7.6%, 1SD; P=0.429) (Figure 5.2A) or 
day 28 (61.8 ±6.1%, 1SD vs. 57.8 ±6.4%, 1SD; P=0.238) (Figure 5.2B).    
 
 
5.2.3 Early fracture healing is slightly delayed in the IL-6 knockout mouse 
 
 
In vitro data using human tissue in chapter 4 demonstrated stromal cell migration and 
ostoegenic differentiation in response to IL-6.  Hence, the absolute requirement for IL-6 was 
investigated using the murine fracture model.  IL-6 null mice also exhibit a normal 
phenotype.  The background strain was C57Bl6 as before.  Hence age, sex and sized-
matched C57Bl6 mice were again used as the controls.   As for the P55-/- and P75-/- mice, 
limbs were harvested at day 3, 7, 14 and 28 post-fracture and histological sectioning of the 
fractured limb as before.   
 
The results are shown in Figure 5.3.  As before, the wild type control exhibited a dense 
inflammatory cell infiltrate at day 7, with callus organisation apparent around a centrally 
situated fracture haematoma and cellular infiltrate.  Consistent with the histological series 
shown in Figure 5.1, the callus exhibited organisation and marginal ossification on the 
muscle side.  At day 14 callus ossification was almost complete on the muscle side, with a 
centrally situated area of residual hypertrophic chondrocytes adjacent to the fracture line.  
Again, bridging was incomplete on the fasciocutaneous side.  Bi-cortical bridging had 
occurred by day 28.   
 
In contrast to the wild-type control (and similar to the P55-/- strain) the inflammatory 
infiltrate was less extensive in the IL-6 knockout strain at day 7.   Additionally, the callus was 
poorly formed on the muscle side, with little evidence of a cartilaginous intermediary.  A 
front of ossification was only visible at the extreme margins of the poorly formed callus.  
The appearance on the fasciocutaneous side, with a centrally situated haematoma 
surrounded by an inflammatory infiltrate, was similar to the appearance at day 3.  However, 
once more, by day 14 callus maturation had caught up, and surpassed the wild type control.   
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Figure 5.3 Early fracture healing is delayed in the IL-6-/- mouse but catch-up occurs by day 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 The murine tibial fracture model was performed as described in section 2.2.20 on 10-12 week 
old, female IL-6 knockout mice and on age, sex and weight-matched C57Bl6 (wild type- WT mice).  
Limbs (≥3 per time point) were harvested at day 3, 7, 14 and 28 post fracture, fixed in 10% formalin, 
decalcified using 10% formic acid and bisected longitudinally.  Histological sections were cut and stained 
using Masson’s trichrome.  A representative section of 1 of 3 limbs is shown.  
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The callus exhibited complete bridging on the muscle side and near-complete bridging on 
the fasciocutaneous side.  At day 28 both cortices had bridged and the callus was 
remodelling in both the knockout and control strains.   
 
 
5.2.4 Fracture healing proceeds normally in the IL-1 receptor knockout mouse 
 
The absolute requirement for IL-1 was also investigated using the murine fracture model.  
The IL-1 receptor null mouse was used as IL-1 exists in 2 isoforms (IL-1α, and IL-1β).  Again, 
IL-1 receptor mice exhibit a normal phenotype and the background strain was C57Bl6 as 
before.  Limbs were harvested at day 3, 7, 14 and 28 post-fracture and histological 
sectioning of the fractured limb as before.   
 
The results are shown in Figure 5.4.  The wild type control exhibited a dense inflammatory 
cell infiltrate on the fasciocutaneous side at day 7 as before.  In the section shown, little 
movement has occurred at the fracture line as evidenced by the anatomical alignment of 
the posterior cortex.  It is likely that this accounted for the relatively smaller callus forming 
on the posterior side, adjacent to the muscle.  As before, however, there is evidence of new 
bone formation marginally.  By contrast the section shown at day 14 represents a fracture 
with a less stable fixation, as evidenced by the greater callus volume and the anatomical 
arrangement of the fracture fragments.  However, as with previous sections new bone 
formation has resulted in near complete bridging on the muscle side, with incomplete 
bridging on the fascocutaneous side.  A centrally placed soft callus with hypertrophic 
chondrocytes is seen.  Bridging is complete at day 28.   
 
At day 7, (like the IL-6-/- and P55-/- mice) the IL-1R-/- mouse exhibited poor callus 
development on the muscle side with evidence of bone formation marginally.  By day 14, 
the appearance of the fracture callus was similar to the wild type.  Unlike the P55-/- mouse 
there was no evidence that this period of “catch up” healing resulted in bi-cortical bridging 
at day 14.    
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Figure 5.4 Fracture healing proceeds normally in the IL-1R-/- mouse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 The murine tibial fracture model was performed as described in section 2.2.20 on 10-12 week 
old, female IL-1 receptor knockout mice and on age, sex and weight-matched C57Bl6 (wild type- WT 
mice).  Limbs (≥3 per time point) were harvested at day 3, 7, 14 and 28 post fracture, fixed in 10% 
formalin, decalcified using 10% formic acid and bisected longitudinally.  Histological sections were cut 
and stained using Masson’s trichrome.  A representative section of 1 of 3 limbs is shown.  
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5.2.5 Callus mineralisation in the IL-6-/- and IL-1R-/- mice are similar to the wild type 
controls at day 14 and day 28 
 
As with the P55-/- and P75-/- strains, callus mineralisation following fracture was evaluated 
quantitatively in the IL-6-/- and IL-1R-/- strains.   Once more, the limbs harvested for 
computer tomographic (CT) imaging at day 14 and day 28 and the mineralised portion of the 
callus calculated from the reconstructed image. 
 
 
Figure 5.5 Callus mineralisation in IL-6-/- and IL-1R-/- mice is similar to wild type mice at day 
14 and day 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 The murine tibial fracture model was performed as described in section 2.2.20 on 10-12 week 
old, female IL-6-/-, IL-1R-/- and C57Bl6 (WT) mice (8-10 per strain).  At day 14 (A) and day 28 (B), the 
fractured tibiae were harvested, stripped of all soft tissue and the pin removed.  The bones were stored in 
70% ethanol, and computer tomographic imaging (CT) was performed (courtesy of Mr. Kevin Mackenzie, 
University of Aberdeen). Callus mineralisation, expressed as a percentage of the total callus volume, was 
calculated from the reconstructed CT image of the callus as described in section 2.2.29 (courtesy of Dr. 
Andrew Freidin, Imperial College).  Statistical analyses were performed using an unpaired t-test with 
Welch’s correction.  There were no statistically significant differences identified.  
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The results are shown in Figure 5.5.  At day 14 the mean percentage callus mineralisation of 
the IL-6-/- group was less than the wild type group (35.6 ±8.1%, 1SD vs. 38.4 ±7.6%, 1SD; 
P=0.522) but the result was not significant (Figure 5.5A).  At day 28 the mean percentage 
callus mineralisation of the IL-6-/- group was similar to the wild type group (57.2 ±3.5%, 1SD 
vs. 57.8 ±6.4%, 1SD; P=0.815) (Figure 5.5B).   At day 14 the mean percentage callus 
mineralisation of the IL-1R-/- group was also less than the wild type group (36.9 ±5.8%, 1SD 
vs. 38.4 ±7.6%, 1SD; P=0.672) but again, the result was not significant (Figure 5.5A).  At day 
28 the mean percentage callus mineralisation of the IL-1R-/- group was similar to the wild 
type group (63.1 ±8.3%, 1SD vs. 57.8 ±6.4%, 1SD; P=0.219) (Figure 5.5B).    
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5.3 The influence of recombinant TNF-α on fracture healing 
 
 
Evidence from the knockout strains suggested that early fracture healing was influenced by 
IL-6 and TNF-α (acting through the P55 receptor) but that redundancy existed within the 
system as neither was an absolute requirement for fracture healing.  Hence, it was 
hypothesised that the exogenous administration of TNF-α or IL-6 would promote fracture 
healing (if there was a dose-dependency) or else would make no difference (if the levels 
occurring endogenously satisfied the requirement).  Given that repeated supraphysiological 
doses of TNF-α have been reported in association with delayed union (Hashimoto et al., 
1989) and given that the highest dose of TNF-α was associated with a rapid decline in ALP 
expression in human MDSC (figure 4.2) it was hypothesised that an additional feature of 
TNF-α administration might be inhibition of fracture healing at a high dose.    
 
 
5.3.1 Locally injected recombinant TNF-α can both promote and inhibit fracture 
healing, depending on the concentration used 
 
Using the murine model fracture healing was evaluated following the administration of 
recombinant TNF-α, IL-6 or IL-1β locally during early fracture healing.  Human recombinant 
TNF-α was selected as it binds to, and initiates cellular responses through the murine P55, 
but not P75 receptor.  Three doses of rhTNF-α were used, representing a “low” dose, an 
“optimal” dose and a “high” dose (determined by provisional in vivo studies).  Similarly 
human IL-6 was used as it is cross reactive with the murine IL-6 receptor.  Murine IL-1β was 
used as it is not cross-reactive.  Limbs were again harvested at day 14 fracture healing 
evaluated by histology.  The murine model was again used, this time with or without a 
single local addition of recombinant TNF-α.  As the in vitro data from chapter 4 suggested 
that the influence of TNF-α on muscle stromal cells was dose dependent, three doses were 
used (guided by the in vitro data from chapter 4, with some provisional in vivo experiments- 
not shown).   
CHAPTER FIVE                                                                                                                                         FRACTURE HEALING 
 236 
Figure 5.6 TNF-α accelerates fracture healing in a murine model within a narrow therapeutic 
window 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results are shown in Figure 5.6.  When injected with recombinant TNF-α at 50ng/kg, 
complete bone bridging was evident on both the muscle and fasciocutaneous cortices.  At 
5ng/kg bridging was incomplete on both muscle and fasciocutaneous cortices, although, as 
usual, bridging was more extensive on the cortex adjacent to muscle.  In terms of callus 
maturity, this appearance was similar to the PBS-injected wild type (WT) control.  When 
TNF-α was injected at 500ng/kg however, the callus remained immature on the muscle 
surface, which was principally on account of the lack of ossification from the proximal 
Figure 5.6 The murine tibial fracture model was performed on 10-12 week old, female C57Bl6 mice with or 
without the local administration of recombinant TNF-α, recombinant IL-6 (both human) or recombinant IL-
1β (murine) in 20µl PBS at the concentrations stated.  The control limbs were injected with 20µl PBS only.  
All injections were performed within 1 hour of surgery and again at 24 hours.  Limbs (≥3 per time point) 
were harvested at day 14 post fracture, fixed in 10% formalin, decalcified using 10% formic acid and 
bisected longitudinally.  Histological sections were cut and stained using Masson’s trichrome.  A 
representative section of 1 of 3 limbs is shown.  
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aspect of the tibial cortex (left side of histological slide).  On the fasciocutaneous surface, 
the callus was poorly developed with some marginal ossification and rudimentary 
cartilaginous intermediary centrally.  
 
By contrast, when injected with recombinant IL-6 at 50µg/ml, and IL-1β at 50ng/ml, the 
appearance of the histological sections at day 14 were similar to the WT control, with 
incomplete bone bridging on both cortical surfaces, but more complete bridging on the 
muscle surface.  Callus maturity was not dependent on the dose of either IL-6 or IL-1β 
administered (not shown).       
 
 
5.3.2 Locally injected recombinant TNF-α can promote callus mineralisation but 
not at a high dose 
 
Histologically, the administration of rhTNF-α at a dose of 50ng/kg appeared to accelerate 
fracture healing at day 14 relative to the PBS-only control, while rhTNF-α at a dose of 
500ng/kg appeared to result in delayed union, especially of the fasciocutaneous cortex.  In 
order to further evaluate the apparent differential effect of TNF-α on fracture healing the 
model was repeated for CT analyses of callus mineralisation.  TNF-α, at a concentration of 
50ng/kg (labelled “low”) and at a concentration of 500ng/kg (labelled “high”) was 
administered as before.  The limbs harvested at day 14 and day 28.   
 
The results are shown in Figure 5.7.  Interestingly, there was no significant difference in 
callus mineralisation at day 14 between the group given the “low” dose of TNF-α and the 
control group (42.6 ±6.1%, 1SD vs. 38.4 ±7.6%, 1SD; P=0.236) or between the group given 
the “high” dose of TNF-α and the control group (44.1 ±7.6%, 1SD vs. 38.4 ±7.6%, 1SD; 
P=0.193) (Figure 5.7A).   However, callus mineralisation in the group given the “low” dose of 
TNF-α was significantly greater than the control group by day 28 (67.3 ±6.2%, 1SD vs. 57.8 
±6.4%, 1SD; P=0.003).  There remained no significant difference between the group given 
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the “high” dose of TNF-α and the control group at day 28 (61.8 ±6.1%, 1SD vs. 57.8 ±6.4%, 
1SD; P=0.239) (Figure 5.7B).    
 
 
Figure 5.7 TNF-α exerts concentration-dependent effects on fracture callus mineralisation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 The murine tibial fracture model was performed on 10-12 week old, female C57Bl6 (8-10 per 
condition) with or without the local administration of recombinant TNF-α in 20µl PBS at the concentrations 
stated.  At day 14 (A) and day 28 (B), the fractured tibiae were harvested, stripped of all soft tissue and the 
pin removed.  CT imaging was performed (courtesy of Mr Kevin Mackenzie, University of Aberdeen). 
Percentage callus mineralisation was calculated from the reconstructed CT image of the callus as described 
in section 2.2.29 (courtesy of Dr. Andrew Freidin, Imperial College).  **: P<0.01; unpaired t-test with 
Welch’s correction.  
 
CHAPTER FIVE                                                                                                                                         FRACTURE HEALING 
 239 
 
5.4 The inflammatory infiltrate in fracture healing 
 
 
An inflammatory infiltrate arises in the proximity of the fracture site within 24 hours 
(Andrew et al., 1994; Szczesny et al., 2007).  This post fracture cellular infiltrate includes 
cells of the innate immune response such as macrophages and neutrophils and cells of the 
adaptive immune response, particularly T cells may also be present (Andrew et al., 1994).  
The temporal and spatial arrangement of these cells was investigated.  It was reasoned that 
as fracture healing adjacent to muscle exhibits characteristics dissimilar to fracture healing 
adjacent to fasciocutaneous tissue (see section 5.2) cellular infiltration may also be 
dissimilar and a comparison was therefore made. 
 
5.4.1 The peri-fracture inflammatory infiltrate contains neutrophils that localise to 
the margins of the fracture callus 
 
Neutrophils are the most abundant of the cells of innate immunity and, by circulating in the 
blood, are also the first to respond to tissue damage and inflammatory signals (Smith, 
1994). The temporal and spatial nature of neutrophil infiltration following fracture was 
explored using immunohistochemistry of histological sections (detailed in section 2.2.26) 
from the murine tibial fracture model terminated at day 3, 7, 14 and 28.  The proteolytic 
enzyme neutrophil elastase is synthesised by neutrophils during inflammation (Smith, 
1994).  Hence, an antibody specific for this protein was chosen as a means of identifying 
neutrophils. 
 
The results are shown in Figure 5.8.  At day 3, a neutrophil infiltrate was already present in 
both the fasciocutaneous tissue adjacent to fracture anteriorly and the muscle adjacent to 
fracture posteriorly.  By day 7 a diffuse pattern of neutrophil infiltration within the 
granulation tissue around the newly forming callus was seen.  On the muscle side however, 
the neutrophils were localised to the junction between the muscle and the callus.   
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Figure 5.8 The peri-fracture inflammatory infiltrate contains neutrophils that localise around 
the periphery of the fracture callus, becoming marginal after day 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 The murine tibial fracture model was performed as described in section 2.2.20 on 12 week old, 
female C57Bl6 mice.  Limbs (3 per time point) were harvested at day 3, 7, 14 and 28 post-fracture.  The 
limb was fixed in 10% formaldehyde, decalcified, and bisected longitudinally.  Histological sections were 
incubated with antibody to neutrophil elastase and the antibody conjugated as described in section 2.2.26 
(Courtesy of Mr. David Essex, Department of Histopathology, Charing Cross hospital).  The slides were 
viewed under light microscopy at x4 magnification (panoramic view).  Areas from the fasciocutaneous (FC) 
side and the muscle (M) side of the fracture (represented by the boxes in the panoramic view) were also 
viewed at x20 magnification (One histological section is shown, as a representative section of the results 
from 3 limbs.  
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At day 14 neutrophils were more abundant on the fasciocutaneous side but on both sides 
were localised to lacunae present in the ossifying callus and marginalised to the callus 
periphery.  At day 28 neutrophils had disappeared from the muscle side but were still 
(sparsely) present on the fasciocutaneous side.     
 
 
5.4.2 The peri-fracture inflammatory infiltrate contains macrophages but not mast 
cells 
 
Macrophages are differentiated monocytes, present within the tissue during an 
inflammatory process.  Macrophages phagocytose cellular and bacterial debris and present 
antigenic material to the adaptive immune system (Aderem and Underhill, 1999).  F4/80 is a 
cell surface glycoprotein expressed by mature murine macrophages (McKnight et al., 1996).  
The temporal and spatial nature of macrophage infiltration following fracture was explored 
using an antibody specific for the F4/80 glycoprotein.   
 
The results are shown in Figure 5.9.  At day 3 there were no macrophages present within 
the granulation tissue on the fasciocutaneous side.  However, there were some 
macrophages present within the thin layer of granulation tissue between muscle and cortex 
on the muscle side.  Macrophages were abundant in the granulation tissue at day 7 on the 
fasciocutaneous side.  These cells localised to the granulation tissue adjacent to the 
ossification margin by day 14.  At day 28 some residual macrophages were present within 
the dermis and subdermal fascia.  By contrast the macrophages had disappeared on the 
muscle side by day 7.  They were similarly absent at day 14 and day 28.   
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Figure 5.9 Macrophages are more abundant on the fasciocutaneous side of the peri-fracture 
inflammatory infiltrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 The murine tibial fracture model was performed as described in section 2.2.20 on 12 week old, 
female C57Bl6 mice.  Limbs (3 per time point) were harvested at day 3, 7, 14 and 28 post-fracture.  The 
limb was fixed in 10% formaldehyde, decalcified, and bisected longitudinally.  Histological sections were 
then incubated with antibody to the macrophage-specific marker F4/80 and bound antibody conjugated as 
described in section 2.2.26.  (Courtesy of Dr. Chung-Yin Lee, Cancer Research UK).  The slides were viewed 
under light microscopy at x4 magnification (panoramic view).  Areas from the fasciocutaneous (FC) side 
and the muscle (M) side of the fracture (represented by the boxes in the panoramic view) were also 
viewed at x20 magnification (One histological section is shown, as a representative section of the results 
from 3 limbs. 
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Mast cells respond to antigen binding by degranulation with the release of cytokines and 
histamine (Mekori and Metcalfe, 2000).  These cells may also regulate an innate immune 
response (Mekori and Metcalfe, 2000).  Mast cells contain granules that are metachromatic, 
staining red/violet with toluidine blue.  Hence the presence of mast cells was investigated 
using panoramic histological sections of the fracture site at day 3, 7, 14 and 28.  The 
sections were stained using a 1% toluidine blue solution.  The results are shown in Figure 
5.10.  Mast cells were not identified at any time point on either the muscle or 
fasciocutaneous sides of the fracture.      
 
 
5.4.3 The peri-fracture inflammatory infiltrate contains T cells  
 
Investigating the peri-fracture infiltrate for cells of innate immunity revealed the presence 
of both neutrophils and macrophages, with each cell type exhibiting unique temporal and 
spatial characteristics.  Next, the presence of T lymphocytes was sought using the same 
methodological approach.   
 
The results are shown in Figure 5.11.  A few isolated lymphocytes are visible at day 3 on the 
fasciocutaneous side.  By day 7, the T cells have increased in number and are diffusely 
spread throughout the granulation tissue.  On day 14, the T cells have localised to the 
margin of the fracture callus.  At day 28 some residual lymphocytes are present in the 
dermis and subdermal fascia.  On the muscle side, T cells are only visible from day 14, where 
they are present within the thin granular layer between the muscle and the cortex.  At day 
28, a few residual T cells are present in the muscle.   
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Figure 5.10 The peri-fracture inflammatory infiltrate does not contain mast cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 The murine tibial fracture model was performed as described in section 2.2.20 on 12 week old, 
female C57Bl6 mice.  Limbs (3 per time point) were harvested at day 3, 7, 14 and 28 post-fracture.  The 
limb was fixed in 10% formaldehyde, decalcified, and bisected longitudinally.  Histological sections were 
then stained using Toluidine blue solution (Courtesy of Mr. David Essex).  The slides were viewed under 
light microscopy at x4 magnification (panoramic view).  Areas from the fasciocutaneous (FC) side and the 
muscle (M) side of the fracture (represented by the boxes in the panoramic view) were also viewed at x20 
magnification (One histological section is shown, as a representative section of the results from 3 limbs. 
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Figure 5.11 The peri-fracture inflammatory infiltrate contains T cells that localise to the 
margins of the callus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 The murine tibial fracture model was performed as described in section 2.2.20 on 12 week old, 
female C57Bl6 mice.  Limbs (3 per time point) were harvested at day 3, 7, 14 and 28 post-fracture.  The 
limb was fixed in 10% formaldehyde, decalcified, and bisected longitudinally.  Histological sections were 
then incubated with antibody to the mature T cell marker CD3 and bound antibody conjugated as 
described in section 2.2.26 (Courtesy of Dr. Chung-Yin Lee).  The slides were viewed under light microscopy 
at x4 magnification (panoramic view).  Areas from the fasciocutaneous (FC) side and the muscle (M) side of 
the fracture (represented by the boxes in the panoramic view) were also viewed at x20 magnification.  One 
histological section is shown, as a representative section of the results from 3 limbs. 
CHAPTER FIVE                                                                                                                                         FRACTURE HEALING 
 246 
 
5.4.4 Neutrophils are present in both muscle and fasciocutaneous tissue adjacent 
to fracture at 6 hours 
 
As neutrophils and some T cells and macrophages were already present within the tissues 
adjacent to fracture at day 3, it was necessary to evaluate an earlier time point.  However, it 
was difficult to bisect the limb to obtain a panoramic view of the fracture site earlier than 
day 3 owing to lack of fracture stability and the non-adherence of the periosteally stripped 
cortex to the surrounding tissue.  Hence, a different approach was used.  The fracture 
model was performed as before.  Limbs, harvested at 3, 6 and 12 hours post fracture were 
transversely divided through the fracture line following pin extraction.  Histological sections 
were prepared for immunohistochemistry or staining as before.     
 
The results are shown in Figure 5.12.  On both the fasciocutaneous side anteriorly and the 
muscle side posteriorly a neutrophil infiltration was present.  There were no macrophages 
and no T cells present in either tissue at 6 hours.  Similarly, there were no mast cells 
present.  Within muscle, the neutrophils accumulated between fascicles.  In 
fasciocutaneous tissue the neutrophils accumulated in the fascial interstitium.  The 
appearance at 3 hours and at 12 hours (not shown) was exactly the same as the appearance 
at 6 hours.   
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 Figure 5.12 At 6 hours post fracture, infiltrate in the muscle adjacent to fracture comprises 
neutrophils only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 The murine tibial fracture model was performed as before.  Limbs (3 per time point) were 
harvested at 6 hours post fracture.  The limb was fixed in 1% paraformaldehyde; the pin was removed 
and the limb divided transversely through the fracture line.  The bone was then removed to permit 
sectioning.  Histological sections were then cut using the proximal half of the limb. Sections were 
incubated with antibodies for Neutrophil elastase, F4/80 or CD3 then bound antibody was conjugated 
as described in section 2.2.26.  Alternatively sections were stained using Toluidine blue solution.  Slides 
were viewed under light microscopy at x40 magnification.  One histological section is shown for each 
stain and is representative of the results from all sections of the same limb and all 3 limbs (IHC courtesy 
of Mr David Essex and Dr Chung-Yin Lee).   
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5.4.5 Mice with severe, combined immunodeficiency exhibit delayed 
mineralisation of the fracture callus 
 
Examination of the transversely cut histological sections revealed the presence of T cells 
within the pericortical inflammatory infiltrate on the muscle (posterior) side of the fracture.  
The influence of cells of the adaptive immune response on fracture healing remains unclear. 
Hence the importance of adaptive immunity in fracture healing was investigated using 
severe, combined immunodeficient (SCID) mice lacking both T and B lymphocytes.  Age, size 
and sex-matched BALB/c mice (the wild type strain for these mice) were used as controls for 
these experiments.  The mice were subject to the fracture model described in section 
2.2.20.  At day 14 and day 28 the limbs were harvested and callus mineralisation evaluated 
using CT analyses. 
 
The results are shown in Figure 5.13.  At day 14 the mean callus mineralisation among the 
SCID mice was significantly less than the mean callus mineralisation among the wild type 
controls (47.1 ± 5.4%, 1SD vs. 58.9 ± 5.5%, 1SD; P=0.007) (Figure 5.13A).  By day 28, the 
early delay had corrected and while the SCID mice exhibited a greater variation in callus 
mineralisation there was no significant difference in callus mineralisation (69.6 ±1.5%, 1SD 
vs. 72.8 ±6.2%, 1SD; P=0.232) (Figure 5.13B).    
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Figure 5.13 Severe, combined immunodeficiency results in delayed early fracture callus 
mineralisation 
 
 
 
 
Figure 5.13 The murine tibial fracture model was performed (as described in section 2.2.20), on 12 week 
old female severe, combined immunodeficient (SCID) mice, and on age, sex and size-matched BALB/c mice 
(the wild type control).  At day 14 (A) and day 28 (B), the fractured tibiae were harvested, stripped of all 
soft tissue and the pin removed.  The bones were stored in 70% ethanol, and computer tomographic 
imaging (CT) was performed (courtesy of Mr Kevin Mackenzie, University of Aberdeen). Callus 
mineralisation, expressed as a percentage of the total callus volume, was calculated from the 
reconstructed CT image of the callus as described in section 2.2.29 (courtesy of Dr. Andrew Freidin, 
Imperial College).  Angulated, rotated or impacted fractures were excluded from further analyses.  **: 
P<0.01, unpaired t-test with Welch’s correction 
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5.5 Discussion 
 
 
Fracture healing was assessed using panoramic histological sections and by calculating 
callus volume and distinguishing the mineralised and unmineralised portions on the 
reconstructed images following micro CT.   Histological sectioning provides a qualitative and 
comparative method of appraising fracture healing.  Using the Masson’s trichrome stain, 
mineralised callus and bone (blue/green) can be distinguished from muscle and connective 
tissue (red) and cells (black).  Crucially, the cartilaginous intermediary or “soft callus” of 
endochondral fracture healing can be distinguished from mineralised “hard callus”, of the 
newly deposited woven bone.  The advantage of CT reconstruction of the callus is that it can 
be quantified in its entirety; that mineralised sections can be quantified, and that the 
orientation of the fracture can be evaluated to ensure that overly comminuted, impacted or 
rotated fractures are excluded from further analyses on the basis that movement (hence 
endochondral ossification) is different in these mobile fractures.    
 
The experiments described in this chapter investigated the influence of the pro-
inflammatory cytokines TNF-α, IL-6 and IL-1β on fracture healing in vivo.  The absence of 
signalling through the P55 receptor was found to inhibit early fracture healing and this 
appeared to result in a “catch-up” phase of fracture healing.  In the absence of IL-6, a similar 
pattern emerged, but the catch-up phase was not as obvious.  In the absence of the IL-1 
receptor signalling, fracture healing proceeded more or less as for the wild type control.  No 
significant differences were observed in callus mineralisation at day 14 or day 28.    
 
Fracture healing using a dual P55/P75 knockout mouse has previously been investigated by 
Gerstenfeld et al.  The model used was a closed, comminuted, non-anatomically reduced 
tibial fracture model, which therefore healed by both intramembranous and endochondral 
ossification (Bonnarens and Einhorn, 1984; Gerstenfeld et al., 2003a).  The authors 
concluded that the dual knockout mouse exhibited a qualitative delay in bone healing in 3 
distinct ways.  The first was a delay in callus formation, attributed by the authors to a 
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primary failure of recruitment of bone healing cells to the fracture site.  The second was a 
delay in callus maturation and mineralisation attributed to diminished chondrocyte 
apoptosis.  The third was deficient remodelling of the mineralised callus.  The authors 
speculated that failure of cell recruitment and differentiation by the TNF receptor null mice 
resulted from failure of TNF-α mediated NF-κB activation, as this pathway has been shown 
be important in the development of tissues of mesenchymal origin (Gerstenfeld et al., 
2003a).  However, interpretation of these results requires caution.  Interestingly, while 
chondrogenic differentiation appeared to be delayed, it subsequently proceeded at an 
elevated rate.  Moreover, there were no significant differences in the area of cartilage in 
callus (assessed histomorphometrically) at any time points.  It is difficult to compare these 
results with the results presented in Figure 5.1.  Firstly, the force was applied to fracture the 
tibia after the tibia was pinned and the histology presented suggests that this force resulted 
in angulation of the pin (Gerstenfeld et al., 2003a).  Hence fracture fixation was inherently 
unstable.  Movement is known to influence callus morphology and rate of maturation 
(Schell et al., 2005) and is unpredictable in an unstable fixation.  The translational appeal of 
this model is also dubious as patients would not be mobilised on unstable fixations.  
Secondly, as a closed fracture model, healing occurred by both intramembranous and 
endochondral ossification.  Thirdly, a dual genetic knockout was used.  It is known that TNF-
α-mediates cellular responses through both P55 and P75 receptors.  These receptors signal 
through distinct pathways (Pinckard et al., 1997).  Hence, the study did not establish which 
of the pathways was responsible for each of the 3 distinct features of delayed fracture 
healing reported.  This is important, as the receptor specificity provides potential targets for 
therapeutic interventions.  By contrast the model used here resulted in a stable fracture 
fixation permitting more predictable healing.  As the periosteum was stripped, 
endochondral fracture healing occurred in isolation.  Single genetic knockouts were 
compared.  As the P55, but not the P75 null mouse exhibited a qualitative delay in early 
callus development these findings suggested that the P55 receptor, but not the P75 
receptor signalled TNF-α induced cell recruitment and osteogenic differentiation.  Hence 
TNF-α was important for the initiation of fracture healing, but that other factors present 
were able to compensate.   
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As demonstrated in Figures 5.6 and 5.7 the influence of TNF-α on fracture healing is 
critically dependent on the concentration of TNF-α acting locally.  Accelerated fracture 
healing was demonstrated qualitatively by the addition of 50ng/kg TNF-α (equivalent to 
around 1ng in 20µl for a 20g mouse) and quantitatively by percentage callus mineralisation 
that was significantly increased at day 28 (although there was no significant difference at 
day 14).  Of equal importance was that fracture healing was delayed by a ten-fold increase 
in TNF-α, although no significant delay in callus mineralisation was observed at day 14 or 
day 28.  Evidence for concentration dependence explains the results of studies that 
appeared to support the conclusion that TNF-α impaired bone formation, including the 
inhibition of bone formation around an intramuscular bone-inducing implant (Yoshikawa et 
al., 1988) and impaired healing in a rib fracture model; a result obtained at a dose of 
400µg/kg/day but not ten-fold less (Hashimoto et al., 1989).  High and persistent levels of 
TNF-α are also implicated in bone erosions in rheumatoid arthritis (Goldring and Gravallese, 
2000).  
 
In view of the data from the P55 and P75 null mice, human recombinant TNF-α was chosen 
for the exogenous addition as it binds to the murine P55 receptor but not the P75 receptor 
(Vandenabeele et al., 1995).  Hence, it can be deduced that the ability of TNF-α to both 
promote and impair fracture healing is mediated by differential effects on the constitutively 
expressed P55 receptor, and not on concentration-dependent induced P75 expression 
(Vandenabeele et al., 1995).  As the P75-/- mouse heals normally it can also be deduced that 
stimulation of the P55 receptor does not occur as a consequence of “ligand-passing” from 
the binding of TNF-α to the high-affinity P75 receptor.  (By this process it is thought that 
P55-expressing cells may respond to low levels of TNF-α expression).  Hence, it must be 
assumed that TNF-α expression in the murine fracture model is sufficient to promote direct 
P55-mediated pro-osteogenic effects.  It must also be assumed that much lower 
concentrations of mTNF-α would be required to induce the same acceleration in fracture 
healing as demonstrated by the addition of rhTNF-α at 50ng/kg (Barbara et al., 1994; 
Vandenabeele et al., 1995).  These findings are in keeping with the proposed function of the 
P75 receptor as a synergistic inducer of TNF-α-mediated cell activity (Vandenabeele et al., 
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1995).  The lack of effect of rhTNF-α at the lowest concentration may have simply reflected 
an inadequate stimulus, particularly in the absence of synergistic induction via mP75 
binding.  Conversely, impaired fracture healing seen at high concentrations of rhTNF-α-
induced mP55 signalling may reflect cell cytotoxicity, which is triggered through the P55-
signalling pathway (Beg and Baltimore, 1996). The failure of the experiment (shown in figure 
5.7) to suppress fracture healing quantitatively at a high concentration may simply have 
indicated that the concentration used was not high enough or not given frequently enough.    
 
As the knockout strains are phenotypically normal TNF-α appears not to be important for 
embryonic skeletal development (Mountziaris and Mikos, 2008; Peschon et al., 1998).  
Hence, endochondral fracture healing is a process distinct from embryonic long bone 
formation and the bone-inducing role of TNF-α in fracture healing is unique to this process  
 
Lack of TNF-α causes an initial delay in callus formation followed by a period of 
compensated callus formation and maturation.  One of the factors that may be responsible 
for this is IL-6 that may act downstream of TNF-α.  Yang et al reported that the IL-6 
knockout mouse exhibited delayed early fracture healing relative to the wild type control.  
The model used was a closed mid shaft femoral fracture stabilised with a pin (hence an 
intramembranous and endochondral fracture healing model of a closed fracture without 
anatomical reduction).  A trend towards significance was reported for callus mineralisation 
(assessed by mineral/matrix ratio of the callus using micro CT) at 2 weeks only, with the IL-6 
knockout mouse exhibiting relatively less mineralisation.  By 4 weeks this trend had 
disappeared.  These findings were similar to the findings described in figures 5.3 and 5.5, 
where a qualitative delay in callus formation was observed at day 7 was followed by a 
period of catch-up by day 14 such that a non-significant reduction in callus mineralisation in 
the IL-6-null mouse was observed at day 14.  Thus, if a delay in fracture healing exists as a 
result of loss of IL-6-mediated pro-inflammatory signalling, it is subtle and transient.  
Furthermore, the exogenous addition of recombinant human IL-6 did not promote fracture 
healing as with TNF-α.  These observations suggest that IL-6 promotes early fracture healing 
and may therefore compensate for the loss of P55-mediated TNF-α signalling in the 
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knockout mouse but that the absence of IL-6 is overcome by other factors (including TNF-α).  
Fracture healing in the absence of both TNF-α and IL-6 would be an interesting next step (if 
such a dual knockout was available).   
 
The role of IL-1 in fracture healing was studied using the receptor knockout as both IL-1α 
and IL-1β can stimulate receptor signalling.  Fracture healing studies using this knockout 
have not been published before.  In any event, apart from a slight delay observed at day 7 
the IL-1R-/- mouse exhibited normal fracture healing.  These data were consistent with the 
results described in chapter 4 suggesting that neither the recruitment of stromal 
osteoprogenitor cells in vitro nor endochondral fracture healing in vivo requires IL-1.  This 
cytokine appears to be a poor candidate for translational fracture healing research.  
 
The implications of these data for human fracture healing are profound.  They suggest that 
the success of fracture healing may be considered not only in terms of the availability of 
cells but on the inflammatory signals acting on those cells.  Specifically, it is suggested that 
delayed fracture healing might be a function of the lack of a pro-inflammatory signal 
mediated through TNF-α or, importantly, the excess of such a signal (Bunn et al., 2004).  
Factors which would pre-dispose to the former include steroid/immunosuppressant’s 
(Murnaghan et al., 2006); the elderly (Gruber et al., 2006) or, following frequent washouts 
(Dirschl et al., 1998).  Factors which predispose to the latter include major trauma, crush 
injuries or a systemic inflammatory response.  While this hypothesis is appealling, hard 
evidence is needed. 
 
Pro-inflammatory cytokines are synthesised by inflammatory cells including cells of both the 
innate and adaptive immune systems.   Immunohistochemistry revealed that neutrophils 
infiltrate both the fasciocutaneous tissue and muscle adjacent to the fracture.  T cells are 
also present within peri-fracture granulation tissue within a few days of fracture.  
Macrophages begin to appear around the same time.  These data suggest multiple potential 
sources of TNF-α and intimate that neutrophils may be the prime source but the evidence is 
circumstantial.  Further studies are needed to confirm the presence of TNF-α locally.  
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These data also revealed unique characteristics of the cellular infiltrate within muscle and 
fasciocutaneous tissue adjacent to fracture.  In general the inflammatory cell infiltrate on 
the fasciocutaneous side was poorly focused around the fracture callus and resided within 
the tissue for longer (to day 28 for some cells).  By contrast, the inflammatory cell infiltrate 
on the muscle side rapidly localised to the periphery of the callus and then rapidly resolved 
as callus maturation progressed.  While cause and effect is difficult to establish it seems 
likely that rapid inflammatory cell localisation and resolution is linked to the superior callus 
maturation seen invariably on the muscle side.   
 
In summary, this chapter has demonstrated that TNF-α is an important cytokine mediating 
fracture healing in vivo.  Furthermore, TNF-α exerts differential effects on fracture healing 
which are dependent on the local concentration.  It is both capable of accelerating fracture 
healing and, at very high and/or repeated doses inhibiting fracture healing.  These effects 
appear to be mediated through P55, which is constitutively expressed, and not through the 
P75 receptor, which the expression of which is inducible.  The pro-inflammatory cytokine IL-
6 is also involved in normal fracture healing but unlike TNF-α, IL-6 administration is not able 
to promote fracture healing in a wild type mouse.  Principal sources of TNF-α in the early 
post-fracture environment may include neutrophils as these cells are found in abundance in 
the early inflammatory milieu.  Mature T cells are also present in the inflammatory milieu 
suggesting that the adaptive immune system is also mobilised following fracture.    
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6.1 Concluding discussion 
 
The need for prompt cover by vascularised tissue following open fractures has long been 
recognised (Godina, 1986).  However, the type of vascularised tissue favoured for soft tissue 
cover remains controversial to this day.  Cover of experimental fractures with muscle has 
long been associated with improved union time and strength (Richards et al., 1987; 
Schemitsch et al., 1997).  Yet the fact remains that the superiority of muscle flaps has failed 
to gain universal acceptance in clinical practice.  Several factors are likely to account for this 
including criticisms of the experimental designs of animal models used to study the 
influence of soft tissue on fracture healing and inconsistent data from clinical trials that are 
likely to be influenced by clinical and patient variables  (Gopal et al., 2000; Naique et al., 
2006; Yazar et al., 2006).  In order to address this, a murine model was pioneered at the 
Kennedy Institute of Rheumatology and the result confirmed the experimental superiority 
of exclusive cover with muscle in a model of endochondral fracture healing (Harry et al., 
2008).  For these findings to be accepted and to enable the development of a translational 
strategy a mechanistic explanation was required.  The aim of this thesis was to provide an 
explanation for these findings and to develop the mechanistic understanding of the process 
that yields such findings.  Further work performed at the Kennedy Institute revealed that 
the vascular density of the fasciocutaneous tissue was superior to that of the muscle, 
suggesting that blood supply and the relative availability of circulating stem-like cells was 
not responsible for the findings (Harry et al., 2009).  It was hypothesised that instead, the 
answer lay in the osteogenic potential of cells found in muscle and it was proposed that 
these cells were recruited to aid fracture healing by soluble signals resulting from the 
fracture itself.   
 
Techniques for the isolation and culture of cells from muscle are well established (Rando 
and Blau, 1994).  Moreover, these cell isolation techniques are now being used to select 
sub-populations for viral transduction to make them differentiate down an osteogenic 
lineage and form bone (Lee et al., 2000; Wright et al., 2001). The work presented in this 
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thesis therefore began by taking the next logical step which was to isolate cells from muscle 
exposed to the fracture site and observe any differences in their characteristics from control 
cell populations.  These experiments isolated cells already committed to osteogenic 
differentiation.  Moreover, the stimulus must have come from bone.  The implication was 
that ex vivo manipulation of the cells; an expensive, time consuming and translationally 
inelegant process was unnecessary as cell recruitment had occurred without exogenous 
intervention.   
 
In a closed system, the peri-fracture environment is a maelstrom of traumatic debris, 
inflammatory cells, regulatory growth factors and chemo attractant molecules.  Thus, it is 
not difficult to imagine that adjacently situated cells respond to these signals by migration, 
growth and differentiation in ways that reflect the physiological response of bone to injury.  
While cell migration to the fracture site from local (Taguchi et al., 2005) and remote bone 
marrow (Shirley et al., 2005) has already been demonstrated a proof of concept was 
required for the recruitment of stromal cells residing in locally situated muscle.  First, eGFP 
adenovirus was injected into the muscle posterior to the mid tibial shaft.  Subsequent 
panoramic histological series following fracture failed to demonstrate eGFP-expressing cells 
in or around the fracture callus.  Hence MDSC, obtained from heterozygous eGFP-
expressing mice were culture-expanded and injected into the muscle posterior to the mid 
shaft of the tibia at the level of the fracture.  The experiment demonstrated localisation of 
the MDSC around the fracture callus (and, incidentally to the dermis of the healing skin 
wound).  Predictably, some auto-fluorescence of the tissues, particularly the marrow was 
also present on UV microscopy and a future repeat of this experiment will aim to address 
this.  Among the techniques that may be attempted include an extra staining step with 
Sudan black or the use of paraformaldehyde to fix the tissue prior to histological sectioning.  
MDSC did not appear to localise in the soft tissue dissection control suggesting that the cell 
distribution observed reflected selective localisation.   Another method of confirming cell 
migration involves the implantation of a microcarrier bead seeded with eGFP-expressing 
MDSC. This is a modification of a technique already in use at the Kennedy Institute of 
Rheumatology (Palmisano and Itoh).  This modification is attractive as cells will stay bound 
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to the bead unless stimulated by chemotaxis, thus reducing the probability of a false 
positive result.  An alternative approach to fluoroscopic imaging would be to use 
immunohistochemical staining for GFP.   
 
Up to this point, murine tissue and model had been used.  This was necessary for the in vivo 
proofs of concept required.  Yet experience from the translational complications associated 
with the BMP work suggested that primary human tissue was likely to yield results of 
greater relevance.  In this regard the study was fortunate to be able to obtain specimens of 
fractured and unfractured bone, muscle and fasciocutaneous tissue from patients 
undergoing surgical management of lower limb trauma at Charing Cross hospital.   Despite, 
as predicted, some biological variation the cells obtained from human muscle samples 
permitted the acquisition of reliable and reproducible results without the translational 
concerns of adapted rodent in vitro data.     
 
At this point it should be stressed that the optimisation work performed during the 
development of the in vitro model required a thorough evaluation of the differences 
observed between MDSC from different donors.  Importantly, while cell surface analysis 
revealed that the heterogenous MDSC populations obtained were similar between all 
donors, the cell populations differed in other ways.  These included their proliferation 
potential in standard culture medium, their cell adhesion characteristics and, of course, 
their differentiation potential.  Cell sex differences have already been described (Deasy et 
al., 2007) and it was thus not surprising that such differences were observed in our system.  
The translational implications of this remain unclear but should be considered when utilising 
or adapting the model.  The same may be said of cells from older patients as they seemed 
incapable of exhibiting the plasticity of cells from younger patients.    
 
 Characterisation of muscle-derived cell populations previously confirmed that these cells 
were likely to be muscle stromal cells at various stages of myogenic differentiation, from 
stem-like precursor cells to quiescent then activated satellite cells and finally myocytes 
(Jankowski et al., 2002).  Predictably, cell surface analysis using FACS, 
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immunohistochemistry and culture in differentiation media confirmed that a population of 
muscle-derived stromal cells capable of mesodermal tri-lineage differentiation had been 
isolated. The heterogeneous population could have been further subdivided into satellite 
cells, fibroblasts, myofibroblasts and myocytes (Deasy et al., 2002; Qu-Petersen et al., 
2002). Techniques employed to do this include immunostaining for co expression, or 
polymerase chain reaction (RT-PCR) for MyoD, Myf5, m-Cadherin, c-met, Desmin and PAX-7 
(Jankowski et al., 2002).  Satellite cells could, in turn have been further subdivided on the 
basis of PAX-7/Myf5 expression (Kuang et al., 2007).  The difficulty remains, however, in 
attributing sub-populations to fracture healing in vivo.   
   
The differentiation characteristics of bone marrow-derived stromal cells, adipose-derived 
stromal cells and even skin-derived cells has attracted interest owing to the potential of 
these tissues to yield precursor cell populations for a number of tissue engineering 
strategies (Lavoie et al., 2009; Lee et al., 2003; Pittenger et al., 1999).  However, the clinical 
scenario that prompted this study demanded a quantitative comparison of the osteogenic 
potential of progenitor cell populations derived from muscle, skin and fat.  As bone marrow 
is an accepted source of progenitor cells for fracture healing (Iwamoto et al., 1993; 
Pittenger et al., 1999) this serves as a useful positive control for comparison.  The 
availability of human tissue enabled matched samples to be obtained.  Predictably from the 
point of view of the in vivo data, the osteogenic potential of the muscle-derived cells 
exceeded that of matched adipose-derived and skin-derived cells.  However, the 
observation that muscle-derived stromal cells exceeded the osteogenic potential of 
matched bone marrow-derived stromal cells was unexpected.  This finding has not been 
reported in the literature before.  Further characterisation of the BMSC populations used 
and an increase in the number of matched samples is probably necessary before any 
definitive conclusions can be drawn.   
 
The novel finding that muscle-derived cells underwent osteogenic differentiation in 
proximity to fracture suggested that a fracture-derived chemical stimulus was responsible 
for cell migration and osteogenic differentiation.  To confirm this hypothesis in vitro a novel 
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human fracture model was developed using supernatants derived from human fracture 
fragments.  These supernatants promoted migration and osteogenic differentiation of 
MDSC.  A proteomic approach was employed to isolate the factor(s) responsible for 
osteogenic differentiation as the Kennedy Institute of Rheumatology had success with a 
similar venture using this approach (Hermansson et al., 2004).  This method, however, was 
not successful, yielding only serum proteins.  ELISAs for bone morphogenetic proteins did 
not correlate with osteogenic activity.  Indeed, neither antibody inhibition of the BMPs in 
supernatant nor culture with recombinant human BMPs influenced cell expression of ALP.  
This was surprising given the volume of literature dedicated to the study of BMPs in fracture 
healing.  Interestingly, osteogenic differentiation of primary human muscle stromal cells by 
rhBMPs has been described rarely.  Musgrave et al described increased ALP expression by 
primary human muscle cells cultured with rhBMP-2 (Musgrave et al., 2002) although only 
specific sub-populations achieved statistically significant results.  Moreover, the 
composition of the media containing rhBMP-2 was unclear.     
 
The observation that fracture-derived supernatants did not invariably stimulate ALP 
expression by MDSC, together with the observation that supernatants from surgically cut 
bone invariably did not, prompted re-evaluation of the active supernatants.  In particular 
the clinical features of each case were reviewed.  From these observations emerged the 
hypothesis that the difference between osteocompetent and non-osteocompetent 
supernatants lay in the inflammatory nature of the environment from which the bone 
fragments emerged.  Work presented in chapter 4 studied this hypothesis in detail.  While 
the concentrations of TNF-α and IL-1β were so low as to be undetectable, the limit of 
sensitivity of the assay did not exclude the presence of physiologically relevant 
concentrations (Frost et al., 1997; Gilbert et al., 2000).  Indeed, the approach was vindicated 
by the observation that antibody inhibition of TNF-α and IL-6 in supernatant inhibited 
supernatant-mediated ALP expression.  Furthermore, rhTNF-α and rhIL-6 stimulated ALP 
expression and bone formation by MDSC in vitro.  In the case of IL-6, the novelty in this 
finding arose from the fact that MDSC were receptive to IL-6-mediated osteogenic 
differentiation.  Previously, IL-6, together with the sIL-6R complex has been shown to 
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promote osteogenic differentiation of committed progenitor cells (Erices et al., 2002; 
Franchimont et al., 2005).  By contrast, the finding that TNF-α promoted osteogenic 
differentiation of MDSC and, importantly, that the effect of TNF-α on MDSC was 
concentration-dependent and inhibitory above 10ng/ml was not only entirely novel but also 
helped to explain some of the existing data that appeared to confirm TNF-α as a potent 
inhibitor of bone formation in vitro (Gilbert et al., 2000) and in vivo (Hashimoto et al., 1989).  
Together with the accepted influence of TNF-α on osteoclastic differentiation and 
maturation (Boyle et al., 2003; Jimi et al., 2004) these data support the hypothesis that the 
influence of TNF-α on bone formation and regulation is more complex than appreciated and 
that under some circumstances TNF-α signals bone formation preferrentially.   
 
The finding that TNF-α and IL-6 also promoted migration of MDSC was the other important 
novel finding described in this chapter.  Once more TNF-α was clearly the more important of 
the two.  Using primary human tissue cell migration (like basal ALP expression) varied 
between donors.  However, cell migration was expressed as a percentage of the untreated 
control enabling a valid comparison.  Moreover, the influence on cell migration of TNF-α 
was very consistent.  This consistency demonstrated a 50% fall in cell migration when TNF-α 
in supernatant was inhibited.  These data suggested that other factors present in 
supernatant also contributed to chemotaxis.  One of these factors was CXCL-8 (IL-8) 
although as this factor was unable to promote cell migration in isolation it suggests that 
either IL-8 promoted cell migration in the presence of other factors or that cells were 
primed to be responsive to IL-8 by other factors, including TNF-α itself (Blades et al., 2002; 
Ponte et al., 2007).  Interestingly, the concentration of rhTNF-α required to promote cell 
migration lends further evidence to the hypothesis that the influence of TNF-α on MDSC is 
dose dependent and physiologically active at concentrations much lower than commonly 
understood.   
 
Ideally, it would have been desirable to investigate the influence of combinations of 
antibody on supernatant-mediated cell differentiation and migration and combinations of 
recombinant cytokines on cell differentiation and migration in media.  Of particular interest 
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was the combination of antibodies to TNF-α and IL-6 in supernatant-mediated 
differentiation and migration assays.  In the case of the latter, combinations of antibodies to 
TNF-α, PDGF and IL-8 were also of interest.  Regarding recombinant cytokines it remains 
unclear whether IL-6 would exert an additive effect on TNF-α-mediated differentiation and 
migration.  It is equally unclear whether MDSC cultured in TNF-α would migrate in response 
to IL-8.         
 
Having obtained data confirming the osteogenic effect of the pro-inflammatory cytokines 
(particularly TNF-α) on MDSC using a human in vitro model these proofs of concept required 
confirmation using a model of fracture healing.  Results presented in chapter 5 confirmed a 
qualitative delay in early fracture healing in the absence of P55 (TNF receptor type 1) 
signalling, although there were no quantitative differences at day 14 or day 28 as callus 
formation and maturation appeared to accelerate to “catch-up” on the initial delay.  The 
influence on fracture healing of the constitutively expressed P55 receptor was confirmed by 
the addition of human recombinant TNF-α, that binds to the murine P55 receptor but not 
P75 receptor (Vandenabeele et al., 1995).  These studies produced the novel finding that 
fracture healing could be both accelerated and delayed by the addition of exogenous TNF-α, 
confirming the hypothesis formulated by the human in vitro data.  Ideally, it would have 
been desirable to demonstrate this quantitatively by callus mineralisation and indeed, at a 
concentration of 50ng/kg, percentage callus mineralisation is significantly greater at day 28 
when TNF-α was added locally at day 0; an observation not repeated when a concentration 
of 500ng/kg was used.  However, further optimisation of the dose regimens was required to 
obtain results that demonstrated the dose-response relationship more clearly.   
 
Another way to explore the relationship between the TNF receptors and fracture healing 
would have been to add murine recombinant (P55 and P75-binding) TNF-α to P55 and P75 
null mice.  It would also have been relevant to explore the differences in fracture healing 
between local and systemically administered TNF-α.  Preliminary fracture healing studies 
demonstrated that the systemic (intraperitoneal) administration of murine anti-TNF (TN3) 
every 3 days did not influence fracture callus mineralisation.  The reason for this was 
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unclear but again, the dose required optimisation. Alternatively, the antibody may have 
failed to inhibit TNF.  Another approach that was considered was to study fracture healing 
in TNF-transgenic mice.  It was reasoned that this approach might provide compelling 
evidence for delayed union at high local concentrations of TNF-α.  However, high baseline 
levels of TNF-α lead to reduced bone mass in these mice making this approach unfeasible.    
 
While analyses of the cellular composition of the inflammatory infiltrate have identified 
neutrophils, macrophages and T cells (Andrew et al., 1994; Szczesny et al., 2007) as 
potential sources of TNF-α, the demonstration in chapter 5 of differences in the temporal 
and spatial composition of the inflammatory infiltrate is a novel finding.  The fact that 
differences exist between the muscle and fasciocutaneous tissue in terms of the post-
fracture inflammatory infiltrate is, perhaps, not surprising given differences in the fracture 
healing characteristics of these tissues.  Nevertheless, the significance of this finding 
remains unclear.  In particular it is not known whether the rapid resolution of the 
inflammatory infiltrate on the muscle side is a cause or consequence of relatively faster 
callus maturation on the muscle side.  Moreover, the significance of the presence of mature 
T cells is also unclear.   
 
As a preliminary investigation into the importance of the adaptive immune system in 
fracture healing, the fracture model was performed using SCID mice, on a BALB/c 
background and a comparison was made with age, sex and size-matched BALB/c controls.  
Contrary to the only previous report (Gaston et al., 2006) fracture healing was significantly 
delayed at day 14 relative to wild type controls.  While the SCID mice lack both T cells and B 
cells, precluding any specific conclusion regarding the importance of T cells, these data 
provided the first in vivo evidence for the importance of the adaptive immune system in 
fracture healing.  Subsequent studies may yield further insights into this, as yet, poorly 
understood relationship.     
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6.2 Future directions 
 
Data presented in this thesis explains the influence of adjacently situated muscle on 
fracture healing in terms of recruitment of muscle-derived osteoprogenitor cells by TNF-α, 
synthesised in the vicinity of the fracture in response to tissue trauma.  Future work will 
target several key areas.    
 
These include the mechanism by which MDSCs form bone in response to TNF-α.  Currently, 
this mechanism remains obscure.  One way to investigate this is to obtain supernatant 
samples from MDSC cultured with TNF-α and identify the constituents by means of ELISAs, 
where specific factors are sought, or by Luminex, where candidate factors are unclear.  In 
particular, as TNF-α is an up-stream regulator of IL-6 (Carpentier et al., 1998; Kozawa et al., 
1997) and as the actions of TNF-α on MDSC are similar to IL-6 it would be desirable to 
determine whether TNF-α induced IL-6 synthesis by MDSC.   
 
Secondly, studies described in chapter 4 investigated the influence of TNF-α, IL-6 and IL-1β 
on MDSC cultured in supernatant and when used in media to culture cells directly.  
However, as these cytokines are all present in vivo experiments using combinations is 
desirable.  While it was demonstrated that TNF-α promoted cell migration this finding 
raised several further questions.  For example, antibody inhibition of TNF-α in supernatant 
suppressed the migratory stimulus by only around 50%.  As antibody inhibition of CXCL-8 
also suppressed supernatant-mediated MDSC migration (by around 40%) the addition of 
both antibodies would be a desirable next step.  If TNF-α promoted the responsiveness of 
MDSC to CXCL-8 (as suggested by the lack of response to rhCXCL-8), then following the 
addition of both antibodies cell migration would not be expected to diminish further than 
that observed by TNF-α inhibition alone. Conversely MDSC, pre-stimulated with rhTNF-α 
would be expected to migrate in response to rhCXCL-8.  This would also help explain the lack 
of response of quiescent cells to rhCXCL-8.  A notable omission from the migration 
experiments was CXCL-12, which has also been implicated in stromal cell migration (Ringe et 
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al., 2007; Stich et al., 2008).  It would be appropriate to include this chemokine in further 
investigations of MDSC migration.   
 
While BMPs were quantified in supernatant and their influence on MDSC studied platelet-
derived growth factor and fibroblast growth factor are two potentially relevant growth 
factors that were not studied.  PDGF has been implicated in accelerated fracture healing 
experimentally (Hollinger et al., 2008; Nash et al., 1994).  Moreover, as described in chapter 
4 rhPDGF-AB promoted cell migration in culture. Quantification of PDGF in supernatant and 
clarification of the role of PDGF in supernatant-mediated cell differentiation and migration 
requires exploration.  There is also some evidence for improved fracture healing following 
local injection with FGF (Nakamura et al., 1998).  The approach proposed for the 
investigation of PDGF is equally relevant here. 
 
Interestingly, TNF-α has been reported to influence osteoblastic cell proliferation (Frost et 
al., 1997).  Once more, this effect was concentration-dependent. Very low concentrations 
promoted cell proliferation and this effect rapidly declined as the concentration increased.  
Failure to reproduce these findings may have reflected the cell type used.  Hence, it would 
be desirable to repeat these experiments using a human osteoblast cell line.   
 
While immunohistochemical staining for cells of the innate and adaptive immune systems 
yielded interesting data regarding the temporal and spatial nature of the inflammatory 
infiltrate, the source of TNF-α providing the theoretical signal for MDSC recruitment was not 
identified by these experiments.  Possible means of confirming the presence of TNF-α in the 
peri-fracture infiltrate include IHC for TNF-α itself.  Alternatively, fluorescent in-situ 
hybridization may be used to highlight the cells synthesising TNF-α.  These cells may be 
identified, in turn, by IHC.  Local and systemic TNF-α production in early fracture healing 
could be compared by harvesting supernatants from cells isolated from tissue samples 
around the fracture site and comparing these with plasma TNF-α, obtained by cardiac 
puncture at termination.   
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The relationship between neutrophils, T cells, cells of the monocyte lineage and MDSC could 
be explored further using an in vitro co-culture system.  Specifically, osteogenic 
differentiation of MDSC co-cultured with immune cells could be investigated with ease 
using the ALP assay as before.  Moreover, the co-culture supernatant could be investigated 
using the Luminex xMAP® methodological approach described in chapter 4, in order to link 
osteogenic differentiation of MDSC with cytokines produced by the immune cells.  
Antibodies or receptor inhibitors for any ligands identified using this approach could help to 
define the response of MDSC to immune cells.   
 
The translational potential of this work is complicated by the apparent narrow therapeutic 
window through which TNF-α exerts a pro-osteogenic effect.   As “supra-optimal” 
concentrations impair fracture healing, the theoretical risk exists of impairing, rather than 
accelerating fracture healing in the clinical setting.  Additionally, inflammation is associated 
with pain.  In a murine model, limb pain can be quantified, and indeed this model is already 
in use at the Kennedy Institute of Rheumatology (McNamee et al.).  Hence it is possible for 
the effect of the addition of TNF-α on limb pain to be quantified, and indeed this is a 
desirable experiment to perform prior to consideration of any translational implication for 
these findings.    
 
Standardisation of the in vitro fracture model requires a clear protocol for the harvesting of 
human tissue.  Specifically, muscle samples must be obtained from young patients, and 
processed as soon as possible to minimise ischaemic time and maximise cell yield.  
Supernatants must be harvested from recent, minimally contaminanted fractures during the 
first trip to theatre (prior to washout and debridement).  As the system is allogeneic, all cell 
samples must be tested with all fracture supernatants to establish the cell response to the 
supernatant before the model can be used experimentally.  If a cell sample is poorly 
responsive to supernatants that otherwise perform well it should be excluded from further 
protocols.  If a fracture supernatant fails to stimulate an osteogenic response in cells that 
otherwise respond well, it must also be excluded or labelled as “inactive”.  Equally, if a 
supernatant has a tendency to cause cell lysis it must also be excluded.  Heat inactivation of 
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complement proteins (while not a standard part of our protocol) can mitigate supernatant-
mediated cell lysis.        
 
 
6.3 Conclusion  
 
In conclusion, muscle is a source of stromal progenitor cells for fracture healing.  This source 
might be especially important following high energy trauma where alternative sources are 
limited.  TNF-α, synthesised by monocytes and neutrophils in the early post-fracture 
inflammatory infiltrate, is the key cytokine mediating the recruitment of these stromal cells 
and their subsequent osteogenic differentiation.  However, TNF-α is pro-osteogenic with 
narrow therapeutic margins.  With rising concentrations of TNF-α locally the pro-osteogenic 
effect becomes inhibitory.  Local TNF-α concentration within the first 24 hours can influence 
the subsequent fracture healing cascade, such that differences can be observed at day 14 in 
a murine model.  Therapeutic interventions that seek to utilise the potential of adjacent 
muscle as a source of progenitor cells may do so through manipulation of local TNF-α 
concentration.  As the therapeutic window is narrow, physiological control is sought 
through an understanding of the up-stream regulation of TNF-α expression in response to 
fracture.  
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